CINXE.COM

News | NorthStar Medical Radioisotopes, LLC

<!DOCTYPE html> <html lang="en"> <head> <!-- Google Tag Manager --> <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-PBBCFFM');</script> <!-- End Google Tag Manager --> <meta charset="utf-8"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <meta name="format-detection" content="telephone=no"> <title>News | NorthStar Medical Radioisotopes, LLC</title> <link rel='preconnect' href='//cdnjs.cloudflare.com' /> <link rel='preconnect' href='//kit.fontawesome.com' /> <link rel='preconnect' href='//pro.fontawesome.com' /> <link rel='preconnect' href='//use.typekit.net' /> <link rel='preconnect' href='//www.googletagmanager.com' /> <link rel='preconnect' href='//www.google-analytics.com' /> <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries --> <!--[if lt IE 9]> <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script> <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script> <![endif]--> <link rel="apple-touch-icon" sizes="57x57" href="https://www.northstarnm.com/wp-content/themes/northstar/img/favicon/apple-icon-57x57.png"> <link rel="apple-touch-icon" sizes="60x60" href="https://www.northstarnm.com/wp-content/themes/northstar/img/favicon/apple-icon-60x60.png"> <link rel="apple-touch-icon" sizes="72x72" href="https://www.northstarnm.com/wp-content/themes/northstar/img/favicon/apple-icon-72x72.png"> <link rel="apple-touch-icon" sizes="76x76" href="https://www.northstarnm.com/wp-content/themes/northstar/img/favicon/apple-icon-76x76.png"> <link rel="apple-touch-icon" sizes="114x114" href="https://www.northstarnm.com/wp-content/themes/northstar/img/favicon/apple-icon-114x114.png"> <link rel="apple-touch-icon" sizes="120x120" href="https://www.northstarnm.com/wp-content/themes/northstar/img/favicon/apple-icon-120x120.png"> <link rel="apple-touch-icon" sizes="144x144" href="https://www.northstarnm.com/wp-content/themes/northstar/img/favicon/apple-icon-144x144.png"> <link rel="apple-touch-icon" sizes="152x152" href="https://www.northstarnm.com/wp-content/themes/northstar/img/favicon/apple-icon-152x152.png"> <link rel="apple-touch-icon" sizes="180x180" href="https://www.northstarnm.com/wp-content/themes/northstar/img/favicon/apple-icon-180x180.png"> <link rel="icon" type="image/png" sizes="192x192" href="https://www.northstarnm.com/wp-content/themes/northstar/img/favicon/android-icon-192x192.png"> <link rel="icon" type="image/png" sizes="32x32" href="https://www.northstarnm.com/wp-content/themes/northstar/img/favicon/favicon-32x32.png"> <link rel="icon" type="image/png" sizes="96x96" href="https://www.northstarnm.com/wp-content/themes/northstar/img/favicon/favicon-96x96.png"> <link rel="icon" type="image/png" sizes="16x16" href="https://www.northstarnm.com/wp-content/themes/northstar/img/favicon/favicon-16x16.png"> <link rel="manifest" href="https://www.northstarnm.com/manifest.json"> <meta name="msapplication-TileColor" content="#ffffff"> <meta name="msapplication-TileImage" content="https://www.northstarnm.com/wp-content/themes/northstar/img/favicon/ms-icon-144x144.png"> <meta name="theme-color" content="#ffffff"> <meta name='robots' content='index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1' /> <!-- This site is optimized with the Yoast SEO Premium plugin v21.9 (Yoast SEO v23.9) - https://yoast.com/wordpress/plugins/seo/ --> <link rel="canonical" href="https://www.northstarnm.com/company/news/" /> <meta property="og:locale" content="en_US" /> <meta property="og:type" content="article" /> <meta property="og:title" content="News" /> <meta property="og:url" content="https://www.northstarnm.com/company/news/" /> <meta property="og:site_name" content="NorthStar Medical Radioisotopes, LLC" /> <meta property="article:modified_time" content="2023-10-17T14:33:40+00:00" /> <meta property="og:image" content="https://www.northstarnm.com/wp-content/uploads/2021/04/ns-logo.png" /> <meta property="og:image:width" content="1200" /> <meta property="og:image:height" content="630" /> <meta property="og:image:type" content="image/png" /> <meta name="twitter:card" content="summary_large_image" /> <meta name="twitter:site" content="@nmradioisotopes" /> <script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"WebPage","@id":"https://www.northstarnm.com/company/news/","url":"https://www.northstarnm.com/company/news/","name":"News","isPartOf":{"@id":"https://www.northstarnm.com/#website"},"datePublished":"2021-04-27T20:31:31+00:00","dateModified":"2023-10-17T14:33:40+00:00","breadcrumb":{"@id":"https://www.northstarnm.com/company/news/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https://www.northstarnm.com/company/news/"]}]},{"@type":"BreadcrumbList","@id":"https://www.northstarnm.com/company/news/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.northstarnm.com/"},{"@type":"ListItem","position":2,"name":"Company","item":"https://www.northstarnm.com/company/"},{"@type":"ListItem","position":3,"name":"News"}]},{"@type":"WebSite","@id":"https://www.northstarnm.com/#website","url":"https://www.northstarnm.com/","name":"NorthStar Medical Radioisotopes, LLC","description":"Emerging leader with new solutions in the field of nuclear medicine technology","publisher":{"@id":"https://www.northstarnm.com/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://www.northstarnm.com/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https://www.northstarnm.com/#organization","name":"NorthStar Medical Radioisotopes, LLC","url":"https://www.northstarnm.com/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https://www.northstarnm.com/#/schema/logo/image/","url":"https://mlbpbqwmetrq.i.optimole.com/vVi-zoA.OkzL~3164f/w:1200/h:630/q:mauto/https://www.northstarnm.com/wp-content/uploads/2021/04/ns-logo.png","contentUrl":"https://mlbpbqwmetrq.i.optimole.com/vVi-zoA.OkzL~3164f/w:1200/h:630/q:mauto/https://www.northstarnm.com/wp-content/uploads/2021/04/ns-logo.png","width":1200,"height":630,"caption":"NorthStar Medical Radioisotopes, LLC"},"image":{"@id":"https://www.northstarnm.com/#/schema/logo/image/"},"sameAs":["https://x.com/nmradioisotopes","https://www.linkedin.com/company/northstar-medical-radioisotopes-llc/","https://www.instagram.com/northstarmedicalradioisotopes/"]}]}</script> <!-- / Yoast SEO Premium plugin. --> <style id='classic-theme-styles-inline-css' type='text/css'> /*! This file is auto-generated */ .wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none} </style> <style id='global-styles-inline-css' type='text/css'> :root{--wp--preset--aspect-ratio--square: 1;--wp--preset--aspect-ratio--4-3: 4/3;--wp--preset--aspect-ratio--3-4: 3/4;--wp--preset--aspect-ratio--3-2: 3/2;--wp--preset--aspect-ratio--2-3: 2/3;--wp--preset--aspect-ratio--16-9: 16/9;--wp--preset--aspect-ratio--9-16: 9/16;--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;--wp--preset--spacing--20: 0.44rem;--wp--preset--spacing--30: 0.67rem;--wp--preset--spacing--40: 1rem;--wp--preset--spacing--50: 1.5rem;--wp--preset--spacing--60: 2.25rem;--wp--preset--spacing--70: 3.38rem;--wp--preset--spacing--80: 5.06rem;--wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);--wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);--wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);--wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1), 6px 6px rgba(0, 0, 0, 1);--wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);}:where(.is-layout-flex){gap: 0.5em;}:where(.is-layout-grid){gap: 0.5em;}body .is-layout-flex{display: flex;}.is-layout-flex{flex-wrap: wrap;align-items: center;}.is-layout-flex > :is(*, div){margin: 0;}body .is-layout-grid{display: grid;}.is-layout-grid > :is(*, div){margin: 0;}:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;} :where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;} :where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;} :root :where(.wp-block-pullquote){font-size: 1.5em;line-height: 1.6;} </style> <link rel='stylesheet' id='wp-pagenavi-css' href='https://www.northstarnm.com/wp-content/plugins/wp-pagenavi/pagenavi-css.css?ver=2.70' type='text/css' media='all' /> <link rel='stylesheet' id='search-filter-plugin-styles-css' href='https://www.northstarnm.com/wp-content/plugins/search-filter-pro/public/assets/css/search-filter.min.css?ver=2.5.17' type='text/css' media='all' /> <script type="text/javascript" src="https://www.northstarnm.com/wp-includes/js/jquery/jquery.min.js?ver=3.7.1" id="jquery-core-js"></script> <script type="text/javascript" src="https://www.northstarnm.com/wp-includes/js/jquery/jquery-migrate.min.js?ver=3.4.1" id="jquery-migrate-js"></script> <script type="text/javascript" id="search-filter-plugin-build-js-extra"> /* <![CDATA[ */ var SF_LDATA = {"ajax_url":"https:\/\/www.northstarnm.com\/wp-admin\/admin-ajax.php","home_url":"https:\/\/www.northstarnm.com\/","extensions":[]}; /* ]]> */ </script> <script type="text/javascript" src="https://www.northstarnm.com/wp-content/plugins/search-filter-pro/public/assets/js/search-filter-build.min.js?ver=2.5.17" id="search-filter-plugin-build-js"></script> <script type="text/javascript" src="https://www.northstarnm.com/wp-content/plugins/search-filter-pro/public/assets/js/chosen.jquery.min.js?ver=2.5.17" id="search-filter-plugin-chosen-js"></script> <style type="text/css" id="wp-custom-css"> .wpforms-submit { color: #fff !important; border-radius: 0 !important; background-color: #4471c0 !important; border-color: !important; font-size: 12px !important; font-weight: 700 !important; text-transform: uppercase !important; padding: 13px 29px !important; } </style> <script src="https://www.northstarnm.com/wp-content/themes/northstar/js/svg-inject.min.js"></script> <link rel="preconnect" href="https://fonts.gstatic.com"> <link href="https://fonts.googleapis.com/css2?family=Montserrat:wght@100;200;300;400;500;600;700&display=swap" rel="stylesheet"> <link rel="stylesheet" href="https://www.northstarnm.com/wp-content/themes/northstar/styles/css/northstar.css?1163160200" /> </head> <body class="page-template-default page page-id-10973 page-parent page-child parent-pageid-10971 page-news top-parent-10971" id="theme-md-blue"> <!-- Google Tag Manager (noscript) --> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-PBBCFFM" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> <nav class="pushy pushy-right" data-focus="#first-link"> <div class="pushy-content"> <ul class="closemenu"> <li><a class="menu-btn" data-dismiss="modal" title="main menu"><i class="far fa-times-square"></i> Close</a> </li> </ul> <ul id="menu-main-menu" class="nav navbar-nav navbar-right nav-primary" itemscope itemtype="http://www.schema.org/SiteNavigationElement"><li id="menu-item-12125" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children dropdown menu-item-12125 nav-item"><a href="https://www.northstarnm.com/radiopharmaceutical-therapy/" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle nav-link" id="menu-item-dropdown-12125"><span itemprop="name">Radiopharmaceutical Therapy</span></a> <ul class="dropdown-menu" aria-labelledby="menu-item-dropdown-12125"> <li id="menu-item-12771" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12771 nav-item"><a itemprop="url" href="https://www.northstarnm.com/radiopharmaceutical-therapy/" class="dropdown-item"><span itemprop="name">Overview</span></a></li> <li id="menu-item-12776" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12776 nav-item"><a itemprop="url" href="https://www.northstarnm.com/radiopharmaceutical-therapy/the-science/" class="dropdown-item"><span itemprop="name">The Science</span></a></li> <li id="menu-item-12775" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12775 nav-item"><a itemprop="url" href="https://www.northstarnm.com/radiopharmaceutical-therapy/why-northstar/" class="dropdown-item"><span itemprop="name">Why NorthStar</span></a></li> <li id="menu-item-12777" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12777 nav-item"><a itemprop="url" href="https://www.northstarnm.com/radiopharmaceutical-therapy/actinium-225/" class="dropdown-item"><span itemprop="name">Actinium-225</span></a></li> <li id="menu-item-12773" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12773 nav-item"><a itemprop="url" href="https://www.northstarnm.com/radiopharmaceutical-therapy/copper-67/" class="dropdown-item"><span itemprop="name">Copper-67</span></a></li> <li id="menu-item-12772" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12772 nav-item"><a itemprop="url" href="https://www.northstarnm.com/radiopharmaceutical-therapy/scientific-advisors/" class="dropdown-item"><span itemprop="name">Scientific Advisors</span></a></li> </ul> </li> <li id="menu-item-12604" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12604 nav-item"><a itemprop="url" href="https://www.northstarnm.com/cdmo-cmo/" class="nav-link"><span itemprop="name">CDMO/CMO</span></a></li> <li id="menu-item-10982" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children dropdown menu-item-10982 nav-item"><a href="https://www.northstarnm.com/development/" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle nav-link" id="menu-item-dropdown-10982"><span itemprop="name">Development</span></a> <ul class="dropdown-menu" aria-labelledby="menu-item-dropdown-10982"> <li id="menu-item-11449" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-11449 nav-item"><a itemprop="url" href="https://www.northstarnm.com/development/" class="dropdown-item"><span itemprop="name">Overview</span></a></li> <li id="menu-item-11154" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-11154 nav-item"><a itemprop="url" href="https://www.northstarnm.com/development/manufacturing/" class="dropdown-item"><span itemprop="name">Manufacturing</span></a></li> <li id="menu-item-12817" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12817 nav-item"><a itemprop="url" href="https://www.northstarnm.com/development/radiopharma-development/" class="dropdown-item"><span itemprop="name">Radiopharma Development</span></a></li> <li id="menu-item-11153" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-11153 nav-item"><a itemprop="url" href="https://www.northstarnm.com/development/pipeline/" class="dropdown-item"><span itemprop="name">Pipeline</span></a></li> </ul> </li> <li id="menu-item-10981" class="menu-item menu-item-type-post_type menu-item-object-page current-page-ancestor current-menu-ancestor current-menu-parent current-page-parent current_page_parent current_page_ancestor menu-item-has-children dropdown active menu-item-10981 nav-item"><a href="https://www.northstarnm.com/company/" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle nav-link" id="menu-item-dropdown-10981"><span itemprop="name">Company</span></a> <ul class="dropdown-menu" aria-labelledby="menu-item-dropdown-10981"> <li id="menu-item-11448" class="menu-item menu-item-type-post_type menu-item-object-page current-page-ancestor current-page-parent menu-item-11448 nav-item"><a itemprop="url" href="https://www.northstarnm.com/company/" class="dropdown-item"><span itemprop="name">Overview</span></a></li> <li id="menu-item-11236" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-11236 nav-item"><a itemprop="url" href="https://www.northstarnm.com/company/leadership/" class="dropdown-item"><span itemprop="name">Leadership</span></a></li> <li id="menu-item-11235" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-10973 current_page_item active menu-item-11235 nav-item"><a itemprop="url" href="https://www.northstarnm.com/company/news/" class="dropdown-item" aria-current="page"><span itemprop="name">News</span></a></li> <li id="menu-item-11233" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-11233 nav-item"><a itemprop="url" href="https://www.northstarnm.com/company/facilities/" class="dropdown-item"><span itemprop="name">Facilities</span></a></li> <li id="menu-item-11421" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-11421 nav-item"><a itemprop="url" href="https://www.northstarnm.com/company/library/" class="dropdown-item"><span itemprop="name">Library</span></a></li> <li id="menu-item-11234" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-11234 nav-item"><a itemprop="url" href="https://www.northstarnm.com/company/contact-us/" class="dropdown-item"><span itemprop="name">Contact Us</span></a></li> </ul> </li> <li id="menu-item-10980" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-10980 nav-item"><a itemprop="url" href="https://www.northstarnm.com/careers/" class="nav-link"><span itemprop="name">Careers</span></a></li> <li id="menu-item-10984" class="searchlink menu-item menu-item-type-custom menu-item-object-custom menu-item-10984 nav-item"><a itemprop="url" href="#search" class="nav-link"><span itemprop="name"><i class="fas fa-search"></i> <span class="navhide">Search</span></span></a></li> </ul> <!-- <ul class="mobile-search"> <li> <form method="get" id="searchform" action="https://www.northstarnm.com" role="search"> <div class="input-group"> <input type="text" class="form-control" placeholder="What are you looking for?" name="s" id="s"> <div class="input-group-btn"> <button class="btn btn-default" type="submit"><i class="glyphicon glyphicon-search"></i></button> </div> </div> </form> </li> </ul> --> </div> </nav> <div class="site-overlay"></div> <div id="container"> <div class="searchdiv"><form method="get" id="searchform" action="https://www.northstarnm.com"> <label for="s" class="screen-reader">Search</label> <input type="search" value="" name="s" id="s" placeholder="Search..." class=""> </form></div> <div class="head-wrap"> <nav class="static-top navbar navbar-expand flex-column flex-md-row"> <div class="container"> <div class="navbar-header"> <a class="menu-btn"><i class="fa fa-bars"></i></a> <a class="navbar-brand" href="https://www.northstarnm.com"><img src="https://www.northstarnm.com/wp-content/themes/northstar/img/logo-w.svg" alt="NorthStar Medical Radioisotopes, LLC Logo" title="NorthStar Medical Radioisotopes, LLC" /></a> </div> <div class="navbar-collapse collapse"> <div class="navbar-nav ml-md-auto"> <ul id="menu-main-menu-1" class="nav navbar-nav navbar-right nav-primary" itemscope itemtype="http://www.schema.org/SiteNavigationElement"><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children dropdown menu-item-12125 nav-item"><a href="https://www.northstarnm.com/radiopharmaceutical-therapy/" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle nav-link" id="menu-item-dropdown-12125"><span itemprop="name">Radiopharmaceutical Therapy</span></a> <ul class="dropdown-menu" aria-labelledby="menu-item-dropdown-12125"> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12771 nav-item"><a itemprop="url" href="https://www.northstarnm.com/radiopharmaceutical-therapy/" class="dropdown-item"><span itemprop="name">Overview</span></a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12776 nav-item"><a itemprop="url" href="https://www.northstarnm.com/radiopharmaceutical-therapy/the-science/" class="dropdown-item"><span itemprop="name">The Science</span></a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12775 nav-item"><a itemprop="url" href="https://www.northstarnm.com/radiopharmaceutical-therapy/why-northstar/" class="dropdown-item"><span itemprop="name">Why NorthStar</span></a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12777 nav-item"><a itemprop="url" href="https://www.northstarnm.com/radiopharmaceutical-therapy/actinium-225/" class="dropdown-item"><span itemprop="name">Actinium-225</span></a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12773 nav-item"><a itemprop="url" href="https://www.northstarnm.com/radiopharmaceutical-therapy/copper-67/" class="dropdown-item"><span itemprop="name">Copper-67</span></a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12772 nav-item"><a itemprop="url" href="https://www.northstarnm.com/radiopharmaceutical-therapy/scientific-advisors/" class="dropdown-item"><span itemprop="name">Scientific Advisors</span></a></li> </ul> </li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12604 nav-item"><a itemprop="url" href="https://www.northstarnm.com/cdmo-cmo/" class="nav-link"><span itemprop="name">CDMO/CMO</span></a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children dropdown menu-item-10982 nav-item"><a href="https://www.northstarnm.com/development/" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle nav-link" id="menu-item-dropdown-10982"><span itemprop="name">Development</span></a> <ul class="dropdown-menu" aria-labelledby="menu-item-dropdown-10982"> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-11449 nav-item"><a itemprop="url" href="https://www.northstarnm.com/development/" class="dropdown-item"><span itemprop="name">Overview</span></a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-11154 nav-item"><a itemprop="url" href="https://www.northstarnm.com/development/manufacturing/" class="dropdown-item"><span itemprop="name">Manufacturing</span></a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12817 nav-item"><a itemprop="url" href="https://www.northstarnm.com/development/radiopharma-development/" class="dropdown-item"><span itemprop="name">Radiopharma Development</span></a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-11153 nav-item"><a itemprop="url" href="https://www.northstarnm.com/development/pipeline/" class="dropdown-item"><span itemprop="name">Pipeline</span></a></li> </ul> </li> <li class="menu-item menu-item-type-post_type menu-item-object-page current-page-ancestor current-menu-ancestor current-menu-parent current-page-parent current_page_parent current_page_ancestor menu-item-has-children dropdown active menu-item-10981 nav-item"><a href="https://www.northstarnm.com/company/" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle nav-link" id="menu-item-dropdown-10981"><span itemprop="name">Company</span></a> <ul class="dropdown-menu" aria-labelledby="menu-item-dropdown-10981"> <li class="menu-item menu-item-type-post_type menu-item-object-page current-page-ancestor current-page-parent menu-item-11448 nav-item"><a itemprop="url" href="https://www.northstarnm.com/company/" class="dropdown-item"><span itemprop="name">Overview</span></a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-11236 nav-item"><a itemprop="url" href="https://www.northstarnm.com/company/leadership/" class="dropdown-item"><span itemprop="name">Leadership</span></a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-10973 current_page_item active menu-item-11235 nav-item"><a itemprop="url" href="https://www.northstarnm.com/company/news/" class="dropdown-item" aria-current="page"><span itemprop="name">News</span></a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-11233 nav-item"><a itemprop="url" href="https://www.northstarnm.com/company/facilities/" class="dropdown-item"><span itemprop="name">Facilities</span></a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-11421 nav-item"><a itemprop="url" href="https://www.northstarnm.com/company/library/" class="dropdown-item"><span itemprop="name">Library</span></a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-11234 nav-item"><a itemprop="url" href="https://www.northstarnm.com/company/contact-us/" class="dropdown-item"><span itemprop="name">Contact Us</span></a></li> </ul> </li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-10980 nav-item"><a itemprop="url" href="https://www.northstarnm.com/careers/" class="nav-link"><span itemprop="name">Careers</span></a></li> <li class="searchlink menu-item menu-item-type-custom menu-item-object-custom menu-item-10984 nav-item"><a itemprop="url" href="#search" class="nav-link"><span itemprop="name"><i class="fas fa-search"></i> <span class="navhide">Search</span></span></a></li> </ul> </div> </div> </div> </nav> </div> <div class="container-subpage"> <section class="section-bg " > <div class="parallax-container section-parallax" data-parallax="scroll" data-position="top" data-bleed="10" data-image-src="https://www.northstarnm.com/wp-content/uploads/2021/06/bg-news-page-scaled.jpg" data-natural-width="891" data-natural-height="2560"></div> <div class="section-content "> <section class="h2_header_short"> <div class="container"> <div class="header-inner"> <a href="https://www.northstarnm.com/company/" class="h2_breadcrumb_link mb-2 white">Company</a> <h1 class="mb-5">NEWS, PRESS RELEASES & EVENTS<br><span>ARCHIVE</span></h1> <div class="h2_intro_box"> <p>View all of our news from our company&#8217;s rich history. Select what you would like to see from the sorting filter below:</p> </div> </div> </div> </section> <section class="m1_news py-normal "> <div class="container"> <div class="p-5 mb-3 bg-white-fade"> <div class="m1-title mb-5 black"> <h3>Sorting Controls</h3> </div> <ul class="nav nav-pills mb-3" id="pills-tab" role="tablist"> <li class="nav-item" role="presentation"> <a class="nav-link active" id="pills-pr-tab" data-toggle="pill" href="#pr" role="tab" aria-controls="pr" aria-selected="true">Press Releases</a> </li> <li class="nav-item" role="presentation"> <a class="nav-link" id="pills-events-tab" data-toggle="pill" href="#events" role="tab" aria-controls="events" aria-selected="false">Events & Presentations</a> </li> <li class="nav-item" role="presentation"> <a class="nav-link" id="pills-news-tab" data-toggle="pill" href="#news" role="tab" aria-controls="news" aria-selected="false">News</a> </li> <li class="nav-item" role="presentation"> <a class="nav-link" id="pills-social-tab" data-toggle="pill" href="#social" role="tab" aria-controls="social" aria-selected="false">Social Media</a> </li> </ul> <hr /> <div class="tab-content" id="pills-tabContent"> <div class="tab-pane fade" id="news" role="tabpanel" aria-labelledby="pills-news-tab"> <div class="row"> <div class="col-md-3 mb-4"> <div class="sticky-top"> <div class="filter-box"> <h3>Filter Your Results</h3> <form data-sf-form-id='533' data-is-rtl='0' data-maintain-state='' data-results-url='https://www.northstarnm.com/company/news/' data-ajax-url='https://www.northstarnm.com/?sfid=533&amp;sf_action=get_data&amp;sf_data=results' data-ajax-form-url='https://www.northstarnm.com/?sfid=533&amp;sf_action=get_data&amp;sf_data=form' data-display-result-method='shortcode' data-use-history-api='1' data-template-loaded='0' data-lang-code='en' data-ajax='1' data-ajax-data-type='json' data-ajax-links-selector='.pagination a' data-ajax-target='#search-filter-results-533' data-ajax-pagination-type='normal' data-update-ajax-url='0' data-only-results-ajax='1' data-scroll-to-pos='window' data-scroll-on-action='all' data-init-paged='1' data-auto-update='1' action='https://www.northstarnm.com/company/news/' method='post' class='searchandfilter' id='search-filter-form-533' autocomplete='off' data-instance-count='1'><ul><li class="sf-field-post_date" data-sf-field-name="_sf_post_date" data-sf-field-type="post_date" data-sf-field-input-type="daterange"><h4>Date Range</h4><ul class="sf_date_field" data-date-format="mm/dd/yy" data-date-use-year-dropdown='1' data-date-use-month-dropdown='1'><li> <label> <input placeholder="From" class="sf-datepicker sf-input-date sf-input-text" name="_sf_post_date[]" type="text" value="" title=""></label> </li><li> <label> <input placeholder="To" class="sf-datepicker sf-input-date sf-input-text" name="_sf_post_date[]" type="text" value="" title=""></label> </li></ul></li><li class="sf-field-search" data-sf-field-name="search" data-sf-field-type="search" data-sf-field-input-type=""><h4>What are you looking for?</h4> <label> <input placeholder="Search…" name="_sf_search[]" class="sf-input-text" type="text" value="" title=""></label> </li></ul></form></div> </div> </div> <div class="col-md-9"> <div class="search-filter-results" id="search-filter-results-533"> <div class="newsbar" id="results-533"> <div class="news-date"> January 22, 2024 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-enabling-radiopharmaceutical-company-success/" title="NorthStar Medical Radioisotopes: Enabling Radiopharmaceutical Company Success">NorthStar Medical Radioisotopes: Enabling Radiopharmaceutical Company Success</a> </div> <div class="news-excerpt"> <p>The exceptional promise of Radiopharmaceutical Therapy needs a robust and reliable infrastructure for radioisotope manufacture and related services. Stephen Merrick, Executive Chairman – NorthStar Medical Radioisotopes LLC An article by NorthStar Medical Radioisotopes LLC, an SNMMI Value Initiative Industry Alliance Principal Member Partner &nbsp; We see many articles and hear many presentations which describe the [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-enabling-radiopharmaceutical-company-success/" title="NorthStar Medical Radioisotopes: Enabling Radiopharmaceutical Company Success" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> December 13, 2023 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/utility-of-modeling-in-operational-health-physics/" title="Utility of Modeling in Operational Health Physics">Utility of Modeling in Operational Health Physics</a> </div> <div class="news-excerpt"> <p>Health Physics Society&#8217;s (HPS) Accelerator Section Newsletter Volume 33 Number 3 | Circulation: 166 Author: Shaun W. Kelley, CHP NorthStar Medical Radioisotopes &nbsp; Health Physicists (HPs) are required to make extensive use of models in their work to predict/estimate doses from many possible sources. Probably the most common models used are for shielding requirements and [&hellip;]</p> <p><a href="https://www.northstarnm.com/utility-of-modeling-in-operational-health-physics/" title="Utility of Modeling in Operational Health Physics" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> August 24, 2023 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/part-of-a-cancer-cure-wisconsin-doctor-discusses-growth-of-nuclear-medicine/" title="Part of a cancer cure? Wisconsin doctor discusses growth of nuclear medicine">Part of a cancer cure? Wisconsin doctor discusses growth of nuclear medicine</a> </div> <div class="news-excerpt"> <p>UW-Madison professor Dr. Steve Cho lauds new prostate cancer therapy, notes shortages of needed radioisotopes Radiation-emitting drugs, or radiopharmaceuticals, are increasingly used to target and kill cancer cells with positive results for patients. In July, during an appearance on Wisconsin Public Radio’s &#8220;The Morning Show,&#8221; the 2023 crowned Miss America Grace Stanke said her father’s [&hellip;]</p> <p><a href="https://www.northstarnm.com/part-of-a-cancer-cure-wisconsin-doctor-discusses-growth-of-nuclear-medicine/" title="Part of a cancer cure? Wisconsin doctor discusses growth of nuclear medicine" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> November 23, 2022 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/from-isotopes-to-internships-uw-madison-partnership-energizes-growing-wisconsin-company/" title="From isotopes to internships, UW-Madison partnership energizes growing Wisconsin company">From isotopes to internships, UW-Madison partnership energizes growing Wisconsin company</a> </div> <div class="news-excerpt"> <p>Written By: Adam Malecek College of Engineering, University of Wisconsin-Madison In late 2019, staff at Beloit, Wisconsin-based company NorthStar Medical Radioisotopes opened a package filled with radioactive materials. The delivery sparked an ongoing research collaboration with the University of Wisconsin-Madison that’s accelerating the company’s emergence into an increasingly important healthcare market. NorthStar produces medical radioisotopes [&hellip;]</p> <p><a href="https://www.northstarnm.com/from-isotopes-to-internships-uw-madison-partnership-energizes-growing-wisconsin-company/" title="From isotopes to internships, UW-Madison partnership energizes growing Wisconsin company" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> October 12, 2022 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/search-and-destroy/" title="Search and Destroy">Search and Destroy</a> </div> <div class="news-excerpt"> <p>Radionuclides that target and kill advanced prostate cancer cells show great promise. It is estimated that 34,500 men in the United States die from prostate cancer each year, making it the second leading cause of cancer death among males in America. Some prostate cancers are slow growing, but others are advanced (metastatic). Approximately one-half of [&hellip;]</p> <p><a href="https://www.northstarnm.com/search-and-destroy/" title="Search and Destroy" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> July 15, 2022 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/uwm-grads-help-provide-domestic-source-of-critical-medical-diagnostic-material/" title="UWM grads help provide domestic source of critical medical diagnostic material">UWM grads help provide domestic source of critical medical diagnostic material</a> </div> <div class="news-excerpt"> <p>A UW-Milwaukee chemistry professor and graduates of his lab are helping two Wisconsin companies produce a vital material that was until recently available only from foreign sources. The material is molybdenum-99, the parent of technetium-99m, the most widely used radioisotope in the world for diagnostic medical imaging, according to UWM Chemistry Professor Mark Dietz. (The [&hellip;]</p> <p><a href="https://www.northstarnm.com/uwm-grads-help-provide-domestic-source-of-critical-medical-diagnostic-material/" title="UWM grads help provide domestic source of critical medical diagnostic material" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 30, 2022 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-and-its-future-with-electron-accelerator-technology/" title="NorthStar and its Future with Electron Accelerator Technology">NorthStar and its Future with Electron Accelerator Technology</a> </div> <div class="news-excerpt"> <p>NorthStar Medical Radioisotopes is poised to become the first-in-class production supply chain for the future of therapeutic radiopharmaceuticals. In September 2019, the company broke ground on a 30,000 ft. building that now houses the company’s first pair of electron beam accelerators. This past September 2021, the company celebrated the successful installation of the accelerators as [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-and-its-future-with-electron-accelerator-technology/" title="NorthStar and its Future with Electron Accelerator Technology" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> August 2, 2021 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/delivering-on-the-promise-of-nuclear-medicine-new-solutions-for-patient-health/" title="Delivering on the Promise of Nuclear Medicine: New Solutions for Patient Health">Delivering on the Promise of Nuclear Medicine: New Solutions for Patient Health</a> </div> <div class="news-excerpt"> <p>This is an exciting time for nuclear medicine. PET and SPECT technologies are providing valuable insights about the molecular structure and function of the body and disease. Theranostics and therapeutic radiopharmaceuticals are expanding with growing scientific interest and public awareness. Read More&#8230;</p> <p><a href="https://www.northstarnm.com/delivering-on-the-promise-of-nuclear-medicine-new-solutions-for-patient-health/" title="Delivering on the Promise of Nuclear Medicine: New Solutions for Patient Health" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> May 19, 2021 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/beloit-company-reaches-major-milestone-in-medical-isotope-production/" title="Beloit company reaches &#8216;major milestone&#8217; in medical isotope production">Beloit company reaches &#8216;major milestone&#8217; in medical isotope production</a> </div> <div class="news-excerpt"> <p>BELOIT — In what’s being hailed as “a major milestone for nuclear medicine,” NorthStar Medical Radioisotopes has received a pair of high-tech machines that will be used to produce radioactive material used in millions of medical procedures each year. The 24-ton particle accelerators arrived in Beloit Tuesday on flatbed trucks, capping a 5,700-mile journey from [&hellip;]</p> <p><a href="https://www.northstarnm.com/beloit-company-reaches-major-milestone-in-medical-isotope-production/" title="Beloit company reaches &#8216;major milestone&#8217; in medical isotope production" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> May 6, 2020 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-construction-growth-strong-amid-covid-19/" title="NorthStar construction, growth strong amid COVID-19">NorthStar construction, growth strong amid COVID-19</a> </div> <div class="news-excerpt"> <p>BELOIT — Company growth at NorthStar Medical Radioisotopes remains uninterrupted by COVID-19, according to CEO Steve Merrick. Work continues at the headquarters on a new electron accelerator production building to expand capacity of the company’s non-uranium domestic supply of molybdenum-99 (Mo-99).  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/northstar-construction-growth-strong-amid-covid-19/" title="NorthStar construction, growth strong amid COVID-19" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 5, 2020 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-expands-into-cardiac-spect-with-new-licensing-deal/" title="NorthStar Expands Into Cardiac SPECT With New Licensing Deal">NorthStar Expands Into Cardiac SPECT With New Licensing Deal</a> </div> <div class="news-excerpt"> <p>NorthStar Medical Technologies is moving further into the cardiac imaging space after signing a new licensing agreement with St. Louis-based Capella Imaging, the companies announced Tuesday. As part of the deal, the Beloit, Wisconsin-based radioisotope company has acquired exclusive rights from Capella to develop and investigate a new fibrin-targeted diagnostic imaging agent used in single-photon [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-expands-into-cardiac-spect-with-new-licensing-deal/" title="NorthStar Expands Into Cardiac SPECT With New Licensing Deal" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> February 20, 2020 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/domestic-radioisotope-supply-driving-solutions-for-patient-healthcare-through-innovation-collaboration-and-shared-commitment/" title="Domestic Radioisotope Supply – Driving Solutions for Patient Healthcare through Innovation, Collaboration and Shared Commitment">Domestic Radioisotope Supply – Driving Solutions for Patient Healthcare through Innovation, Collaboration and Shared Commitment</a> </div> <div class="news-excerpt"> <p>When industry, academia, the U.S. government and scientific and professional societies share a common vision to address a medical supply need, the results can benefit patient healthcare. Such was the case in securing a reliable domestic supply of molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), for the United States. Read more&#8230;</p> <p><a href="https://www.northstarnm.com/domestic-radioisotope-supply-driving-solutions-for-patient-healthcare-through-innovation-collaboration-and-shared-commitment/" title="Domestic Radioisotope Supply – Driving Solutions for Patient Healthcare through Innovation, Collaboration and Shared Commitment" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> December 12, 2018 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/molecular-imaging-news-a-new-link-in-the-chain/" title="Molecular Imaging News: A New Link in the Chain">Molecular Imaging News: A New Link in the Chain</a> </div> <div class="news-excerpt"> <p>Medical radioisotopes are crucial components of modern health care, but the supply chain that ensures access to them is fragile. For example, SNMMI issued a molybdenum-99 (Mo-99) shortage alert for the first half of November, due to a continuing outage at a reactor in South Africa and an unanticipated shutdown of a reactor in the [&hellip;]</p> <p><a href="https://www.northstarnm.com/molecular-imaging-news-a-new-link-in-the-chain/" title="Molecular Imaging News: A New Link in the Chain" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> May 14, 2018 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/made-in-the-usa-department-of-energy-labs-help-advance-technology-to-ensure-supply-of-key-medical-isotopes/" title="Made in the USA: Department of Energy Labs Help Advance Technology to Ensure Supply of Key Medical Isotopes">Made in the USA: Department of Energy Labs Help Advance Technology to Ensure Supply of Key Medical Isotopes</a> </div> <div class="news-excerpt"> <p>&#8211; ORNL, others provide R&amp;D help to make molybdenum-99 and technetium-99m without highly enriched uranium &#8211; “Made in the USA.” That can now be said of the radioactive isotope molybdenum-99 (Mo-99), last made in the United States in the late 1980s.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/made-in-the-usa-department-of-energy-labs-help-advance-technology-to-ensure-supply-of-key-medical-isotopes/" title="Made in the USA: Department of Energy Labs Help Advance Technology to Ensure Supply of Key Medical Isotopes" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 30, 2018 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/fda-clears-path-for-first-domestic-supply-of-tc-99m-isotope/" title="FDA Clears Path for First Domestic Supply of Tc-99m Isotope">FDA Clears Path for First Domestic Supply of Tc-99m Isotope</a> </div> <div class="news-excerpt"> <p>The U.S. Food and Drug Administration (FDA) and the Nuclear Regulatory Commission (NRC) took steps in February to ensure a stable and secure supply of a critical radioactive imaging tracer used to detect potentially life-threatening diseases.  Read more&#8230; </p> <p><a href="https://www.northstarnm.com/fda-clears-path-for-first-domestic-supply-of-tc-99m-isotope/" title="FDA Clears Path for First Domestic Supply of Tc-99m Isotope" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> February 21, 2018 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/fda-approves-new-way-to-make-medical-imaging-isotope/" title="FDA approves new way to make medical imaging isotope">FDA approves new way to make medical imaging isotope</a> </div> <div class="news-excerpt"> <p>&#8211; System will be the US’s first domestic source of molybdenum-99 for 30 years &#8211; The US Food and Drug Administration (FDA) has approved a new system for generating the diagnostic radioisotope technetium-99m that it hopes will address shortages.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/fda-approves-new-way-to-make-medical-imaging-isotope/" title="FDA approves new way to make medical imaging isotope" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> February 9, 2018 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/fda-nod-for-northstar-device-clears-way-to-make-medical-radioisotope/" title="FDA Nod for NorthStar Device Clears Way to Make Medical Radioisotope">FDA Nod for NorthStar Device Clears Way to Make Medical Radioisotope</a> </div> <div class="news-excerpt"> <p>A Wisconsin company has moved one step closer to becoming the first domestic producer in decades of a crucial medical radioisotope after receiving a key approval from the FDA on Thursday.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/fda-nod-for-northstar-device-clears-way-to-make-medical-radioisotope/" title="FDA Nod for NorthStar Device Clears Way to Make Medical Radioisotope" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> February 8, 2018 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/u-s-oks-medical-isotope-system-not-based-on-bomb-grade-uranium/" title="U.S. OKs medical isotope system not based on bomb-grade uranium">U.S. OKs medical isotope system not based on bomb-grade uranium</a> </div> <div class="news-excerpt"> <p>WASHINGTON (Reuters) &#8211; The U.S. federal government on Thursday approved a device made by a private company in Wisconsin that will allow the first domestic production of a medical imaging isotope in 25 years, a move the government said would enhance national security by reducing the need to transport weapons-grade uranium. Read more&#8230;</p> <p><a href="https://www.northstarnm.com/u-s-oks-medical-isotope-system-not-based-on-bomb-grade-uranium/" title="U.S. OKs medical isotope system not based on bomb-grade uranium" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> February 8, 2018 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/doe-nnsa-partnership-u-s-healthcare-industry-results-fda-approval-domestically-produced-non-uranium-based-molybdenum-99-2/" title="DOE/NNSA Partnership With U.S. Healthcare Industry Results in FDA Approval of Domestically-Produced, Non-Uranium Based Molybdenum-99">DOE/NNSA Partnership With U.S. Healthcare Industry Results in FDA Approval of Domestically-Produced, Non-Uranium Based Molybdenum-99</a> </div> <div class="news-excerpt"> <p>WASHINGTON – Efforts by the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) to ensure a reliable supply of a vital medical isotope have paved the way for today’s announcement by the U.S. Food and Drug Administration (FDA) on the approval of the first domestically-produced, non-uranium based molybdenum-99 (Mo-99). Read more&#8230;</p> <p><a href="https://www.northstarnm.com/doe-nnsa-partnership-u-s-healthcare-industry-results-fda-approval-domestically-produced-non-uranium-based-molybdenum-99-2/" title="DOE/NNSA Partnership With U.S. Healthcare Industry Results in FDA Approval of Domestically-Produced, Non-Uranium Based Molybdenum-99" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> February 8, 2018 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/statement-fda-commissioner-scott-gottlieb-m-d-groundbreaking-approval-interagency-approach-bring-stable-supply-critical-medical-imaging-isotope-u-s/" title="Statement from FDA Commissioner Scott Gottlieb, M.D., on groundbreaking approval and interagency approach to bring stable supply of critical medical imaging isotope to the U.S.">Statement from FDA Commissioner Scott Gottlieb, M.D., on groundbreaking approval and interagency approach to bring stable supply of critical medical imaging isotope to the U.S.</a> </div> <div class="news-excerpt"> <p>Today, I’m proud to acknowledge the role the FDA played in the groundbreaking effort to develop a new imaging technology – the RadioGenix System. Read more&#8230;</p> <p><a href="https://www.northstarnm.com/statement-fda-commissioner-scott-gottlieb-m-d-groundbreaking-approval-interagency-approach-bring-stable-supply-critical-medical-imaging-isotope-u-s/" title="Statement from FDA Commissioner Scott Gottlieb, M.D., on groundbreaking approval and interagency approach to bring stable supply of critical medical imaging isotope to the U.S." class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> February 8, 2018 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/doe-nnsa-partnership-u-s-healthcare-industry-results-fda-approval-domestically-produced-non-uranium-based-molybdenum-99/" title="DOE/NNSA partnership with U.S. healthcare industry results in FDA approval of domestically-produced, non-uranium based Molybdenum-99">DOE/NNSA partnership with U.S. healthcare industry results in FDA approval of domestically-produced, non-uranium based Molybdenum-99</a> </div> <div class="news-excerpt"> <p>WASHINGTON – Efforts by the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA) to ensure a reliable supply of a vital medical isotope have paved the way for today’s announcement by the U.S. Food and Drug Administration (FDA) on the approval of the first domestically-produced, non-uranium based molybdenum-99 (Mo-99). Read more&#8230;</p> <p><a href="https://www.northstarnm.com/doe-nnsa-partnership-u-s-healthcare-industry-results-fda-approval-domestically-produced-non-uranium-based-molybdenum-99/" title="DOE/NNSA partnership with U.S. healthcare industry results in FDA approval of domestically-produced, non-uranium based Molybdenum-99" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> February 8, 2018 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/fda-media-availability/" title="FDA Media Availability">FDA Media Availability</a> </div> <div class="news-excerpt"> <p>FDA Media Transcripts:  https://www.fda.gov/NewsEvents/Newsroom/MediaTranscripts/default.htm Listen to FDA Media Briefing: [player id=1469]</p> <p><a href="https://www.northstarnm.com/fda-media-availability/" title="FDA Media Availability" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> February 8, 2018 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/fda-nrc-pave-way-first-domestic-supply-commonly-used-medical-isotope-diagnostic-imaging/" title="FDA and NRC pave way for the first domestic supply of the most commonly used medical isotope in diagnostic imaging">FDA and NRC pave way for the first domestic supply of the most commonly used medical isotope in diagnostic imaging</a> </div> <div class="news-excerpt"> <p>FDA and NRC pave way for the first domestic supply of the most commonly used medical isotope in diagnostic imaging.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/fda-nrc-pave-way-first-domestic-supply-commonly-used-medical-isotope-diagnostic-imaging/" title="FDA and NRC pave way for the first domestic supply of the most commonly used medical isotope in diagnostic imaging" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> July 22, 2016 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/intuitive-petg-thermoformed-package-shines-for-northstar/" title="Intuitive PETG Thermoformed Package Shines for NorthStar">Intuitive PETG Thermoformed Package Shines for NorthStar</a> </div> <div class="news-excerpt"> <p>NorthStar Medical Radioisotopes’ Radiogenix™ Isotope Separation System’s product packaging is convenient, intuitive, creative and unconventional.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/intuitive-petg-thermoformed-package-shines-for-northstar/" title="Intuitive PETG Thermoformed Package Shines for NorthStar" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> November 14, 2014 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/nnsa-announces-funding-isotope-projects/" title="NNSA announces funding for isotope projects">NNSA announces funding for isotope projects</a> </div> <div class="news-excerpt"> <p>According to NNSA, NorthStar Medical Radioisotopes is to receive $5.2 million to further develop its technology to produce Mo-99 via neutron capture, bringing the total NNSA support for the project to $16.1 million to date.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/nnsa-announces-funding-isotope-projects/" title="NNSA announces funding for isotope projects" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> August 18, 2014 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-will-supply-ge-mo-99/" title="NorthStar will supply GE with Mo-99">NorthStar will supply GE with Mo-99</a> </div> <div class="news-excerpt"> <p>NorthStar also signed a similar agreement with Triad Isotopes, Inc. in June.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/northstar-will-supply-ge-mo-99/" title="NorthStar will supply GE with Mo-99" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> August 14, 2014 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-signs-letter-intent-ge-healthcare/" title="NorthStar Medical Radioisotopes Signs Letter of Intent with GE Healthcare">NorthStar Medical Radioisotopes Signs Letter of Intent with GE Healthcare</a> </div> <div class="news-excerpt"> <p>MADISON, Wis., Aug 14, 2014 (BUSINESS WIRE) &#8212; NorthStar Medical Radioisotopes LLC has signed a non-exclusive letter of intent with GE Healthcare, a division of General Electric Company GE, -0.42% marking further progress toward establishing the first existing commercially viable domestic source of the radioisotope 99molybdenum (99Mo).  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-signs-letter-intent-ge-healthcare/" title="NorthStar Medical Radioisotopes Signs Letter of Intent with GE Healthcare" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> July 17, 2014 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-building-begin/" title="NorthStar building to begin">NorthStar building to begin</a> </div> <div class="news-excerpt"> <p>Twelve years ago George Messina met with a scientist about a new patent that would likely change how medical diagnostic testing would be done in the United States.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/northstar-building-begin/" title="NorthStar building to begin" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> July 16, 2014 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/north-star-medical-expansion-bring-150-jobs-beloit/" title="North Star Medical Expansion to Bring 150 Jobs to Beloit">North Star Medical Expansion to Bring 150 Jobs to Beloit</a> </div> <div class="news-excerpt"> <p>BELOIT (WIFR) &#8212; One medical company is bringing more jobs to the Beloit area, but that may not be the biggest factor of the move.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/north-star-medical-expansion-bring-150-jobs-beloit/" title="North Star Medical Expansion to Bring 150 Jobs to Beloit" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> July 16, 2014 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-breaks-ground-new-facility-beloit-wis-2/" title="NorthStar Medical Radioisotopes: Breaks ground for new facility in Beloit, Wis.">NorthStar Medical Radioisotopes: Breaks ground for new facility in Beloit, Wis.</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. – NorthStar Medical Radioisotopes LLC broke ground today for a new 50,000-square-foot facility at 1800 Gateway Blvd. in Beloit, Wis. When completed in late 2014, the facility will house the company’s headquarters and activities related to the production of the medical radioisotope molybdenum-99 (Mo-99).  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-breaks-ground-new-facility-beloit-wis-2/" title="NorthStar Medical Radioisotopes: Breaks ground for new facility in Beloit, Wis." class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> May 22, 2012 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/wanted-money-entrepreneurs/" title="Wanted: Money for entrepreneurs">Wanted: Money for entrepreneurs</a> </div> <div class="news-excerpt"> <p>Everybody loves the entrepreneur, the little guy or gal with the big idea who launches and expands a business. Politicians of every stripe correctly tout start-up companies as key to creating more jobs.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/wanted-money-entrepreneurs/" title="Wanted: Money for entrepreneurs" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> November 5, 2011 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/race-isotope-shows-wisconsins-strength/" title="Race for isotope shows Wisconsin&#8217;s strength">Race for isotope shows Wisconsin&#8217;s strength</a> </div> <div class="news-excerpt"> <p>What does it say about a state&#8217;s innovation-based economy when it boasts not one but two of the four U.S. companies racing to produce a medical isotope so essential that it&#8217;s used in 50,000 clinical tests per day?  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/race-isotope-shows-wisconsins-strength/" title="Race for isotope shows Wisconsin&#8217;s strength" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> November 1, 2011 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/nnsa-signs-cooperative-agreement-produce-molybdenum-99-united-states-without-use-highly-enriched-uranium/" title="NNSA Signs Cooperative Agreement to Produce Molybdenum-99 in the United States without the use of Highly Enriched Uranium">NNSA Signs Cooperative Agreement to Produce Molybdenum-99 in the United States without the use of Highly Enriched Uranium</a> </div> <div class="news-excerpt"> <p>WASHINGTON, D.C. – The National Nuclear Security Administration’s (NNSA) Global Threat Reduction Initiative announced today the signing of a cooperative agreement with NorthStar Medical Radioisotopes, LLC, to further the development of accelerator-based technology to produce molybdenum-99 (Mo-99) in the United States.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/nnsa-signs-cooperative-agreement-produce-molybdenum-99-united-states-without-use-highly-enriched-uranium/" title="NNSA Signs Cooperative Agreement to Produce Molybdenum-99 in the United States without the use of Highly Enriched Uranium" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> November 1, 2011 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/nuclear-agency-share-cost-developing-beloit-plant/" title="Nuclear agency to share cost of developing Beloit plant">Nuclear agency to share cost of developing Beloit plant</a> </div> <div class="news-excerpt"> <p>NorthStar Medical Radioisotopes LLC said Tuesday it has signed a $4.6 million agreement with the National Nuclear Security Administration that will help the Madison company develop architectural and site plans for a Beloit plant to produce medical isotopes.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/nuclear-agency-share-cost-developing-beloit-plant/" title="Nuclear agency to share cost of developing Beloit plant" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 18, 2011 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-finds-way-produce-medical-isotope-quickly-safely/" title="NorthStar Finds Way to Produce Medical Isotope Quickly, Safely">NorthStar Finds Way to Produce Medical Isotope Quickly, Safely</a> </div> <div class="news-excerpt"> <p>As problems go, NorthStar Medical Radioisotopes LLC was founded on a big one. Production issues at several nuclear power plants outside the U.S. during the last few years and worries about nuclear proliferation prompted the federal government in 2009 to look for ways to make a critical medical isotope more safely and closer to home.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/northstar-finds-way-produce-medical-isotope-quickly-safely/" title="NorthStar Finds Way to Produce Medical Isotope Quickly, Safely" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 12, 2011 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-produce-mo-99-isotope-ge-hitachi-exelon/" title="NorthStar to produce Mo-99 isotope with GE Hitachi, Exelon">NorthStar to produce Mo-99 isotope with GE Hitachi, Exelon</a> </div> <div class="news-excerpt"> <p>NorthStar Medical Radioisotopes has entered a tentative deal with GE Hitachi Nuclear Energy and Exelon for the production of the medical isotope molybdenum-99.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/northstar-produce-mo-99-isotope-ge-hitachi-exelon/" title="NorthStar to produce Mo-99 isotope with GE Hitachi, Exelon" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 12, 2011 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-produce-mo-99-isotope/" title="Beloit plant could produce key medical isotope">Beloit plant could produce key medical isotope</a> </div> <div class="news-excerpt"> <p>NorthStar Medical Radioisotopes LLC, a Madison nuclear medicine company, has signed a tentative agreement for its Beloit facility to process radioactive material into a key isotope used for medical procedures.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/northstar-produce-mo-99-isotope/" title="Beloit plant could produce key medical isotope" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> August 11, 2011 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/bioforward-announces-winners-2011-bioscience-vision-summits-emerging-company-showcase/" title="BioForward Announces Winners of 2011 Bioscience Vision Summit&#8217;s Emerging Company Showcase">BioForward Announces Winners of 2011 Bioscience Vision Summit&#8217;s Emerging Company Showcase</a> </div> <div class="news-excerpt"> <p>MADISON, Wis.&#8211;(BUSINESS WIRE)&#8211;Six Wisconsin bioscience companies have been selected as the winners of BioForward’s 2011 Emerging Company Showcase.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/bioforward-announces-winners-2011-bioscience-vision-summits-emerging-company-showcase/" title="BioForward Announces Winners of 2011 Bioscience Vision Summit&#8217;s Emerging Company Showcase" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 22, 2011 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/high-tech-jobs-may-coming-beloit/" title="High tech jobs may be coming to Beloit">High tech jobs may be coming to Beloit</a> </div> <div class="news-excerpt"> <p>NorthStar Medical Radioisotopes, LLC plans to locate a new 82,000 square foot production facility in Beloit. Read more&#8230;</p> <p><a href="https://www.northstarnm.com/high-tech-jobs-may-coming-beloit/" title="High tech jobs may be coming to Beloit" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 22, 2011 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-build-194-million-plant-beloit/" title="NorthStar Medical to build $194 million plant in Beloit">NorthStar Medical to build $194 million plant in Beloit</a> </div> <div class="news-excerpt"> <p>NorthStar Medical Radioisotopes LLC is planning to build a $194 million production plant in Beloit that could employ as many as 150 people by 2016. Read more&#8230;</p> <p><a href="https://www.northstarnm.com/northstar-medical-build-194-million-plant-beloit/" title="NorthStar Medical to build $194 million plant in Beloit" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 22, 2011 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-firm-build-plant-beloit/" title="NorthStar medical firm to build plant in Beloit">NorthStar medical firm to build plant in Beloit</a> </div> <div class="news-excerpt"> <p>NorthStar Medical Radioisotopes, Madison, will build an 82,000-square-foot manufacturing plant in Beloit.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/northstar-medical-firm-build-plant-beloit/" title="NorthStar medical firm to build plant in Beloit" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 22, 2011 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-build-194-million-radioisotopes-plant-beloit/" title="NorthStar Medical to build $194 million radioisotopes plant in Beloit">NorthStar Medical to build $194 million radioisotopes plant in Beloit</a> </div> <div class="news-excerpt"> <p>NorthStar Medical Radioisotopes LLC is planning to build a $194 million production plant in Beloit that could employ as many as 150 workers by 2016. Read more&#8230;</p> <p><a href="https://www.northstarnm.com/northstar-medical-build-194-million-radioisotopes-plant-beloit/" title="NorthStar Medical to build $194 million radioisotopes plant in Beloit" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 22, 2011 &nbsp; &nbsp; &nbsp; News </div> <div class="news-title"> <a href="https://www.northstarnm.com/high-tech-firm-picks-beloit-194-million-development/" title="High-tech firm picks Beloit for $194 million development">High-tech firm picks Beloit for $194 million development</a> </div> <div class="news-excerpt"> <p>A highly-specialized company serving the needs of the nuclear medicine market plans to locate its $194 million, 82,000-square foot production facility in Beloit.  Read more&#8230;</p> <p><a href="https://www.northstarnm.com/high-tech-firm-picks-beloit-194-million-development/" title="High-tech firm picks Beloit for $194 million development" class="read-more">Read more &raquo;</a></p> </div> <hr> </div> </div> </div> </div> </div> <div class="tab-pane fade show active" id="pr" role="tabpanel" aria-labelledby="pills-pr-tab"> <div class="row"> <div class="col-md-3 mb-4"> <div class="sticky-top"> <div class="filter-box"> <h3>Filter Your Results</h3> <form data-sf-form-id='546' data-is-rtl='0' data-maintain-state='' data-results-url='https://www.northstarnm.com/company/news/' data-ajax-url='https://www.northstarnm.com/?sfid=546&amp;sf_action=get_data&amp;sf_data=results' data-ajax-form-url='https://www.northstarnm.com/?sfid=546&amp;sf_action=get_data&amp;sf_data=form' data-display-result-method='shortcode' data-use-history-api='1' data-template-loaded='0' data-lang-code='en' data-ajax='1' data-ajax-data-type='json' data-ajax-links-selector='.pagination a' data-ajax-target='#search-filter-results-546' data-ajax-pagination-type='normal' data-update-ajax-url='0' data-only-results-ajax='1' data-scroll-to-pos='window' data-scroll-on-action='all' data-init-paged='1' data-auto-update='1' action='https://www.northstarnm.com/company/news/' method='post' class='searchandfilter' id='search-filter-form-546' autocomplete='off' data-instance-count='1'><ul><li class="sf-field-post_date" data-sf-field-name="_sf_post_date" data-sf-field-type="post_date" data-sf-field-input-type="daterange"><h4>Date Range</h4><ul class="sf_date_field" data-date-format="mm/dd/yy" data-date-use-year-dropdown='1' data-date-use-month-dropdown='0'><li> <label> <input placeholder="From" class="sf-datepicker sf-input-date sf-input-text" name="_sf_post_date[]" type="text" value="" title=""></label> </li><li> <label> <input placeholder="To" class="sf-datepicker sf-input-date sf-input-text" name="_sf_post_date[]" type="text" value="" title=""></label> </li></ul></li><li class="sf-field-search" data-sf-field-name="search" data-sf-field-type="search" data-sf-field-input-type=""><h4>What are you looking?</h4> <label> <input placeholder="Search…" name="_sf_search[]" class="sf-input-text" type="text" value="" title=""></label> </li></ul></form></div> </div> </div> <div class="col-md-9"> <div class="search-filter-results" id="search-filter-results-546"> <div class="newsbar" id="results-546"> <div class="news-date"> November 21, 2024 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-executes-supply-agreement-with-cellectar-biosciences-for-therapeutic-radioisotope-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes Executes Supply Agreement with Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)">NorthStar Medical Radioisotopes Executes Supply Agreement with Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)</a> </div> <div class="news-excerpt"> <p>NorthStar to provide non-carrier added actinium-225 (n.c.a. Ac-225) to Cellectar for use in its expanded portfolio of clinical programs This includes CLR 121225 an actinium-labeled phospholipid ether (PLE), expected to enter a Phase 1 study in pancreatic cancer in 2025 BELOIT, WI, November 21, 2024 – NorthStar Medical Radioisotopes, LLC today announced the signing of [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-executes-supply-agreement-with-cellectar-biosciences-for-therapeutic-radioisotope-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes Executes Supply Agreement with Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> October 22, 2024 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-unveils-radiopharmaceutical-contract-development-manufacturing-cdmo-facility/" title="NorthStar Medical Radioisotopes Unveils Radiopharmaceutical Contract Development &#038; Manufacturing (CDMO) Facility">NorthStar Medical Radioisotopes Unveils Radiopharmaceutical Contract Development &#038; Manufacturing (CDMO) Facility</a> </div> <div class="news-excerpt"> <p>NorthStar will be the only U.S. based company to have co-located, commercial scale multi-radioisotope production and radiopharmaceutical manufacturing State-of-the-art facility will provide development services and dose manufacturing capacity for key medical radioisotopes, including Ac-225, Lu-177, Cu-64, Cu-67, and In-111, amongst others Purpose-built 52,000 sq ft facility serves as important milestone for the organization and the [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-unveils-radiopharmaceutical-contract-development-manufacturing-cdmo-facility/" title="NorthStar Medical Radioisotopes Unveils Radiopharmaceutical Contract Development &#038; Manufacturing (CDMO) Facility" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> October 3, 2024 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-2024-oppenheimer-conference/" title="NorthStar Medical Radioisotopes to Participate in October 2024 Oppenheimer Conference">NorthStar Medical Radioisotopes to Participate in October 2024 Oppenheimer Conference</a> </div> <div class="news-excerpt"> <p>2nd Annual Oppenheimer Summit focused on Radiopharmaceutical Therapies in Oncology Frank Scholz, Ph.D., President and Chief Executive Officer of NorthStar will participate as expert panelist in “Supply Chain Challenges and Controversies – Ac-225 Availability, Pb-212 Logistics, The Last Mile” session BELOIT, Wis., and CAMBRIDGE, Mass., Oct 3, 2024 – NorthStar Medical Radioisotopes, LLC, a global [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-2024-oppenheimer-conference/" title="NorthStar Medical Radioisotopes to Participate in October 2024 Oppenheimer Conference" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> August 13, 2024 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-convergent-therapeutics-inc-expand-strategic-collaboration-around-conv01/" title="NorthStar Medical Radioisotopes and Convergent Therapeutics, Inc. Expand Strategic Collaboration Around CONV01-α">NorthStar Medical Radioisotopes and Convergent Therapeutics, Inc. Expand Strategic Collaboration Around CONV01-α</a> </div> <div class="news-excerpt"> <p>NorthStar will supply Convergent’s CONV01-α clinical program with non-carrier added (n.c.a) Ac-225 supply The collaboration provides Convergent a unique opportunity to locate Ac-225 production and large-scale drug product manufacture at NorthStar’s single-campus U.S. facility ready for shipment to clinical sites NorthStar will provide Convergent research and development services to support process improvements and development of [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-convergent-therapeutics-inc-expand-strategic-collaboration-around-conv01/" title="NorthStar Medical Radioisotopes and Convergent Therapeutics, Inc. Expand Strategic Collaboration Around CONV01-α" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> July 30, 2024 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-sponsors-study-entitled-program-to-find-a-cure-for-anca-associated-vasculitis-through-research/" title="NorthStar Medical Radioisotopes Sponsors Study Entitled “Program to Find a Cure for ANCA-associated Vasculitis Through Research”">NorthStar Medical Radioisotopes Sponsors Study Entitled “Program to Find a Cure for ANCA-associated Vasculitis Through Research”</a> </div> <div class="news-excerpt"> <p>Agreement between NorthStar and major U.S. research institution aims to shift treatment paradigms and find a cure for a group of inflammatory diseases which affect small blood vessels in organs including the kidneys, lungs, skin and nervous system, among others Multi-faceted study will include projects focused on the use of radionuclides1 for diagnosis and treatment, [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-sponsors-study-entitled-program-to-find-a-cure-for-anca-associated-vasculitis-through-research/" title="NorthStar Medical Radioisotopes Sponsors Study Entitled “Program to Find a Cure for ANCA-associated Vasculitis Through Research”" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> July 22, 2024 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-bwxt-medical-sign-supply-agreement/" title="NorthStar Medical Radioisotopes and BWXT Medical Sign Supply Agreement Supporting Actinium-225 Production">NorthStar Medical Radioisotopes and BWXT Medical Sign Supply Agreement Supporting Actinium-225 Production</a> </div> <div class="news-excerpt"> <p>Highlights: Multi-year supply agreement for radium-226 processing and purification Collaboration will work to provide Ac-225 for clinical trials and commercial supply Beloit, WI and OTTAWA, Ontario – July 22, 2024 – NorthStar Medical Radioisotopes, LLC (NorthStar) and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT) today announced that they have signed a [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-bwxt-medical-sign-supply-agreement/" title="NorthStar Medical Radioisotopes and BWXT Medical Sign Supply Agreement Supporting Actinium-225 Production" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 11, 2024 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/monopar-and-northstar-amend-extend-collaboration/" title="Monopar and NorthStar Amend &#038; Extend Collaboration">Monopar and NorthStar Amend &#038; Extend Collaboration</a> </div> <div class="news-excerpt"> <p>Highlights: Builds on Companies’ respective core strengths Aligns intellectual property rights Establishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar’s development and potential future commercial programs WILMETTE, IL and Beloit, WI, June 11, 2024 – Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company, and NorthStar Medical Radioisotopes, LLC, a global innovator [&hellip;]</p> <p><a href="https://www.northstarnm.com/monopar-and-northstar-amend-extend-collaboration/" title="Monopar and NorthStar Amend &#038; Extend Collaboration" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 4, 2024 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-marks-critical-milestone-in-readiness-for-clinical-batch-production/" title="NorthStar Medical Radioisotopes Marks Critical Milestone in Readiness for Clinical Batch Production">NorthStar Medical Radioisotopes Marks Critical Milestone in Readiness for Clinical Batch Production</a> </div> <div class="news-excerpt"> <p>Company’s first fully equipped cleanroom facility to support batch production for radiopharmaceutical clinical trials was completed in 6 months Enables support functions and processes necessary to manufacture, release and ship a patient-ready final drug product at scale required for late-stage registration trials BELOIT, Wis., June 4, 2024 &#8211; NorthStar Medical Radioisotopes, LLC, a global innovator [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-marks-critical-milestone-in-readiness-for-clinical-batch-production/" title="NorthStar Medical Radioisotopes Marks Critical Milestone in Readiness for Clinical Batch Production" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> April 15, 2024 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-appoints-peter-pfreundschuh-to-board-of-managers/" title="NorthStar Appoints Peter Pfreundschuh to Board of Managers">NorthStar Appoints Peter Pfreundschuh to Board of Managers</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., April 15, 2024 – NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-appoints-peter-pfreundschuh-to-board-of-managers/" title="NorthStar Appoints Peter Pfreundschuh to Board of Managers" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> April 10, 2024 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-llc-enters-clinical-supply-agreement-to-support-clarity-cu-67-sar-bispsma-pivotal-trials/" title="NorthStar Medical Radioisotopes, LLC Enters Clinical Supply Agreement to Support Clarity Cu-67 SAR-bisPSMA Pivotal Trials">NorthStar Medical Radioisotopes, LLC Enters Clinical Supply Agreement to Support Clarity Cu-67 SAR-bisPSMA Pivotal Trials</a> </div> <div class="news-excerpt"> <p>Highlights New Clinical Supply Agreement with Clarity for production of 67Cu-SAR-bisPSMA drug product ensures seamless product supply as Clarity pursues upcoming pivotal therapy trials NorthStar is uniquely able to provide large-scale U.S. manufacturing of both the therapeutic isotope (Cu-67) and cGMP radiopharmaceutical product ready for shipment to clinical sites NorthStar’s vertically integrated manufacturing offers significant [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-llc-enters-clinical-supply-agreement-to-support-clarity-cu-67-sar-bispsma-pivotal-trials/" title="NorthStar Medical Radioisotopes, LLC Enters Clinical Supply Agreement to Support Clarity Cu-67 SAR-bisPSMA Pivotal Trials" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> April 4, 2024 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-participation-in-upcoming-2024-jefferies-radiopharma-innovation-summit/" title="NorthStar Medical Radioisotopes Announces Participation in Upcoming 2024 Jefferies Radiopharma Innovation Summit">NorthStar Medical Radioisotopes Announces Participation in Upcoming 2024 Jefferies Radiopharma Innovation Summit</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., April 4, 2024 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production, and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced that Frank Scholz, Ph.D., President and Chief Executive Officer will present at the upcoming 2024 Jefferies Radiopharma Innovation Summit. Presentation Details: Date: [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-participation-in-upcoming-2024-jefferies-radiopharma-innovation-summit/" title="NorthStar Medical Radioisotopes Announces Participation in Upcoming 2024 Jefferies Radiopharma Innovation Summit" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> February 27, 2024 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-llc-announces-appointment-of-barbara-bodem-and-david-keeling-to-board-of-managers/" title="NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers">NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., February 27, 2024 – NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-llc-announces-appointment-of-barbara-bodem-and-david-keeling-to-board-of-managers/" title="NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> January 8, 2024 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-alpha-9-oncology-enter-strategic-long-term-agreement-for-supply-of-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225 (Ac-225)">NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225 (Ac-225)</a> </div> <div class="news-excerpt"> <p>Highlights Long term, multi-year supply agreement provides Alpha-9 with NorthStar’s high purity non-carrier added (n.c.a.) Ac-225 to be used in Alpha-9’s targeted radiopharmaceutical programs for treatment of solid and liquid tumors Agreement will support Alpha-9’s ongoing development and clinical programs in addition to multiple undisclosed discovery-stage programs NorthStar is positioned to be one of the [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-alpha-9-oncology-enter-strategic-long-term-agreement-for-supply-of-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes and Alpha-9 Oncology Enter Strategic Long-term Agreement for Supply of Actinium-225 (Ac-225)" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> January 3, 2024 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-curadh-mtr-enter-strategic-collaboration-agreement-for-development-and-production-of-actinium-225-ac-225-based-therapeutic-radiopharmaceuticals-for-treatment-of-p/" title="NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors">NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors</a> </div> <div class="news-excerpt"> <p>Highlights Collaboration expands August 2023 agreement under which NorthStar’s environmentally preferable, high purity n.c.a. Ac-225 will be used in Curadh’s molecularly targeted radiation (MTR) programs for treatment of solid tumors. Under the new agreement, NorthStar will manufacture and distribute patient doses for ongoing Curadh Ac-225 clinical studies and provide Ac-225 for commercial use upon NorthStar’s [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-curadh-mtr-enter-strategic-collaboration-agreement-for-development-and-production-of-actinium-225-ac-225-based-therapeutic-radiopharmaceuticals-for-treatment-of-p/" title="NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> December 7, 2023 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-participation-in-upcoming-2023-truist-securities-biopharma-symposium/" title="NorthStar Medical Radioisotopes Announces Participation in Upcoming 2023 Truist Securities Biopharma Symposium">NorthStar Medical Radioisotopes Announces Participation in Upcoming 2023 Truist Securities Biopharma Symposium</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., November 6, 2023 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used to detect and treat cancer, today announced that it will participate in the upcoming 2023 Truist Securities Biopharma Symposium being held November 8 to 9, 2023, in New York, NY. NorthStar executives Stephen [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-participation-in-upcoming-2023-truist-securities-biopharma-symposium/" title="NorthStar Medical Radioisotopes Announces Participation in Upcoming 2023 Truist Securities Biopharma Symposium" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> August 29, 2023 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-curadh-mtr-announce-a-strategic-long-term-supply-agreement-for-therapeutic-radioisotope-actinium-225/" title="NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)">NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)</a> </div> <div class="news-excerpt"> <p>Highlights NorthStar’s high purity non-carrier added (n.c.a.) Ac-225 to be used in Curadh’s molecularly targeted radiation (MTR) programs for treatment of solid tumors NorthStar is positioned to be the first commercial-scale producer of n.c.a. Ac-225 for advancing clinical research and commercial radiopharmaceutical therapy products BELOIT, Wis. And CHESTER SPRINGS, Pa., August 29, 2023 – NorthStar [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-curadh-mtr-announce-a-strategic-long-term-supply-agreement-for-therapeutic-radioisotope-actinium-225/" title="NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> August 28, 2023 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/first-participant-treated-using-northstar-medical-radioisotopes-electron-accelerator/" title="First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma">First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma</a> </div> <div class="news-excerpt"> <p>Highlights First participant of cohort 4 of the theranostic CL04 trial investigating 64Cu/67Cu SARTATE in neuroblastoma has been treated at the highest dose cohort of 375MBq/kg body weight using NorthStar’s electron accelerator-produced Cu-67, marking a key milestone in NorthStar’s agreement to exclusively supply Cu-67 to Clarity NorthStar now routinely produces high-activity, high specific-activity and high-purity [&hellip;]</p> <p><a href="https://www.northstarnm.com/first-participant-treated-using-northstar-medical-radioisotopes-electron-accelerator/" title="First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> July 17, 2023 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-executes-supply-agreement-with-bayer-for-therapeutic-radioisotope-actinium%e2%80%90225-ac%e2%80%90225/" title="NorthStar Medical Radioisotopes Executes Supply Agreement with Bayer for Therapeutic Radioisotope Actinium‐225 (Ac‐225)">NorthStar Medical Radioisotopes Executes Supply Agreement with Bayer for Therapeutic Radioisotope Actinium‐225 (Ac‐225)</a> </div> <div class="news-excerpt"> <p>−NorthStar’s non‐carrier added (n.c.a.) Ac‐225 to be used in Bayer’s radiopharmaceutical programs − BELOIT, Wis., July 18, 2023 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the signing of a supply agreement for the therapeutic medical radioisotope, actinium‐225 [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-executes-supply-agreement-with-bayer-for-therapeutic-radioisotope-actinium%e2%80%90225-ac%e2%80%90225/" title="NorthStar Medical Radioisotopes Executes Supply Agreement with Bayer for Therapeutic Radioisotope Actinium‐225 (Ac‐225)" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 27, 2023 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-supply-agreement-with-nucleus-radiopharma-for-alpha-emitting-therapeutic-radioisotope-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)">NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)</a> </div> <div class="news-excerpt"> <p>− NorthStar’s high purity non-carrier-added (n.c.a.) Ac-225 to be used in advancing Nucleus’ partners radioligand therapies to treat cancer − BELOIT, Wis. and ROCHESTER, Minn., June 27, 2023 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Nucleus RadioPharma, a [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-supply-agreement-with-nucleus-radiopharma-for-alpha-emitting-therapeutic-radioisotope-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 26, 2023 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/nmr-now-routinely-manufacturing-high-activity-copper-67/" title="NorthStar Medical Radioisotopes Now Routinely Manufacturing High Activity Copper-67 on its Electron Accelerators for Clarity Pharmaceuticals&#8217; Therapy Clinical Programs">NorthStar Medical Radioisotopes Now Routinely Manufacturing High Activity Copper-67 on its Electron Accelerators for Clarity Pharmaceuticals&#8217; Therapy Clinical Programs</a> </div> <div class="news-excerpt"> <p>Highlights NorthStar is now producing high activity, high specific activity and high purity copper-67 (Cu-67 or 67Cu) suitable for Clarity’s ongoing clinical programs. Initial shipments by NorthStar for Clarity’s Targeted Copper Theranostic (TCT) clinical programs were completed under the exclusive supply agreement. Large-scale production of Cu-67 uses a highly efficient, environmentally preferable electron accelerator technology [&hellip;]</p> <p><a href="https://www.northstarnm.com/nmr-now-routinely-manufacturing-high-activity-copper-67/" title="NorthStar Medical Radioisotopes Now Routinely Manufacturing High Activity Copper-67 on its Electron Accelerators for Clarity Pharmaceuticals&#8217; Therapy Clinical Programs" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 19, 2023 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-llc-appoints-frank-scholz-ph-d-as-president-and-chief-executive-officer/" title="NorthStar Medical Technologies, LLC Appoints Frank Scholz, Ph.D., as President and Chief Executive Officer">NorthStar Medical Technologies, LLC Appoints Frank Scholz, Ph.D., as President and Chief Executive Officer</a> </div> <div class="news-excerpt"> <p>− Former Chief Executive Officer Stephen Merrick Appointed Executive Chairman − − Planned transition part of NorthStar’s strategy for continued growth and industry leadership in domestic radioisotope production and radiopharmaceutical development to meet needs of patients, pharmaceutical companies and radiopharmacies− BELOIT, Wis., June 19, 2023 – NorthStar Medical Technologies, LLC, a global innovator in the [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-llc-appoints-frank-scholz-ph-d-as-president-and-chief-executive-officer/" title="NorthStar Medical Technologies, LLC Appoints Frank Scholz, Ph.D., as President and Chief Executive Officer" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> May 9, 2023 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-participation-in-upcoming-2023-guggenheim-radiopharmaceuticals-day/" title="NorthStar Medical Radioisotopes Announces Participation in Upcoming 2023 Guggenheim Radiopharmaceuticals Day">NorthStar Medical Radioisotopes Announces Participation in Upcoming 2023 Guggenheim Radiopharmaceuticals Day</a> </div> <div class="news-excerpt"> <p>Beloit, Wis., May 9, 2023 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that it will be participating in the upcoming 2023 Guggenheim Radiopharmaceuticals Day. The event will be held in New York, NY, on May 15, 2023, [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-participation-in-upcoming-2023-guggenheim-radiopharmaceuticals-day/" title="NorthStar Medical Radioisotopes Announces Participation in Upcoming 2023 Guggenheim Radiopharmaceuticals Day" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> April 18, 2023 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-expands-management-team-with-appointment-of-jean-noel-david-mba-ms-as-vice-president-operations/" title="NorthStar Medical Radioisotopes Expands Management Team with Appointment of Jean-Noel David, MBA, MS, as Vice President, Operations">NorthStar Medical Radioisotopes Expands Management Team with Appointment of Jean-Noel David, MBA, MS, as Vice President, Operations</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., April 18, 2023 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the appointment of Jean-Noel David, MBA, MS, as Vice President, Operations. In this new position, he brings more than 20 years of operational and leadership [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-expands-management-team-with-appointment-of-jean-noel-david-mba-ms-as-vice-president-operations/" title="NorthStar Medical Radioisotopes Expands Management Team with Appointment of Jean-Noel David, MBA, MS, as Vice President, Operations" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> April 12, 2023 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-promotion-of-jason-vinyard-mba-mha-to-vice-president-business-development-therapeutic-technologies/" title="NorthStar Medical Radioisotopes Announces Promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies">NorthStar Medical Radioisotopes Announces Promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., April 12, 2022 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies. Mr. Vinyard, who has been with NorthStar since 2021, was previously [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-promotion-of-jason-vinyard-mba-mha-to-vice-president-business-development-therapeutic-technologies/" title="NorthStar Medical Radioisotopes Announces Promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> April 3, 2023 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-provides-updates-on-corporate-progress-and-upcoming-milestones-3/" title="NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones">NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones</a> </div> <div class="news-excerpt"> <p>− Company positioned for continued strong growth in domestic radioisotope production and radiopharmaceutical development to meet needs of pharmaceutical companies, radiopharmacies and patients – − NorthStar’s Mo-99 program continues at the forefront of U.S. radioisotope production as the only commercialized producer of key medical radioisotopes molybdenum-99 (Mo-99)/technetium-99m (Tc-99m) − − Company poised as first commercial-scale [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-provides-updates-on-corporate-progress-and-upcoming-milestones-3/" title="NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 30, 2023 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-presentations-at-upcoming-jefferies-radiopharma-innovation-summit/" title="NorthStar Medical Radioisotopes Announces Presentations at Upcoming Jefferies Radiopharma Innovation Summit">NorthStar Medical Radioisotopes Announces Presentations at Upcoming Jefferies Radiopharma Innovation Summit</a> </div> <div class="news-excerpt"> <p>Beloit, Wis., March 30, 2023 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that it will be presenting at the upcoming Jefferies Radiopharma Innovation Summit. The event will be held in New York, NY, on April 3, 2023. [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-presentations-at-upcoming-jefferies-radiopharma-innovation-summit/" title="NorthStar Medical Radioisotopes Announces Presentations at Upcoming Jefferies Radiopharma Innovation Summit" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 1, 2023 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-receives-electron-beam-accelerator-for-first-of-its-kind-commercial-scale-u-s-production-of-important-therapeutic-radioisotope-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes Receives Electron Beam Accelerator for First-of-its-Kind, Commercial-scale U.S. Production of Important Therapeutic Radioisotope Actinium-225 (Ac-225)">NorthStar Medical Radioisotopes Receives Electron Beam Accelerator for First-of-its-Kind, Commercial-scale U.S. Production of Important Therapeutic Radioisotope Actinium-225 (Ac-225)</a> </div> <div class="news-excerpt"> <p>− NorthStar is poised to be the first commercial-scale producer of rare radioisotope, in chronic short supply, for use in clinical studies and patient healthcare to treat many types of cancer – BELOIT, Wis., March 1, 2023 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-receives-electron-beam-accelerator-for-first-of-its-kind-commercial-scale-u-s-production-of-important-therapeutic-radioisotope-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes Receives Electron Beam Accelerator for First-of-its-Kind, Commercial-scale U.S. Production of Important Therapeutic Radioisotope Actinium-225 (Ac-225)" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> February 27, 2023 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/monopar-and-northstar-announce-expanded-radiopharma-program-positive-preclinical-results-and-visibility-toward-human-trials/" title="Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials">Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials</a> </div> <div class="news-excerpt"> <p>WILMETTE, Ill. and BELOIT, Wis., Feb. 27, 2023 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, Ill.) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis.), today announced an expansion of their radiopharmaceutical collaboration along with a new radiolabeled MNPR-101 imaging candidate designated as MNPR-101-Zr. Based on promising recently generated preclinical imaging results with MNPR-101-Zr showing high [&hellip;]</p> <p><a href="https://www.northstarnm.com/monopar-and-northstar-announce-expanded-radiopharma-program-positive-preclinical-results-and-visibility-toward-human-trials/" title="Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> January 11, 2023 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-sets-new-industry-precedent-in-advancing-non-uranium-based-commercial-production-of-molybdenum-99-mo-99/" title="NorthStar Medical Radioisotopes Sets New Industry Precedent in Advancing Non-uranium based Commercial Production of Molybdenum-99 (Mo-99)">NorthStar Medical Radioisotopes Sets New Industry Precedent in Advancing Non-uranium based Commercial Production of Molybdenum-99 (Mo-99)</a> </div> <div class="news-excerpt"> <p>− Proprietary electron accelerator technology achieves “two beams on target” milestone, validating proof of concept for large-scale U.S. Mo-99 production without the use of uranium – − NorthStar has provided the only commercial, domestic U.S. supply of Mo-99 for more than four years; electron accelerator technology will increase production capability to nearly 40% of U.S. [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-sets-new-industry-precedent-in-advancing-non-uranium-based-commercial-production-of-molybdenum-99-mo-99/" title="NorthStar Medical Radioisotopes Sets New Industry Precedent in Advancing Non-uranium based Commercial Production of Molybdenum-99 (Mo-99)" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> January 4, 2023 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-inhibrx-enter-into-collaboration-agreement-for-the-development-and-production-of-radiopharmaceutical-candidates/" title="NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates">NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. and SAN DIEGO, January 4, 2023 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Inhibrx, Inc. (Nasdaq: INBX), a biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced a collaboration to [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-inhibrx-enter-into-collaboration-agreement-for-the-development-and-production-of-radiopharmaceutical-candidates/" title="NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> November 18, 2022 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-statement-on-availability-of-technetium-99m-generators-and-the-fda-drug-shortages-list/" title="NorthStar Medical Radioisotopes Statement on Availability of Technetium 99m Generators and the FDA Drug Shortages List">NorthStar Medical Radioisotopes Statement on Availability of Technetium 99m Generators and the FDA Drug Shortages List</a> </div> <div class="news-excerpt"> <p>November 18, 2022 Statement Attributable to: Frank Scholz, Ph.D., President and COO, NorthStar Medical Radioisotopes NorthStar Medical Radioisotopes, located in Beloit, Wisconsin, (“NorthStar”) recognizes the urgent medical need for technetium-99m (Tc-99m) to ensure patients have access to critical diagnostic imaging tests. Tc-99m is generated from molybdenum-99 (Mo-99) and used in over 40,000 patient studies per [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-statement-on-availability-of-technetium-99m-generators-and-the-fda-drug-shortages-list/" title="NorthStar Medical Radioisotopes Statement on Availability of Technetium 99m Generators and the FDA Drug Shortages List" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> November 15, 2022 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-expands-business-platform-with-new-patient-focused-radiopharmaceutical-contract-development-and-manufacturing-organization-cdmo-services-unit/" title="NorthStar Medical Radioisotopes Expands Business Platform with New, Patient-focused, Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) Services Unit">NorthStar Medical Radioisotopes Expands Business Platform with New, Patient-focused, Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) Services Unit</a> </div> <div class="news-excerpt"> <p>− Complements NorthStar’s growing radioisotope production programs, providing powerhouse combination of capabilities and expertise to advance patient care – − Full-scale CDMO services for collaborating companies designed to facilitate radiopharmaceutical development and commercialization in complex, highly regulated radiopharmaceutical sector – − NorthStar to be the first and only U.S. company housing commercial scale, multi-radioisotope production [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-expands-business-platform-with-new-patient-focused-radiopharmaceutical-contract-development-and-manufacturing-organization-cdmo-services-unit/" title="NorthStar Medical Radioisotopes Expands Business Platform with New, Patient-focused, Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) Services Unit" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> November 3, 2022 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-statement-on-current-disruptions-in-the-molybdenum-99-mo-99-supply-chain/" title="NorthStar Medical Radioisotopes Statement on Current Disruptions in the Molybdenum-99 (Mo-99) Supply Chain">NorthStar Medical Radioisotopes Statement on Current Disruptions in the Molybdenum-99 (Mo-99) Supply Chain</a> </div> <div class="news-excerpt"> <p>November 2, 2022 Statement Attributable to: Frank Scholz, Ph.D., President and COO, NorthStar Medical Radioisotopes NorthStar Medical Radioisotopes, located in Beloit, Wisconsin, recognizes the urgent medical need for technetium-99m (Tc-99m) to ensure patients have access to critical diagnostic imaging tests. Tc-99m is generated from molybdenum-99 (Mo-99) and used in approximately 40,000 patient studies per day [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-statement-on-current-disruptions-in-the-molybdenum-99-mo-99-supply-chain/" title="NorthStar Medical Radioisotopes Statement on Current Disruptions in the Molybdenum-99 (Mo-99) Supply Chain" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> October 26, 2022 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/radiopharm-theranostics-signs-agreement-with-northstar-medical-radioisotopes-for-the-supply-of-non-carrier-added-n-c-a-actinium-225/" title="Radiopharm Theranostics signs agreement with NorthStar Medical Radioisotopes for the supply of non-carrier added (n.c.a.) Actinium-225">Radiopharm Theranostics signs agreement with NorthStar Medical Radioisotopes for the supply of non-carrier added (n.c.a.) Actinium-225</a> </div> <div class="news-excerpt"> <p>Sydney, Australia and Beloit, Wisconsin, U.S. – October 26, 2022 &#8212; Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced they [&hellip;]</p> <p><a href="https://www.northstarnm.com/radiopharm-theranostics-signs-agreement-with-northstar-medical-radioisotopes-for-the-supply-of-non-carrier-added-n-c-a-actinium-225/" title="Radiopharm Theranostics signs agreement with NorthStar Medical Radioisotopes for the supply of non-carrier added (n.c.a.) Actinium-225" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> October 11, 2022 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/eckert-ziegler-to-build-production-line-for-northstar-medical-radioisotopes-dedicated-actinium-225-production-facility/" title="Eckert &#038; Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility">Eckert &#038; Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. and Berlin, Germany, 11 October 2022 &#8211; NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Eckert &amp; Ziegler Isotope Technologies Dresden (ITD), a specialist for radiopharmaceutical plant engineering and fully owned subsidiary of Eckert &amp; Ziegler AG (ISIN [&hellip;]</p> <p><a href="https://www.northstarnm.com/eckert-ziegler-to-build-production-line-for-northstar-medical-radioisotopes-dedicated-actinium-225-production-facility/" title="Eckert &#038; Ziegler to Build Production Line for NorthStar Medical Radioisotopes’ Dedicated Actinium-225 Production Facility" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 20, 2022 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-iba-sign-agreement-for-two-additional-rhodotron-electron-beam-accelerators-for-commercial-production-of-radioisotopes/" title="NorthStar Medical Radioisotopes and IBA Sign Agreement for Two Additional Rhodotron® Electron Beam Accelerators for Commercial Production of Radioisotopes">NorthStar Medical Radioisotopes and IBA Sign Agreement for Two Additional Rhodotron® Electron Beam Accelerators for Commercial Production of Radioisotopes</a> </div> <div class="news-excerpt"> <p>− NorthStar is further expanding commercial-scale domestic radioisotope production capabilities using IBA’s environmentally preferable Rhodotron® accelerator technology – BELOIT, Wis., USA and Louvain-La-Neuve, Belgium, September 20, 2022 – NorthStar Medical Radioisotopes, LLC (‘NorthStar’), a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and IBA (Ion Beam [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-iba-sign-agreement-for-two-additional-rhodotron-electron-beam-accelerators-for-commercial-production-of-radioisotopes/" title="NorthStar Medical Radioisotopes and IBA Sign Agreement for Two Additional Rhodotron® Electron Beam Accelerators for Commercial Production of Radioisotopes" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> August 23, 2022 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-supply-agreement-with-aktis-oncology-inc-for-alpha-emitting-therapeutic-radioisotope-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)">NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)</a> </div> <div class="news-excerpt"> <p>− NorthStar’s high purity non-carrier-added (n.c.a.) Ac-225 to be used in advancing Aktis Oncology’s pipeline of precision-engineered alpha radiotherapies to treat cancer − BELOIT, Wis., August 23, 2022 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the signing [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-supply-agreement-with-aktis-oncology-inc-for-alpha-emitting-therapeutic-radioisotope-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> July 19, 2022 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-supply-agreement-with-clovis-oncology-for-therapeutic-radioisotope-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes Announces Supply Agreement with Clovis Oncology for Therapeutic Radioisotope Actinium-225 (Ac-225)">NorthStar Medical Radioisotopes Announces Supply Agreement with Clovis Oncology for Therapeutic Radioisotope Actinium-225 (Ac-225)</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., July 19, 2022 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the signing of a long-term supply agreement with Clovis Oncology, Inc. (NASDAQ: CLVS) for the therapeutic medical radioisotope, actinium-225 (Ac-225). Under terms of the agreement, [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-supply-agreement-with-clovis-oncology-for-therapeutic-radioisotope-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes Announces Supply Agreement with Clovis Oncology for Therapeutic Radioisotope Actinium-225 (Ac-225)" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 20, 2022 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-llc-announces-promotion-of-frank-scholz-ph-d-to-president-and-chief-operating-officer/" title="NorthStar Medical Technologies, LLC Announces Promotion of Frank Scholz, Ph.D., to President and Chief Operating Officer">NorthStar Medical Technologies, LLC Announces Promotion of Frank Scholz, Ph.D., to President and Chief Operating Officer</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., June 20, 2022 – NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of diagnostic and therapeutic radiopharmaceuticals, today announced the promotion of one of its key executives. The announcement comes as NorthStar reaches a pivotal stage in its growth and industry influence. Dr. Frank Scholz has been named [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-llc-announces-promotion-of-frank-scholz-ph-d-to-president-and-chief-operating-officer/" title="NorthStar Medical Technologies, LLC Announces Promotion of Frank Scholz, Ph.D., to President and Chief Operating Officer" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 7, 2022 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-curie-therapeutics-announce-priority-access-supply-agreement-for-therapeutic-radioisotope-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes and Curie Therapeutics Announce Priority Access Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)">NorthStar Medical Radioisotopes and Curie Therapeutics Announce Priority Access Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)</a> </div> <div class="news-excerpt"> <p>− Curie Therapeutics will be provided with priority access to NorthStar’s high purity non-carrier added (n.c.a.) Ac-225, which will be used to advance its multimodal pipeline of precision radiopharmaceuticals to address broad unmet needs in treatment of patients with solid tumors − BELOIT, Wis., and Cambridge, Mass., June 7, 2022 – NorthStar Medical Radioisotopes, LLC [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-curie-therapeutics-announce-priority-access-supply-agreement-for-therapeutic-radioisotope-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes and Curie Therapeutics Announce Priority Access Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> May 24, 2022 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-enhances-management-team-with-appointment-of-monica-andersen-as-vice-president-human-resources/" title="NorthStar Medical Radioisotopes Enhances Management Team with Appointment of Monica Andersen as Vice President, Human Resources">NorthStar Medical Radioisotopes Enhances Management Team with Appointment of Monica Andersen as Vice President, Human Resources</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., May 24, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Monica Andersen as Vice President, Human Resources. In this new position, she will hold responsibility for the Company’s Human Resources and Organizational [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-enhances-management-team-with-appointment-of-monica-andersen-as-vice-president-human-resources/" title="NorthStar Medical Radioisotopes Enhances Management Team with Appointment of Monica Andersen as Vice President, Human Resources" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 29, 2022 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-provides-updates-on-corporate-progress-and-upcoming-milestones-2/" title="NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones">NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones</a> </div> <div class="news-excerpt"> <p>− NorthStar positioned for continued strong growth and setting leadership standards for domestic, environmentally sustainable radioisotope production across its portfolio to meet needs of health systems, radiopharmacies and patients – − NorthStar continues as the only U.S. commercial producer of diagnostic imaging radioisotopes non-uranium molybdenum-99 (Mo-99)/technetium-99m (Tc-99m), for more than three years − − Company [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-provides-updates-on-corporate-progress-and-upcoming-milestones-2/" title="NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 9, 2022 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-convergent-therapeutics-announce-supply-agreement-for-therapeutic-radioisotope-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)">NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)</a> </div> <div class="news-excerpt"> <p>− NorthStar’s high purity non-carrier-added (n.c.a.) Ac-225 to be used in Convergent’s lead, dual-targeted radionuclide program for prostate cancer, CONV01-α − BELOIT, Wis., and CAMBRIDGE, Mass., March 9, 2022 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Convergent Therapeutics, [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-convergent-therapeutics-announce-supply-agreement-for-therapeutic-radioisotope-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 8, 2022 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-to-participate-in-upcoming-oppenheimer-co-inc-event-radiopharmaceutical-therapies-come-of-age/" title="NorthStar Medical Radioisotopes to Participate in Upcoming Oppenheimer &#038; Co. Inc. Event, “Radiopharmaceutical Therapies Come of Age”">NorthStar Medical Radioisotopes to Participate in Upcoming Oppenheimer &#038; Co. Inc. Event, “Radiopharmaceutical Therapies Come of Age”</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., March 8, 2022 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will participate in an upcoming corporate event hosted by Oppenheimer &amp; Co. Inc. [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-to-participate-in-upcoming-oppenheimer-co-inc-event-radiopharmaceutical-therapies-come-of-age/" title="NorthStar Medical Radioisotopes to Participate in Upcoming Oppenheimer &#038; Co. Inc. Event, “Radiopharmaceutical Therapies Come of Age”" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> November 29, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-expands-management-team-with-appointment-of-adam-lynch-as-vice-president-corporate-development-and-external-affairs/" title="NorthStar Medical Radioisotopes Expands Management Team with Appointment of Adam Lynch as Vice President, Corporate Development and External Affairs">NorthStar Medical Radioisotopes Expands Management Team with Appointment of Adam Lynch as Vice President, Corporate Development and External Affairs</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., November 29, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Adam D. Lynch as Vice President, Corporate Development and External Affairs. In this new position, he brings to the Company more than [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-expands-management-team-with-appointment-of-adam-lynch-as-vice-president-corporate-development-and-external-affairs/" title="NorthStar Medical Radioisotopes Expands Management Team with Appointment of Adam Lynch as Vice President, Corporate Development and External Affairs" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> November 18, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-iba-sign-contract-for-rhodotron-electron-beam-accelerator-for-commercial-production-of-therapeutic-radioisotope-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes and IBA Sign Contract for Rhodotron® Electron Beam Accelerator for Commercial Production of Therapeutic Radioisotope Actinium-225 (Ac-225)">NorthStar Medical Radioisotopes and IBA Sign Contract for Rhodotron® Electron Beam Accelerator for Commercial Production of Therapeutic Radioisotope Actinium-225 (Ac-225)</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., USA and Louvain-La-Neuve, Belgium, November 18, 2021 – NorthStar Medical Radioisotopes, LLC (‘NorthStar’), a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announced a new contract in which NorthStar [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-iba-sign-contract-for-rhodotron-electron-beam-accelerator-for-commercial-production-of-therapeutic-radioisotope-actinium-225-ac-225/" title="NorthStar Medical Radioisotopes and IBA Sign Contract for Rhodotron® Electron Beam Accelerator for Commercial Production of Therapeutic Radioisotope Actinium-225 (Ac-225)" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> October 14, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-expansion-event-unveils-advanced-radioisotope-production-equipment-and-breaks-ground-on-first-in-kind-therapeutic-radioisotope-production-facility/" title="NorthStar Medical Radioisotopes Expansion Event Unveils Advanced Radioisotope Production Equipment and Breaks Ground on First-in-Kind Therapeutic Radioisotope Production Facility">NorthStar Medical Radioisotopes Expansion Event Unveils Advanced Radioisotope Production Equipment and Breaks Ground on First-in-Kind Therapeutic Radioisotope Production Facility</a> </div> <div class="news-excerpt"> <p>− Marking Company’s progress in advancing innovative and environmentally sound production of diagnostic imaging and therapeutic radioisotopes for the United States and Wisconsin − BELOIT, Wis., October 14, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, hosted a growth [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-expansion-event-unveils-advanced-radioisotope-production-equipment-and-breaks-ground-on-first-in-kind-therapeutic-radioisotope-production-facility/" title="NorthStar Medical Radioisotopes Expansion Event Unveils Advanced Radioisotope Production Equipment and Breaks Ground on First-in-Kind Therapeutic Radioisotope Production Facility" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> October 7, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-launch-of-new-website-to-showcase-companys-expanding-commercial-success-pipeline-progress-and-plans-for-the-future/" title="NorthStar Medical Radioisotopes Announces Launch of New Website to Showcase Company’s Expanding Commercial Success, Pipeline Progress and Plans for the Future">NorthStar Medical Radioisotopes Announces Launch of New Website to Showcase Company’s Expanding Commercial Success, Pipeline Progress and Plans for the Future</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., October 7, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, is proud to announce the launch of its newly redesigned corporate website. The new site includes increased functionality and a number of enhancements. Expanded content includes latest [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-launch-of-new-website-to-showcase-companys-expanding-commercial-success-pipeline-progress-and-plans-for-the-future/" title="NorthStar Medical Radioisotopes Announces Launch of New Website to Showcase Company’s Expanding Commercial Success, Pipeline Progress and Plans for the Future" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 8, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-point-biopharma-announce-supply-agreement-for-therapeutic-medical-radioisotope-actinium-225/" title="NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225">NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. and INDIANAPOLIS, Ind., September 8, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the signing [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-point-biopharma-announce-supply-agreement-for-therapeutic-medical-radioisotope-actinium-225/" title="NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 8, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-to-present-at-upcoming-h-c-wainwright-23rd-annual-global-investment-conference/" title="NorthStar Medical Radioisotopes to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference">NorthStar Medical Radioisotopes to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., September 8, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-to-present-at-upcoming-h-c-wainwright-23rd-annual-global-investment-conference/" title="NorthStar Medical Radioisotopes to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> August 30, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/u-s-department-of-energys-national-nuclear-security-administration-awards-northstar-medical-radioisotopes-37-million-in-cooperative-agreement-funds-to-further-domestic-molybdenum-99-mo-99/" title="U.S. Department of Energy’s National Nuclear Security Administration Awards NorthStar Medical Radioisotopes $37 Million in Cooperative Agreement Funds to Further Domestic Molybdenum-99 (Mo-99) Production">U.S. Department of Energy’s National Nuclear Security Administration Awards NorthStar Medical Radioisotopes $37 Million in Cooperative Agreement Funds to Further Domestic Molybdenum-99 (Mo-99) Production</a> </div> <div class="news-excerpt"> <p>− Supports neutron capture and accelerator production technology to further increase NorthStar’s production capacity of commercially available non-uranium based Mo-99 − BELOIT, Wis., August 30, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, announced today that it has been [&hellip;]</p> <p><a href="https://www.northstarnm.com/u-s-department-of-energys-national-nuclear-security-administration-awards-northstar-medical-radioisotopes-37-million-in-cooperative-agreement-funds-to-further-domestic-molybdenum-99-mo-99/" title="U.S. Department of Energy’s National Nuclear Security Administration Awards NorthStar Medical Radioisotopes $37 Million in Cooperative Agreement Funds to Further Domestic Molybdenum-99 (Mo-99) Production" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> August 3, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-ge-healthcare-sign-exclusive-u-s-manufacturing-and-distribution-agreement/" title="NorthStar Medical Radioisotopes and GE Healthcare Sign Exclusive U.S. Manufacturing and Distribution Agreement">NorthStar Medical Radioisotopes and GE Healthcare Sign Exclusive U.S. Manufacturing and Distribution Agreement</a> </div> <div class="news-excerpt"> <p>− Collaboration will produce and distribute Iodine-123 (I-123) capsules, the proven radiopharmaceutical standard in diagnostic imaging studies for thyroid disease – BELOIT, Wis. and Arlington Heights, Ill., August 3, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, and GE [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-ge-healthcare-sign-exclusive-u-s-manufacturing-and-distribution-agreement/" title="NorthStar Medical Radioisotopes and GE Healthcare Sign Exclusive U.S. Manufacturing and Distribution Agreement" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 21, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-llc-announces-appointment-of-frank-scholz-ph-d-as-senior-vice-president-and-chief-operating-officer/" title="NorthStar Medical Technologies, LLC Announces Appointment of Frank Scholz, Ph.D., as Senior Vice President and Chief Operating Officer">NorthStar Medical Technologies, LLC Announces Appointment of Frank Scholz, Ph.D., as Senior Vice President and Chief Operating Officer</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., June 21, 2021 – NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of diagnostic and therapeutic radiopharmaceuticals, today announced the appointment of Frank Scholz, Ph.D., as Senior Vice President and Chief Operating Officer. In this new position, he brings more than 20 years of relevant operational experience in [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-llc-announces-appointment-of-frank-scholz-ph-d-as-senior-vice-president-and-chief-operating-officer/" title="NorthStar Medical Technologies, LLC Announces Appointment of Frank Scholz, Ph.D., as Senior Vice President and Chief Operating Officer" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 10, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-presentations-at-upcoming-society-of-nuclear-medicine-and-molecular-imaging-snmmi-annual-meeting/" title="NorthStar Medical Radioisotopes Announces Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting">NorthStar Medical Radioisotopes Announces Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., June 10, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, being held in a virtual format from June 11 −15, 2021. NorthStar [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-presentations-at-upcoming-society-of-nuclear-medicine-and-molecular-imaging-snmmi-annual-meeting/" title="NorthStar Medical Radioisotopes Announces Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> May 26, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/monopar-and-northstar-announce-filing-of-composition-of-matter-patent-protecting-mnpr-101-radiotherapeutic/" title="Monopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic">Monopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic</a> </div> <div class="news-excerpt"> <p>WILMETTE, Ill. and BELOIT, Wis., May 26, 2021 – Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional composition of matter patent titled “Urokinase Plasminogen Activator Receptor-Targeted Radiopharmaceutical” covering a radiotherapeutic consisting of Monopar’s proprietary antibody MNPR-101 bound to Actinium-225 (Ac-225) via the metal binding agent PCTA. This [&hellip;]</p> <p><a href="https://www.northstarnm.com/monopar-and-northstar-announce-filing-of-composition-of-matter-patent-protecting-mnpr-101-radiotherapeutic/" title="Monopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> May 25, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-enters-u-s-supply-agreement-for-commercial-supply-of-therapeutic-radioisotope-copper-67-cu-67-exclusively-to-clarity-pharmaceuticals-for-its-targeted-copper-theranos/" title="NorthStar Medical Radioisotopes Enters U.S. Supply Agreement for Commercial Supply of Therapeutic Radioisotope Copper-67 (Cu-67) Exclusively to Clarity Pharmaceuticals for its Targeted Copper Theranostics Programs">NorthStar Medical Radioisotopes Enters U.S. Supply Agreement for Commercial Supply of Therapeutic Radioisotope Copper-67 (Cu-67) Exclusively to Clarity Pharmaceuticals for its Targeted Copper Theranostics Programs</a> </div> <div class="news-excerpt"> <p>− Master Supply Agreement encompasses clinical development and commercial supply for Clarity’s Cu-67-based candidates to treat neuroblastoma, breast and prostate cancers, among others − BELOIT, Wis. and Sydney, Australia – May 25, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-enters-u-s-supply-agreement-for-commercial-supply-of-therapeutic-radioisotope-copper-67-cu-67-exclusively-to-clarity-pharmaceuticals-for-its-targeted-copper-theranos/" title="NorthStar Medical Radioisotopes Enters U.S. Supply Agreement for Commercial Supply of Therapeutic Radioisotope Copper-67 (Cu-67) Exclusively to Clarity Pharmaceuticals for its Targeted Copper Theranostics Programs" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> May 24, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/monopar-and-northstar-announce-patent-filing-on-promising-radiopharmaceutical-discovery/" title="Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery">Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery</a> </div> <div class="news-excerpt"> <p>&#8211; Potential to significantly improve the yield of Actinium-based radiopharmaceuticals CHICAGO, Ill. and BELOIT, Wis., May 24, 2021 – Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, Ill) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis), today announced the filing of a provisional patent with the U.S. Patent and Trademark Office (USPTO) titled “Bio-Targeted Radiopharmaceutical Compositions Containing Ac-225 and Methods [&hellip;]</p> <p><a href="https://www.northstarnm.com/monopar-and-northstar-announce-patent-filing-on-promising-radiopharmaceutical-discovery/" title="Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> May 11, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-receives-electron-beam-accelerators-for-first-of-its-kind-advanced-medical-radioisotope-production/" title="NorthStar Medical Radioisotopes Receives Electron Beam Accelerators for First-of-its-Kind Advanced Medical Radioisotope Production">NorthStar Medical Radioisotopes Receives Electron Beam Accelerators for First-of-its-Kind Advanced Medical Radioisotope Production</a> </div> <div class="news-excerpt"> <p>− NorthStar, leading the way as the sole U.S. commercial supplier of molybdenum-99 (Mo-99), continues expansion efforts for increased capacity and ongoing reliable supply for diagnostic imaging − BELOIT, Wis., May 11, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-receives-electron-beam-accelerators-for-first-of-its-kind-advanced-medical-radioisotope-production/" title="NorthStar Medical Radioisotopes Receives Electron Beam Accelerators for First-of-its-Kind Advanced Medical Radioisotope Production" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> May 4, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-to-present-at-the-emerging-medtech-summit-2021/" title="NorthStar Medical Radioisotopes to Present at the Emerging Medtech Summit 2021">NorthStar Medical Radioisotopes to Present at the Emerging Medtech Summit 2021</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., May 4, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present a corporate overview at the Emerging Medtech Summit 2021, on May [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-to-present-at-the-emerging-medtech-summit-2021/" title="NorthStar Medical Radioisotopes to Present at the Emerging Medtech Summit 2021" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> April 13, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-provides-updates-on-corporate-progress-and-upcoming-milestones/" title="NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones">NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones</a> </div> <div class="news-excerpt"> <p>− NorthStar has provided reliable molybdenum-99 (Mo-99)/technetium-99m (Tc-99m) supply for more than two years as the only U.S. commercial Mo-99 producer − Second NorthStar Mo-99 production and processing facility nearing completion ensuring even more reliable supply and additional Mo-99 production capability − RadioGenix® System sales continue growth, reliably providing hundreds of thousands of Tc-99m doses [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-provides-updates-on-corporate-progress-and-upcoming-milestones/" title="NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 8, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-iba-expand-collaboration-to-enable-global-availability-of-diagnostic-radioisotope-technetium-99m-tc-99m/" title="NorthStar Medical Radioisotopes and IBA Expand Collaboration to Enable Global Availability of Diagnostic Radioisotope Technetium-99m (Tc-99m)">NorthStar Medical Radioisotopes and IBA Expand Collaboration to Enable Global Availability of Diagnostic Radioisotope Technetium-99m (Tc-99m)</a> </div> <div class="news-excerpt"> <p>− Technetium-99m is the daughter isotope of molybdenum-99 (Mo-99) – − Collaboration enables integrating technology expertise to provide Tc-99m Generation Systems (TCM Generation Systems) that utilize non-uranium based Mo-99 produced using electron beam accelerators − − Diagnostic imaging studies using Tc-99m inform healthcare decisions for approximately 30 million patients annually around the world – BELOIT, [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-and-iba-expand-collaboration-to-enable-global-availability-of-diagnostic-radioisotope-technetium-99m-tc-99m/" title="NorthStar Medical Radioisotopes and IBA Expand Collaboration to Enable Global Availability of Diagnostic Radioisotope Technetium-99m (Tc-99m)" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 3, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-advances-focus-on-therapeutic-and-specialized-spect-radiopharmaceuticals/" title="NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals">NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals</a> </div> <div class="news-excerpt"> <p>− Organizational change positions NorthStar for next stage of growth and ongoing U.S. molybdenum-99 (Mo-99) production expansion − − NorthStar poised to be first commercial-scale supplier of important therapeutic radioisotopes Copper-67 (Cu-67) and Actinium-225 (Ac-225); Initial specialized SPECT imaging portfolio includes fibrin-targeted FibroScint, with potential indications in cardiovascular disease − BELOIT, Wis., March 3, 2021 [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-advances-focus-on-therapeutic-and-specialized-spect-radiopharmaceuticals/" title="NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 2, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-to-present-at-the-h-c-wainwright-global-life-sciences-conference/" title="NorthStar Medical Radioisotopes to Present at the H.C. Wainwright Global Life Sciences Conference">NorthStar Medical Radioisotopes to Present at the H.C. Wainwright Global Life Sciences Conference</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., March 2, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-to-present-at-the-h-c-wainwright-global-life-sciences-conference/" title="NorthStar Medical Radioisotopes to Present at the H.C. Wainwright Global Life Sciences Conference" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> January 6, 2021 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-fda-approval-for-enhanced-u-s-mo-99-radioisotope-production-capacity/" title="NorthStar Medical Radioisotopes Announces FDA Approval for Enhanced U.S. Mo-99 Radioisotope Production Capacity">NorthStar Medical Radioisotopes Announces FDA Approval for Enhanced U.S. Mo-99 Radioisotope Production Capacity</a> </div> <div class="news-excerpt"> <p>− Concentrated molybdenum-98 (cMo-98) enables up to four-fold increase of critical medical radioisotope Mo-99 production in U.S. – − First and only commercial-scale application of innovative cMo-98 production technology – BELOIT, Wis., January 6, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radiopharmaceuticals used for medical imaging and [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-fda-approval-for-enhanced-u-s-mo-99-radioisotope-production-capacity/" title="NorthStar Medical Radioisotopes Announces FDA Approval for Enhanced U.S. Mo-99 Radioisotope Production Capacity" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> December 10, 2020 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/monopar-and-northstar-announce-selection-of-uprit-candidate-for-potential-treatment-of-severe-covid-19/" title="MONOPAR AND NORTHSTAR ANNOUNCE SELECTION OF uPRIT CANDIDATE FOR POTENTIAL TREATMENT OF SEVERE COVID-19">MONOPAR AND NORTHSTAR ANNOUNCE SELECTION OF uPRIT CANDIDATE FOR POTENTIAL TREATMENT OF SEVERE COVID-19</a> </div> <div class="news-excerpt"> <p>Wilmette, IL, and Beloit, WI, December 10, 2020– Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase plasminogen activator receptor targeted radio-immuno-therapeutic (uPRIT) for the potential treatment of severe COVID-19, today announced the selection of a uPRIT clinical candidate. Monopar and NorthStar partnered with IsoTherapeutics Group LLC to [&hellip;]</p> <p><a href="https://www.northstarnm.com/monopar-and-northstar-announce-selection-of-uprit-candidate-for-potential-treatment-of-severe-covid-19/" title="MONOPAR AND NORTHSTAR ANNOUNCE SELECTION OF uPRIT CANDIDATE FOR POTENTIAL TREATMENT OF SEVERE COVID-19" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> December 8, 2020 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-to-participate-in-upcoming-biotech-showcase-2021-digital-industry-conference/" title="NorthStar Medical Technologies to Participate in Upcoming Biotech Showcase 2021 Digital Industry Conference">NorthStar Medical Technologies to Participate in Upcoming Biotech Showcase 2021 Digital Industry Conference</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. – December 8, 2020 – NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Biotech Showcase™ 2021, being delivered digitally January 11 ‒ 15, 2021. Biotech Showcase is an investor conference focused on driving advances [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-to-participate-in-upcoming-biotech-showcase-2021-digital-industry-conference/" title="NorthStar Medical Technologies to Participate in Upcoming Biotech Showcase 2021 Digital Industry Conference" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> October 5, 2020 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-llc-announces-promotion-of-cfo-paul-estrem-to-executive-vice-president-and-appointment-to-northstar-board-of-managers/" title="NorthStar Medical Technologies, LLC Announces Promotion of CFO Paul Estrem to Executive Vice President and Appointment to NorthStar Board of Managers">NorthStar Medical Technologies, LLC Announces Promotion of CFO Paul Estrem to Executive Vice President and Appointment to NorthStar Board of Managers</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., October 5, 2020 – NorthStar Medical Technologies, LLC, a global innovator in the development, production and commercialization of diagnostic and therapeutic radiopharmaceuticals, today announced the promotion of Chief Financial Officer Paul Estrem, to Executive Vice President. Mr. Estrem has also been appointed to the NorthStar Board of Managers, effective October 12, 2020, and [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-llc-announces-promotion-of-cfo-paul-estrem-to-executive-vice-president-and-appointment-to-northstar-board-of-managers/" title="NorthStar Medical Technologies, LLC Announces Promotion of CFO Paul Estrem to Executive Vice President and Appointment to NorthStar Board of Managers" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 17, 2020 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/u-s-deputy-secretary-of-energy-mark-w-menezes-visits-northstar-medical-radioisotopes/" title="U.S. Deputy Secretary of Energy Mark W. Menezes Visits NorthStar Medical Radioisotopes">U.S. Deputy Secretary of Energy Mark W. Menezes Visits NorthStar Medical Radioisotopes</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis., September 17, 2020 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that Deputy Secretary of Energy Mark W. Menezes visited the Company’s Beloit, Wis. headquarters on September 11, 2020. His travel to Wisconsin underscored the Department of Energy’s commitment to [&hellip;]</p> <p><a href="https://www.northstarnm.com/u-s-deputy-secretary-of-energy-mark-w-menezes-visits-northstar-medical-radioisotopes/" title="U.S. Deputy Secretary of Energy Mark W. Menezes Visits NorthStar Medical Radioisotopes" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 9, 2020 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/monopar-and-northstar-collaborating-with-texas-lung-injury-institute-for-testing-of-novel-potential-therapeutic-for-severe-covid-19/" title="Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19">Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19</a> </div> <div class="news-excerpt"> <p>WILMETTE, Ill., BELOIT, Wis. and TYLER, Texas, Sept. 09, 2020 &#8211; Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing urokinase plasminogen activator receptor targeted radio-immuno-therapeutics (uPRITs) for the potential treatment of patients with severe COVID-19, today announced a collaboration with The University of Texas Health Science Center at Tyler [&hellip;]</p> <p><a href="https://www.northstarnm.com/monopar-and-northstar-collaborating-with-texas-lung-injury-institute-for-testing-of-novel-potential-therapeutic-for-severe-covid-19/" title="Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> August 10, 2020 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/monopar-and-northstar-partner-with-isotherapeutics-for-the-manufacturing-of-potential-therapeutic-for-severe-covid-19/" title="Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19">Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19</a> </div> <div class="news-excerpt"> <p>WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI), who are collaborating on the development of Radio-Immuno-Therapeutics (RITs) to treat patients with severe COVID-19, today announced a partnership with IsoTherapeutics Group, LLC (Angleton, TX), to develop [&hellip;]</p> <p><a href="https://www.northstarnm.com/monopar-and-northstar-partner-with-isotherapeutics-for-the-manufacturing-of-potential-therapeutic-for-severe-covid-19/" title="Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> July 23, 2020 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-updated-statement-on-novel-coronavirus-and-reliable-u-s-mo-99-supply/" title="NorthStar Medical Radioisotopes Updated Statement on Novel Coronavirus and Reliable U.S. Mo-99 Supply">NorthStar Medical Radioisotopes Updated Statement on Novel Coronavirus and Reliable U.S. Mo-99 Supply</a> </div> <div class="news-excerpt"> <p>July 23, 2020 Statement Attributable to: Stephen Merrick, President and CEO, NorthStar Medical Radioisotopes NorthStar Medical Radioisotopes supplies a medically critical isotope pair, Mo-99 and Tc-99m, which is used in more than 40,000 U.S. diagnostic imaging procedures daily. Information provided by these scans informs the care and treatment of patients with heart disease and cancer, [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-updated-statement-on-novel-coronavirus-and-reliable-u-s-mo-99-supply/" title="NorthStar Medical Radioisotopes Updated Statement on Novel Coronavirus and Reliable U.S. Mo-99 Supply" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> July 8, 2020 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-participation-in-society-of-nuclear-medicine-and-molecular-imaging-snmmi-molybdenum-99-mo-99-supply-outlook-panel/" title="NorthStar Medical Radioisotopes Announces Participation in Society of Nuclear Medicine and Molecular Imaging (SNMMI) Molybdenum-99 (Mo-99) Supply Outlook Panel">NorthStar Medical Radioisotopes Announces Participation in Society of Nuclear Medicine and Molecular Imaging (SNMMI) Molybdenum-99 (Mo-99) Supply Outlook Panel</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. – July 8, 2020 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced its participation in the Society of Nuclear Medicine and Molecular Imaging (SNMMI) webinar, “Industry Outlook on Current and Future Mo-99 Supply.” James Harvey, PhD, Chief Scientific Officer of [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-participation-in-society-of-nuclear-medicine-and-molecular-imaging-snmmi-molybdenum-99-mo-99-supply-outlook-panel/" title="NorthStar Medical Radioisotopes Announces Participation in Society of Nuclear Medicine and Molecular Imaging (SNMMI) Molybdenum-99 (Mo-99) Supply Outlook Panel" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 16, 2020 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/monopar-and-northstar-join-forces-to-develop-radio-immuno-therapeutics-rits-targeting-severe-covid-19/" title="Monopar and NorthStar Join Forces to Develop Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19">Monopar and NorthStar Join Forces to Develop Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19</a> </div> <div class="news-excerpt"> <p>Chicago, IL and Beloit, WI, June 16, 2020 &#8211; Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today a 50/50 collaboration to develop potential Radio-Immuno-Therapeutics (RITs) to treat severe COVID-19 (patients with SARS-CoV-2 infection). Monopar is a clinical-stage biopharmaceutical company and NorthStar is a commercial producer and supplier [&hellip;]</p> <p><a href="https://www.northstarnm.com/monopar-and-northstar-join-forces-to-develop-radio-immuno-therapeutics-rits-targeting-severe-covid-19/" title="Monopar and NorthStar Join Forces to Develop Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> April 14, 2020 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/world-council-on-isotopes-honors-northstar-medical-radioisotopes-with-presidents-award/" title="World Council on Isotopes Honors NorthStar Medical Radioisotopes with President’s Award">World Council on Isotopes Honors NorthStar Medical Radioisotopes with President’s Award</a> </div> <div class="news-excerpt"> <p>&#8211; Award Recognizes Outstanding Contributions to Isotopes and Their Uses to Benefit Mankind &#8211; BELOIT, Wis., April 14, 2020 &#8212; NorthStar Medical Radioisotopes, LLC, a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it has received the President’s Award from the World Council on Isotopes (WCI). The [&hellip;]</p> <p><a href="https://www.northstarnm.com/world-council-on-isotopes-honors-northstar-medical-radioisotopes-with-presidents-award/" title="World Council on Isotopes Honors NorthStar Medical Radioisotopes with President’s Award" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 20, 2020 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-statement-on-novel-coronavirus-and-reliable-u-s-mo-99-supply/" title="NorthStar Medical Radioisotopes Statement on Novel Coronavirus and Reliable U.S. Mo-99 Supply">NorthStar Medical Radioisotopes Statement on Novel Coronavirus and Reliable U.S. Mo-99 Supply</a> </div> <div class="news-excerpt"> <p>March 19, 2020 Statement Attributable to: Stephen Merrick, President and CEO, NorthStar Medical Radioisotopes NorthStar Medical Radioisotopes supplies a medically critical isotope pair, Mo-99 and Tc-99m, which is used in more than 40,000 U.S. diagnostic imaging procedures daily. Information provided by these scans informs the care and treatment of patients with heart disease and cancer, [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-statement-on-novel-coronavirus-and-reliable-u-s-mo-99-supply/" title="NorthStar Medical Radioisotopes Statement on Novel Coronavirus and Reliable U.S. Mo-99 Supply" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 16, 2020 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-provides-progress-update-on-radiogenix-system-reliable-u-s-molybdenum-99-mo-99-supply-production-expansion-and-rd-advancements/" title="NorthStar Medical Radioisotopes Provides Progress Update on RadioGenix® System, Reliable U.S. Molybdenum-99 (Mo-99) Supply, Production Expansion, and R&#038;D Advancements">NorthStar Medical Radioisotopes Provides Progress Update on RadioGenix® System, Reliable U.S. Molybdenum-99 (Mo-99) Supply, Production Expansion, and R&#038;D Advancements</a> </div> <div class="news-excerpt"> <p>Highlights include: Company marks reliable U.S. Mo-99 production and supply for customers despite ongoing domestic industry supply shortages FDA approval of RadioGenix System version 1.2 enhancements Initiatives for increased domestic Mo-99 production capacity on track: U.S. Food and Drug Administration (FDA)-approved Mo-99 filling lines; isotope processing and accelerator production facilities construction on schedule Strategic acquisition [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-provides-progress-update-on-radiogenix-system-reliable-u-s-molybdenum-99-mo-99-supply-production-expansion-and-rd-advancements/" title="NorthStar Medical Radioisotopes Provides Progress Update on RadioGenix® System, Reliable U.S. Molybdenum-99 (Mo-99) Supply, Production Expansion, and R&#038;D Advancements" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 3, 2020 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-expands-portfolio-with-exclusive-worldwide-licensing-of-investigational-fibrin-targeted-cardiac-diagnostic-imaging-agent/" title="NorthStar Medical Technologies Expands Portfolio with Exclusive, Worldwide Licensing of Investigational Fibrin-targeted Cardiac Diagnostic Imaging Agent">NorthStar Medical Technologies Expands Portfolio with Exclusive, Worldwide Licensing of Investigational Fibrin-targeted Cardiac Diagnostic Imaging Agent</a> </div> <div class="news-excerpt"> <p>− Acquisition of technetium-99m (Tc-99m) SPECT agent expands company portfolio as strategic complement to commercially available RadioGenix® System − − Builds on NorthStar’s leadership expertise in development and commercialization of novel radiopharmaceuticals – − Exploratory Phase 1 study planned to investigate FibroScint (Tc-99m F4A) use in identifying thrombus in heart failure patients with assisted devices; [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-expands-portfolio-with-exclusive-worldwide-licensing-of-investigational-fibrin-targeted-cardiac-diagnostic-imaging-agent/" title="NorthStar Medical Technologies Expands Portfolio with Exclusive, Worldwide Licensing of Investigational Fibrin-targeted Cardiac Diagnostic Imaging Agent" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> February 18, 2020 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/fda-approves-additional-molybdenum-99-mo-99-filling-lines-at-northstar-medical-radioisotopes-columbia-mo-facility/" title="FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes’ Columbia, Mo. Facility">FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes’ Columbia, Mo. Facility</a> </div> <div class="news-excerpt"> <p>− State-of-the art equipment to increase production efficiency and output for U.S.-based Mo-99 supply – Beloit, Wis., February 18, 2020 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has approved the addition of two [&hellip;]</p> <p><a href="https://www.northstarnm.com/fda-approves-additional-molybdenum-99-mo-99-filling-lines-at-northstar-medical-radioisotopes-columbia-mo-facility/" title="FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes’ Columbia, Mo. Facility" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> February 11, 2020 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-signs-letter-of-intent-with-clarity-pharmaceuticals-to-supply-therapeutic-radioisotope-copper-67-cu-67/" title="NorthStar Medical Technologies Signs Letter of Intent with Clarity Pharmaceuticals to Supply Therapeutic Radioisotope Copper-67 (Cu-67)">NorthStar Medical Technologies Signs Letter of Intent with Clarity Pharmaceuticals to Supply Therapeutic Radioisotope Copper-67 (Cu-67)</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. and Sydney, Australia – February 11, 2020 – NorthStar Medical Technologies, LLC (NorthStar), a global innovator in the production and distribution of radioisotopes used for medical imaging, and Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, today announced the signing of a Letter of Intent for the commercial supply [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-signs-letter-of-intent-with-clarity-pharmaceuticals-to-supply-therapeutic-radioisotope-copper-67-cu-67/" title="NorthStar Medical Technologies Signs Letter of Intent with Clarity Pharmaceuticals to Supply Therapeutic Radioisotope Copper-67 (Cu-67)" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> January 21, 2020 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-to-present-at-upcoming-emerging-medtech-summit-2020/" title="NorthStar Medical Technologies to Present at Upcoming Emerging Medtech Summit 2020">NorthStar Medical Technologies to Present at Upcoming Emerging Medtech Summit 2020</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. – January 21, 2020 – NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Emerging Medtech Summit 2020 conference, being held February 18 ‒ 20, 2020, in Dana Point, Ca. The Emerging Medtech Summit 2020 [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-to-present-at-upcoming-emerging-medtech-summit-2020/" title="NorthStar Medical Technologies to Present at Upcoming Emerging Medtech Summit 2020" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> December 16, 2019 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-to-present-at-upcoming-biotech-showcase-2020/" title="NorthStar Medical Technologies to Present at Upcoming Biotech Showcase 2020">NorthStar Medical Technologies to Present at Upcoming Biotech Showcase 2020</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. – December 16, 2019 – NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Biotech Showcase™ 2020, being held January 13 ‒ 15, 2020, in San Francisco, Ca. Biotech Showcase is an investor conference focused [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-to-present-at-upcoming-biotech-showcase-2020/" title="NorthStar Medical Technologies to Present at Upcoming Biotech Showcase 2020" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> November 27, 2019 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-marks-12-months-of-continuous-u-s-molybdenum-99-mo-99-production-and-supply/" title="NorthStar Medical Radioisotopes Marks 12 Months of Continuous U.S. Molybdenum-99 (Mo-99) Production and Supply">NorthStar Medical Radioisotopes Marks 12 Months of Continuous U.S. Molybdenum-99 (Mo-99) Production and Supply</a> </div> <div class="news-excerpt"> <p>− RadioGenix® Systems have enabled reliable technetium 99m (Tc-99m) supply for patients’ diagnostic imaging procedures since product launch, despite ongoing industry supply shortages – Beloit, Wis., November 27, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, announced a landmark for its RadioGenix System [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-marks-12-months-of-continuous-u-s-molybdenum-99-mo-99-production-and-supply/" title="NorthStar Medical Radioisotopes Marks 12 Months of Continuous U.S. Molybdenum-99 (Mo-99) Production and Supply" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> October 15, 2019 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/representatives-from-the-u-s-department-of-energys-national-nuclear-security-administration-state-of-wisconsin-medical-societies-and-customers-join-northstar-medical-radioisotopes/" title="Representatives from the U.S. Department of Energy’s National Nuclear Security Administration, State of Wisconsin, Medical Societies and Customers Join NorthStar Medical Radioisotopes’ Groundbreaking and Speaker Event">Representatives from the U.S. Department of Energy’s National Nuclear Security Administration, State of Wisconsin, Medical Societies and Customers Join NorthStar Medical Radioisotopes’ Groundbreaking and Speaker Event</a> </div> <div class="news-excerpt"> <p>&#8211; Marking NorthStar expansion progress to increase U.S. production of non-highly enriched uranium produced molybdenum-99 (Mo-99), used in producing important medical isotope technetium-99m (Tc-99m) ‒ ‒ Recognizing RadioGenix® System contributions in addressing ongoing Mo-99 supply shortages by providing customers with nearly a year of continuous medical radioisotope supply since launch ‒ Beloit, Wis., October 14, [&hellip;]</p> <p><a href="https://www.northstarnm.com/representatives-from-the-u-s-department-of-energys-national-nuclear-security-administration-state-of-wisconsin-medical-societies-and-customers-join-northstar-medical-radioisotopes/" title="Representatives from the U.S. Department of Energy’s National Nuclear Security Administration, State of Wisconsin, Medical Societies and Customers Join NorthStar Medical Radioisotopes’ Groundbreaking and Speaker Event" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 9, 2019 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-participates-in-coolest-thing-made-in-wisconsin-competition-with-radiogenix-system/" title="NorthStar Medical Radioisotopes Participates in &#8220;Coolest Thing Made in Wisconsin&#8221; Competition with RadioGenix® System">NorthStar Medical Radioisotopes Participates in &#8220;Coolest Thing Made in Wisconsin&#8221; Competition with RadioGenix® System</a> </div> <div class="news-excerpt"> <p>‒ Voting Begins September 9, 2019 at www.madeinwis.com ‒ Beloit, Wis., September 9, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced its participation in the 4th Annual Coolest Thing Made in Wisconsin contest. The event highlights Wisconsin’s vibrant manufacturing industry, its [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-participates-in-coolest-thing-made-in-wisconsin-competition-with-radiogenix-system/" title="NorthStar Medical Radioisotopes Participates in &#8220;Coolest Thing Made in Wisconsin&#8221; Competition with RadioGenix® System" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> August 28, 2019 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-to-present-at-upcoming-atoms-for-humanity-summit/" title="NorthStar Medical Technologies to Present at Upcoming Atoms for Humanity Summit">NorthStar Medical Technologies to Present at Upcoming Atoms for Humanity Summit</a> </div> <div class="news-excerpt"> <p>‒ Panel to discuss domestic Tc-99m radioisotope production, role of nuclear diagnostics and treatments in advancing personalized medicine &#8211; BELOIT, Wis. – August 28, 2019 – NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Atoms for [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-to-present-at-upcoming-atoms-for-humanity-summit/" title="NorthStar Medical Technologies to Present at Upcoming Atoms for Humanity Summit" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> August 20, 2019 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/purdue-university-college-of-pharmacy-and-northstar-medical-radioisotopes-announce-collaborative-agreement-expanding-nuclear-pharmacy-training-curriculum/" title="Purdue University College of Pharmacy and NorthStar Medical Radioisotopes Announce Collaborative Agreement Expanding Nuclear Pharmacy Training Curriculum">Purdue University College of Pharmacy and NorthStar Medical Radioisotopes Announce Collaborative Agreement Expanding Nuclear Pharmacy Training Curriculum</a> </div> <div class="news-excerpt"> <p>Beloit, Wis. and W. Lafayette, Ind., August 20, 2019 – NorthStar Medical Radioisotopes, LLC and Purdue University’s College of Pharmacy today announced a collaborative agreement which expands the College of Pharmacy’s nuclear pharmacy training program. As part of the collaboration, NorthStar has provided a RadioGenix® System to the College of Pharmacy for use in training [&hellip;]</p> <p><a href="https://www.northstarnm.com/purdue-university-college-of-pharmacy-and-northstar-medical-radioisotopes-announce-collaborative-agreement-expanding-nuclear-pharmacy-training-curriculum/" title="Purdue University College of Pharmacy and NorthStar Medical Radioisotopes Announce Collaborative Agreement Expanding Nuclear Pharmacy Training Curriculum" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> July 23, 2019 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-awarded-30-million-cooperative-agreement-by-u-s-department-of-energys-national-nuclear-security-administration-to-expand-domestic-molybdenum-99-mo-99-produ/" title="NorthStar Medical Radioisotopes Awarded $30 Million Cooperative Agreement by U.S. Department of Energy’s National Nuclear Security Administration to Expand Domestic Molybdenum-99 (Mo-99) Production">NorthStar Medical Radioisotopes Awarded $30 Million Cooperative Agreement by U.S. Department of Energy’s National Nuclear Security Administration to Expand Domestic Molybdenum-99 (Mo-99) Production</a> </div> <div class="news-excerpt"> <p>&#8211; Supports enhancements for commercially available RadioGenix® System and technology to increase NorthStar’s current production capacity of non-uranium based Mo-99 &#8211; BELOIT, Wis. – July 23, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it has been awarded $15 million [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-awarded-30-million-cooperative-agreement-by-u-s-department-of-energys-national-nuclear-security-administration-to-expand-domestic-molybdenum-99-mo-99-produ/" title="NorthStar Medical Radioisotopes Awarded $30 Million Cooperative Agreement by U.S. Department of Energy’s National Nuclear Security Administration to Expand Domestic Molybdenum-99 (Mo-99) Production" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> July 17, 2019 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-construction-completion-of-beloit-wisconsin-processing-facility-for-expanded-domestic-production-of-medically-important-molybdenum-99-mo-99/" title="NorthStar Medical Radioisotopes Announces Construction Completion of Beloit, Wisconsin Processing Facility for Expanded Domestic Production of Medically Important Molybdenum-99 (Mo-99)">NorthStar Medical Radioisotopes Announces Construction Completion of Beloit, Wisconsin Processing Facility for Expanded Domestic Production of Medically Important Molybdenum-99 (Mo-99)</a> </div> <div class="news-excerpt"> <p>─ Facility part of staged, dual production pathway plan to expand Mo-99 production and efficiency in parallel with RadioGenix® System enhancements ─ RadioGenix System customers provided with reliable Mo-99 supply throughout eight months since commercial launch, helping mitigate concurrent industry disruptions BELOIT, Wis. – July 16, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-construction-completion-of-beloit-wisconsin-processing-facility-for-expanded-domestic-production-of-medically-important-molybdenum-99-mo-99/" title="NorthStar Medical Radioisotopes Announces Construction Completion of Beloit, Wisconsin Processing Facility for Expanded Domestic Production of Medically Important Molybdenum-99 (Mo-99)" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 12, 2019 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-presentations-on-mo-99-supply-and-the-radiogenix-system-at-upcoming-society-of-nuclear-medicine-and-molecular-imaging-snmmi-annual-meeting/" title="NorthStar Medical Radioisotopes Announces Presentations on Mo-99 Supply and the RadioGenix® System at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting">NorthStar Medical Radioisotopes Announces Presentations on Mo-99 Supply and the RadioGenix® System at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. – June 12, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced upcoming presentations at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI), from June 22 – 26, 2018 in Anaheim, Ca. Presentation topics encompass ongoing domestic [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-presentations-on-mo-99-supply-and-the-radiogenix-system-at-upcoming-society-of-nuclear-medicine-and-molecular-imaging-snmmi-annual-meeting/" title="NorthStar Medical Radioisotopes Announces Presentations on Mo-99 Supply and the RadioGenix® System at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> April 23, 2019 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-closes-100-million-financing-with-oberland-capital-to-expand-domestic-mo-99-radioisotope-production-capacity-and-implement-radiogenix-system-enhancements/" title="NorthStar Medical Closes $100 Million Financing with Oberland Capital to Expand Domestic Mo-99 Radioisotope Production Capacity and Implement RadioGenix® System Enhancements">NorthStar Medical Closes $100 Million Financing with Oberland Capital to Expand Domestic Mo-99 Radioisotope Production Capacity and Implement RadioGenix® System Enhancements</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. – April 23, 2019 – NorthStar Medical Technologies, LLC, (“NorthStar” or the “Company”) a global innovator in the production and distribution of radioisotopes used for medical imaging and therapy, today announced the closing of a $100 million secured financing with funds managed by Oberland Capital Management LLC (“Oberland Capital”). NorthStar received $75 million [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-closes-100-million-financing-with-oberland-capital-to-expand-domestic-mo-99-radioisotope-production-capacity-and-implement-radiogenix-system-enhancements/" title="NorthStar Medical Closes $100 Million Financing with Oberland Capital to Expand Domestic Mo-99 Radioisotope Production Capacity and Implement RadioGenix® System Enhancements" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 29, 2019 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-llc-signs-contract-with-iba-for-eight-rhodotron-electron-beam-accelerators-to-expand-u-s-production-of-non-uranium-based-radioisotope-mo-99/" title="NorthStar Medical Radioisotopes, LLC Signs Contract with IBA for Eight Rhodotron® Electron Beam Accelerators to Expand U.S. Production of Non-uranium Based Radioisotope Mo-99">NorthStar Medical Radioisotopes, LLC Signs Contract with IBA for Eight Rhodotron® Electron Beam Accelerators to Expand U.S. Production of Non-uranium Based Radioisotope Mo-99</a> </div> <div class="news-excerpt"> <p>– Accelerator technology key component of NorthStar’s multi-pronged Mo-99 production strategy &#8211; BELOIT, Wis. – March 29, 2019 – NorthStar Medical Radioisotopes, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, and IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-llc-signs-contract-with-iba-for-eight-rhodotron-electron-beam-accelerators-to-expand-u-s-production-of-non-uranium-based-radioisotope-mo-99/" title="NorthStar Medical Radioisotopes, LLC Signs Contract with IBA for Eight Rhodotron® Electron Beam Accelerators to Expand U.S. Production of Non-uranium Based Radioisotope Mo-99" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> February 5, 2019 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-llc-announces-business-update-and-commercial-progress-on-radiogenix-system-launch/" title="NorthStar Medical Radioisotopes, LLC Announces Business Update and Commercial Progress on RadioGenix® System Launch">NorthStar Medical Radioisotopes, LLC Announces Business Update and Commercial Progress on RadioGenix® System Launch</a> </div> <div class="news-excerpt"> <p>&#8211; Positive RadioGenix System market momentum continues &#8211; &#8211; Increasing weekly domestic production of non-uranium based Mo-99 &#8211; Highlights include: Strategically-planned RadioGenix System roll out on track; initial units in use Numerous RadioGenix System commercial sites in regulatory licensure review process; many additional sites anticipated in 2019 Every week, an increasing number of technetium-99m (Tc-99m) [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-llc-announces-business-update-and-commercial-progress-on-radiogenix-system-launch/" title="NorthStar Medical Radioisotopes, LLC Announces Business Update and Commercial Progress on RadioGenix® System Launch" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> December 18, 2018 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-llc-announces-appointment-of-paul-estrem-cpa-as-senior-vice-president-and-chief-financial-officer/" title="NorthStar Medical Technologies, LLC Announces Appointment of Paul Estrem, CPA, as Senior Vice President and Chief Financial Officer">NorthStar Medical Technologies, LLC Announces Appointment of Paul Estrem, CPA, as Senior Vice President and Chief Financial Officer</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. – December 18, 2018 –NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced the appointment of Paul Estrem, CPA, as Senior Vice President and Chief Financial Officer. Mr. Estrem holds financial responsibility for the operations of company, reporting to President and Chief [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-llc-announces-appointment-of-paul-estrem-cpa-as-senior-vice-president-and-chief-financial-officer/" title="NorthStar Medical Technologies, LLC Announces Appointment of Paul Estrem, CPA, as Senior Vice President and Chief Financial Officer" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> October 1, 2018 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/u-s-department-of-energys-national-nuclear-security-administration-honors-northstar-medical-radioisotopes-as-first-u-s-producer-of-medical-radioisotope-molybdenum-99-in-nearly-30-years/" title="U.S. Department of Energy’s National Nuclear Security Administration Honors NorthStar Medical Radioisotopes as First U.S. Producer of Medical Radioisotope Molybdenum-99 in Nearly 30 Years">U.S. Department of Energy’s National Nuclear Security Administration Honors NorthStar Medical Radioisotopes as First U.S. Producer of Medical Radioisotope Molybdenum-99 in Nearly 30 Years</a> </div> <div class="news-excerpt"> <p>&#8211; Award for Outstanding Achievement presented at 2018 Molybdenum-99 Topical Meeting &#8211; Beloit, Wis., October 1, 2018 – NorthStar Medical Radioisotopes, LLC, a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it received an Award for Outstanding Achievement from the U.S. Department of Energy’s National Nuclear Security [&hellip;]</p> <p><a href="https://www.northstarnm.com/u-s-department-of-energys-national-nuclear-security-administration-honors-northstar-medical-radioisotopes-as-first-u-s-producer-of-medical-radioisotope-molybdenum-99-in-nearly-30-years/" title="U.S. Department of Energy’s National Nuclear Security Administration Honors NorthStar Medical Radioisotopes as First U.S. Producer of Medical Radioisotope Molybdenum-99 in Nearly 30 Years" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 17, 2018 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-llc-announces-appointment-of-stephen-merrick-as-president-and-chief-executive-officer/" title="NorthStar Medical Technologies, LLC Announces Appointment of Stephen Merrick as President and Chief Executive Officer">NorthStar Medical Technologies, LLC Announces Appointment of Stephen Merrick as President and Chief Executive Officer</a> </div> <div class="news-excerpt"> <p>&#8211; Former Chairman and CEO George Messina named Chairman Emeritus; appointed President and Chief Executive Officer of NorthStar Nuclear Therapies LLC – &#8211; Diane Hendricks appointed as Chairperson of the Board &#8211; BELOIT, Wis. – Sept. 14, 2018 – The Board of Managers of NorthStar Medical Technologies, LLC (“NorthStar” or the “Company”), a global innovator [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-llc-announces-appointment-of-stephen-merrick-as-president-and-chief-executive-officer/" title="NorthStar Medical Technologies, LLC Announces Appointment of Stephen Merrick as President and Chief Executive Officer" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> July 24, 2018 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-fda-approval-of-beloit-wis-facility-for-radiogenix-system-manufacturing-and-provides-update-on-commercial-launch-status/" title="NorthStar Medical Radioisotopes Announces FDA Approval of Beloit, Wis. Facility for RadioGenix™ System Manufacturing and Provides Update on Commercial Launch Status">NorthStar Medical Radioisotopes Announces FDA Approval of Beloit, Wis. Facility for RadioGenix™ System Manufacturing and Provides Update on Commercial Launch Status</a> </div> <div class="news-excerpt"> <p>&#8211; Approval enables expanded manufacturing capacity and supports commercial launch of RadioGenix Systems to produce critically important diagnostic imaging radioisotope technetium-99m from domestic, non-uranium based molybdenum-99 &#8211; BELOIT, Wis. – July 24, 2018 – NorthStar Medical Radioisotopes, LLC (NorthStar), a company involved in the production and distribution of radioisotopes used for medical imaging, today announced [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-fda-approval-of-beloit-wis-facility-for-radiogenix-system-manufacturing-and-provides-update-on-commercial-launch-status/" title="NorthStar Medical Radioisotopes Announces FDA Approval of Beloit, Wis. Facility for RadioGenix™ System Manufacturing and Provides Update on Commercial Launch Status" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 19, 2018 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-mo-99-supply-update-presentation-at-upcoming-society-of-nuclear-medicine-and-molecular-imaging-snmmi-annual-meeting/" title="NorthStar Medical Radioisotopes Announces Mo-99 Supply Update Presentation at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting">NorthStar Medical Radioisotopes Announces Mo-99 Supply Update Presentation at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. – June 19, 2018 – NorthStar Medical Radioisotopes, LLC (NorthStar), a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in a panel session on molybdenum-99 (Mo-99) supply at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI), from June 23 [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-announces-mo-99-supply-update-presentation-at-upcoming-society-of-nuclear-medicine-and-molecular-imaging-snmmi-annual-meeting/" title="NorthStar Medical Radioisotopes Announces Mo-99 Supply Update Presentation at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 18, 2018 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-updates-progress-on-actinium-225-radioisotope-program/" title="NorthStar Medical Technologies Updates Progress on Actinium-225 Radioisotope Program">NorthStar Medical Technologies Updates Progress on Actinium-225 Radioisotope Program</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. – June 18, 2018 – NorthStar Medical Technologies (NorthStar), a company involved in the development, production and distribution of radioisotopes for medical imaging and therapeutics, today provided a progress update on its actinium-225 (Ac-225) radioisotope program. Ac-225 is a high energy alpha-emitting radioisotope with potential therapeutic applications as a Targeted Alpha Therapy (TAT) [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-updates-progress-on-actinium-225-radioisotope-program/" title="NorthStar Medical Technologies Updates Progress on Actinium-225 Radioisotope Program" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> April 30, 2018 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/representatives-from-the-u-s-department-of-energys-national-nuclear-security-administration-and-state-of-wisconsin-join-northstar-medical-radioisotopes-groundbreaking-and-speaker-ev/" title="Representatives from the U.S. Department of Energy’s National Nuclear Security Administration and State of Wisconsin Join NorthStar Medical Radioisotopes’ Groundbreaking and Speaker Event">Representatives from the U.S. Department of Energy’s National Nuclear Security Administration and State of Wisconsin Join NorthStar Medical Radioisotopes’ Groundbreaking and Speaker Event</a> </div> <div class="news-excerpt"> <p>&#8211; Event recognizes recent U.S. Food and Drug approval of NorthStar’s RadioGenix™ System for use in producing the widely used medical isotope technetium-99m (Tc-99m) from non-uranium produced molybdenum-99 (Mo-99), the first domestic production in more than 25 years &#8211; BELOIT, Wis. – April 30, 2018 – NorthStar Medical Radioisotopes, LLC (NorthStar), a company involved in [&hellip;]</p> <p><a href="https://www.northstarnm.com/representatives-from-the-u-s-department-of-energys-national-nuclear-security-administration-and-state-of-wisconsin-join-northstar-medical-radioisotopes-groundbreaking-and-speaker-ev/" title="Representatives from the U.S. Department of Energy’s National Nuclear Security Administration and State of Wisconsin Join NorthStar Medical Radioisotopes’ Groundbreaking and Speaker Event" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> February 8, 2018 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/u-s-fda-approves-northstar-medical-radioisotopes-radiogenix-system-technetium-tc-99m-generator-non-uranium-sourced-molybdenum-99-mo-99-production-imaging-isotope-techneti/" title="U.S. FDA Approves NorthStar Medical Radioisotopes’ RadioGenix™ System (Technetium Tc 99m Generator) for Non-uranium Sourced Molybdenum-99 (Mo-99) Production of Imaging Isotope Technetium-99m (Tc-99m)">U.S. FDA Approves NorthStar Medical Radioisotopes’ RadioGenix™ System (Technetium Tc 99m Generator) for Non-uranium Sourced Molybdenum-99 (Mo-99) Production of Imaging Isotope Technetium-99m (Tc-99m)</a> </div> <div class="news-excerpt"> <p>&#8211; Enables domestic Mo-99 supply produced without uranium for U.S. healthcare &#8211; &#8211; First U.S. source of medical radioisotope Mo-99 in more than 25 years &#8211; BELOIT, Wis. – February 8, 2018 – NorthStar Medical Radioisotopes, LLC, (NorthStar) a company involved in the production and distribution of radioisotopes used for medical imaging, today announced that the U.S. Food [&hellip;]</p> <p><a href="https://www.northstarnm.com/u-s-fda-approves-northstar-medical-radioisotopes-radiogenix-system-technetium-tc-99m-generator-non-uranium-sourced-molybdenum-99-mo-99-production-imaging-isotope-techneti/" title="U.S. FDA Approves NorthStar Medical Radioisotopes’ RadioGenix™ System (Technetium Tc 99m Generator) for Non-uranium Sourced Molybdenum-99 (Mo-99) Production of Imaging Isotope Technetium-99m (Tc-99m)" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 23, 2017 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/lisa-holst-joins-northstar-medical-radioisotopes-vice-president-sales-marketing/" title="Lisa Holst Joins NorthStar Medical Radioisotopes as Vice President of Sales and Marketing">Lisa Holst Joins NorthStar Medical Radioisotopes as Vice President of Sales and Marketing</a> </div> <div class="news-excerpt"> <p>Holst has more than 25 years of sales and marketing experience in the pharmaceutical and medical imaging industries, most recently as senior director of marketing at Navidea Biopharmaceuticals. She joins NorthStar as it advances toward U.S. Food and Drug Administration (FDA) approval of its RadioGenix™ intelligent isotope separation system and its non-fission, non-uranium-based brand of [&hellip;]</p> <p><a href="https://www.northstarnm.com/lisa-holst-joins-northstar-medical-radioisotopes-vice-president-sales-marketing/" title="Lisa Holst Joins NorthStar Medical Radioisotopes as Vice President of Sales and Marketing" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> December 20, 2016 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-receives-follow-award-national-nuclear-security-administration-2/" title="NorthStar Medical Technologies Receives Follow-on Award from National Nuclear Security Administration">NorthStar Medical Technologies Receives Follow-on Award from National Nuclear Security Administration</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. – NorthStar Medical Technologies LLC, parent company of NorthStar Medical Radioisotopes LLC, has received additional matching funds from the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA), bringing to $11.1 million the total funded for NorthStar Medical Radioisotopes’ accelerator method of producing the medical radioisotope molybdenum-99 (Mo-99). The award supports the process’ [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-receives-follow-award-national-nuclear-security-administration-2/" title="NorthStar Medical Technologies Receives Follow-on Award from National Nuclear Security Administration" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 13, 2016 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/james-harvey-ph-d-northstar-medical-radioisotopes-present-nnsa-2016-mo-99-topical-meeting-2/" title="James Harvey, Ph.D. of NorthStar Medical Radioisotopes to Present at NNSA 2016 Mo-99 Topical Meeting">James Harvey, Ph.D. of NorthStar Medical Radioisotopes to Present at NNSA 2016 Mo-99 Topical Meeting</a> </div> <div class="news-excerpt"> <p>ST. LOUIS (Sept. 13, 2016) – At the National Nuclear Security Administration’s (NNSA) 2016 Mo-99 Topical Meeting in St. Louis, NorthStar Medical Radioisotopes LLC Senior Vice President and Chief Science Officer James Harvey, Ph.D. will report on the company’s progress toward establishing a domestic supply of the medical radioisotope molybdenum-99 (Mo-99) produced without the use [&hellip;]</p> <p><a href="https://www.northstarnm.com/james-harvey-ph-d-northstar-medical-radioisotopes-present-nnsa-2016-mo-99-topical-meeting-2/" title="James Harvey, Ph.D. of NorthStar Medical Radioisotopes to Present at NNSA 2016 Mo-99 Topical Meeting" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 12, 2016 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-adds-regulatory-affairs-engineering-leaders-management-team/" title="NorthStar Medical Radioisotopes Adds Regulatory Affairs and Engineering Leaders to its Management Team">NorthStar Medical Radioisotopes Adds Regulatory Affairs and Engineering Leaders to its Management Team</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. (Sept. 12, 2016) – NorthStar Medical Radioisotopes LLC has hired James Brodack as vice president of regulatory affairs/quality assurance and Rim Milunas as vice president of engineering. Brodack oversees day-to-day regulatory and quality operations at NorthStar. Milunas spearheads research and development. product design and engineering, with a strong focus on product development and [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-adds-regulatory-affairs-engineering-leaders-management-team/" title="NorthStar Medical Radioisotopes Adds Regulatory Affairs and Engineering Leaders to its Management Team" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 10, 2016 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-receives-three-patents-trademark-approval-radiogenix-isotope-separation-system-key-components-patented-brand-molybdenum-99-trademarked/" title="NorthStar Medical Radioisotopes Receives Three Patents and Trademark Approval RadioGenix™ Isotope Separation System and Key Components Patented; Brand of Molybdenum-99 Trademarked">NorthStar Medical Radioisotopes Receives Three Patents and Trademark Approval RadioGenix™ Isotope Separation System and Key Components Patented; Brand of Molybdenum-99 Trademarked</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. (June 10, 2016) – NorthStar Medical Radioisotopes LLC has been awarded three patents and a trademark approval from the United States Patent and Trademark Office. Patents were granted for the RadioGenix™ isotope separation system and two of its key components – the Molybdenum-99 (Mo-99) Source Vessel and the Technetium-99m (Tc-99m) Product Cartridge. A [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-receives-three-patents-trademark-approval-radiogenix-isotope-separation-system-key-components-patented-brand-molybdenum-99-trademarked/" title="NorthStar Medical Radioisotopes Receives Three Patents and Trademark Approval RadioGenix™ Isotope Separation System and Key Components Patented; Brand of Molybdenum-99 Trademarked" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> May 11, 2016 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-expanding-murr-operations-quadrupling-molybdenum-99-dispensing-capacity/" title="NorthStar Medical Radioisotopes Expanding MURR Operations, Quadrupling Molybdenum-99 Dispensing Capacity">NorthStar Medical Radioisotopes Expanding MURR Operations, Quadrupling Molybdenum-99 Dispensing Capacity</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. – NorthStar Medical Radioisotopes LLC is enhancing its production operations at the University of Missouri Research Reactor (MURR) in Columbia, Missouri, adding a new filling line that will quadruple the company’s capacity there to dispense the medical radioisotope molybdenum-99 (Mo-99). NorthStar has contracted with Von Gahlen International Inc. to design and install the system, which will include [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-expanding-murr-operations-quadrupling-molybdenum-99-dispensing-capacity/" title="NorthStar Medical Radioisotopes Expanding MURR Operations, Quadrupling Molybdenum-99 Dispensing Capacity" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> May 2, 2016 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/stephen-merrick-joins-northstar-medical-radioisotopes-coo/" title="Stephen Merrick Joins NorthStar Medical Radioisotopes as COO">Stephen Merrick Joins NorthStar Medical Radioisotopes as COO</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. – Stephen Merrick has joined NorthStar Medical Radioisotopes LLC as Senior Vice President and Chief Operating Officer, a newly created position with the company. Merrick brings 24 years of experience in the biotechnology/pharmaceutical/life sciences sector, having held multiple executive positions with leading global companies. He will oversee day-to-day operations at NorthStar – including engineering, production and customer [&hellip;]</p> <p><a href="https://www.northstarnm.com/stephen-merrick-joins-northstar-medical-radioisotopes-coo/" title="Stephen Merrick Joins NorthStar Medical Radioisotopes as COO" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> October 22, 2015 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-receives-11-75-million-national-nuclear-security-administration/" title="NorthStar Medical Radioisotopes Receives $11.75 Million from National Nuclear Security Administration">NorthStar Medical Radioisotopes Receives $11.75 Million from National Nuclear Security Administration</a> </div> <div class="news-excerpt"> <p>MADISON, Wis. – NorthStar Medical Radioisotopes LLC has received $11.75 million from the U.S. Department of Energy’s (DOE) National Nuclear Security Administration (NNSA) for continued development and commercialization of two technologies to produce the medical radioisotope molybdenum-99 (Mo-99) without the use of highly enriched uranium (HEU). NNSA provided $8.86 million to support NorthStar’s neutron capture production process and $2.89 million for the company’s accelerator production process. [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-receives-11-75-million-national-nuclear-security-administration/" title="NorthStar Medical Radioisotopes Receives $11.75 Million from National Nuclear Security Administration" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 9, 2015 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-westinghouse-explore-potential-new-process-producing-medical-radioisotopes/" title="NorthStar and Westinghouse to Explore Potential New Process for Producing Medical Radioisotopes">NorthStar and Westinghouse to Explore Potential New Process for Producing Medical Radioisotopes</a> </div> <div class="news-excerpt"> <p>MADISON, Wis. – NorthStar Medical Radioisotopes LLC and the Westinghouse Electric Company LLC have completed a memorandum of understanding under which the companies will explore the potential for producing medical radioisotopes in commercial nuclear reactors. Of particular interest is the generation of molybdenum-99 (Mo-99) via the irradiation of molybdenum-98 (Mo-98) in the commercial nuclear reactor core. This collaboration is [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-westinghouse-explore-potential-new-process-producing-medical-radioisotopes/" title="NorthStar and Westinghouse to Explore Potential New Process for Producing Medical Radioisotopes" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> August 31, 2015 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-receives-approval-begin-routine-production-molybdenum-99-university-missouri-research-reactor/" title="NorthStar Medical Radioisotopes Receives Approval to Begin Routine Production of Molybdenum-99 at University of Missouri Research Reactor">NorthStar Medical Radioisotopes Receives Approval to Begin Routine Production of Molybdenum-99 at University of Missouri Research Reactor</a> </div> <div class="news-excerpt"> <p>MADISON, Wis. – NorthStar Medical Radioisotopes LLC has received approval to begin routine production of molybdenum-99 (Mo-99) at the University of Missouri Research Reactor (MURR) facility in Columbia, Mo. The company will now be able regularly operate its proprietary aliquoting system at the MURR site to fill source vessels with Mo-99, enabling the company to establish a weekly production [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-receives-approval-begin-routine-production-molybdenum-99-university-missouri-research-reactor/" title="NorthStar Medical Radioisotopes Receives Approval to Begin Routine Production of Molybdenum-99 at University of Missouri Research Reactor" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> May 6, 2015 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-completes-first-production-scale-test-run-molybdenum-99-aliquoting-system-university-missouri-research-reactor/" title="NorthStar Medical Radioisotopes Completes First Production-Scale Test Run of Molybdenum-99 Aliquoting System at the University of Missouri Research Reactor">NorthStar Medical Radioisotopes Completes First Production-Scale Test Run of Molybdenum-99 Aliquoting System at the University of Missouri Research Reactor</a> </div> <div class="news-excerpt"> <p>MADISON, Wis. – NorthStar Medical Radioisotopes LLC has completed its first production-scale test run of the molybdenum-99 (Mo-99) aliquoting system installed at the University of Missouri Research Reactor (MURR) in Columbia, Missouri. The test and subsequent shipment of the resulting Mo-99 to NorthStar’s Madison facility is another milestone in the establishment of domestic production of the vital medical radioisotope. [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-completes-first-production-scale-test-run-molybdenum-99-aliquoting-system-university-missouri-research-reactor/" title="NorthStar Medical Radioisotopes Completes First Production-Scale Test Run of Molybdenum-99 Aliquoting System at the University of Missouri Research Reactor" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 10, 2015 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/james-harvey-ph-d-northstar-medical-radioisotopes-present-american-pharmacists-association-annual-meeting-exposition/" title="James Harvey, Ph.D. of NorthStar Medical Radioisotopes to Present at American Pharmacists Association Annual Meeting &#038; Exposition">James Harvey, Ph.D. of NorthStar Medical Radioisotopes to Present at American Pharmacists Association Annual Meeting &#038; Exposition</a> </div> <div class="news-excerpt"> <p>MADISON, Wis. – James Harvey, Ph.D., senior vice president and chief science officer of NorthStar Medical Radioisotopes LLC, will be a featured speaker at the American Pharmacists Association Annual Meeting &amp; Exposition (APhA2015) in San Diego later this month, highlighting new technologies and techniques that will create a commercially viable domestic supply of the medical radioisotope molybdenum-99 (Mo-99). Harvey [&hellip;]</p> <p><a href="https://www.northstarnm.com/james-harvey-ph-d-northstar-medical-radioisotopes-present-american-pharmacists-association-annual-meeting-exposition/" title="James Harvey, Ph.D. of NorthStar Medical Radioisotopes to Present at American Pharmacists Association Annual Meeting &#038; Exposition" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> November 14, 2014 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-awarded-additional-funding-national-nuclear-security-administration/" title="NorthStar Medical Radioisotopes Awarded Additional Funding from National Nuclear Security Administration">NorthStar Medical Radioisotopes Awarded Additional Funding from National Nuclear Security Administration</a> </div> <div class="news-excerpt"> <p>MADISON, Wis. – NorthStar Medical Radioisotopes LLC has been awarded $5.2 million in additional funding by the U.S. Department of Energy’s (DOE) National Nuclear Security Administration (NNSA). The grant supports the continued development and commercialization of the company’s neutron capture process for producing the medical radioisotope molybdenum-99 (Mo-99) without the use of highly enriched uranium (HEU). Under the terms of the cooperative agreement [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-awarded-additional-funding-national-nuclear-security-administration/" title="NorthStar Medical Radioisotopes Awarded Additional Funding from National Nuclear Security Administration" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> August 14, 2014 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-signs-letter-intent-ge-healthcare-2/" title="NorthStar Medical Radioisotopes Signs Letter of Intent with GE Healthcare">NorthStar Medical Radioisotopes Signs Letter of Intent with GE Healthcare</a> </div> <div class="news-excerpt"> <p>Madison, Wis. – August 14, 2014 – NorthStar Medical Radioisotopes LLC has signed a non-exclusive letter of intent with GE Healthcare, a division of General Electric Company (NYSE: GE), marking further progress toward establishing the first existing commercially viable domestic source of the radioisotope 99molybdenum (99Mo). 99Mo is the parent isotope of 99mtechnetium (99mTc), the most widely [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-signs-letter-intent-ge-healthcare-2/" title="NorthStar Medical Radioisotopes Signs Letter of Intent with GE Healthcare" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> July 22, 2014 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-breaks-ground-new-facility-beloit-wis/" title="NorthStar Medical Radioisotopes Breaks Ground for New Facility in Beloit, Wis.">NorthStar Medical Radioisotopes Breaks Ground for New Facility in Beloit, Wis.</a> </div> <div class="news-excerpt"> <p>BELOIT, Wis. – July 22, 2014 – NorthStar Medical Radioisotopes LLC broke ground today for a new 50,000-square-foot facility at 1800 Gateway Blvd. in Beloit, Wis. When completed in late 2014, the facility will house the company’s headquarters and activities related to the production of the medical radioisotope molybdenum-99 (Mo-99). Video Courtesy WKOW News NorthStar Medical Radioisotopes Breaks Ground [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-breaks-ground-new-facility-beloit-wis/" title="NorthStar Medical Radioisotopes Breaks Ground for New Facility in Beloit, Wis." class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> July 15, 2014 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-mo-99-topical-meeting-chief-science-officer-reports-continued-progress-toward-non-uranium-based-production-mo-99/" title="NorthStar Medical Radioisotopes at the Mo-99 Topical Meeting">NorthStar Medical Radioisotopes at the Mo-99 Topical Meeting</a> </div> <div class="news-excerpt"> <p>WASHINGTON, D.C. – July 15, 2014 – NorthStar Medical Radioisotopes LLC is making continued progress towards establishing a commercially viable domestic supply of the radioisotope molybdenum-99 (Mo-99), according to NorthStar’s chief science officer, James T. Harvey, Ph. D. Harvey provided an update on NorthStar’s progress in two presentations at the 2014 Mo-99 Topical Meeting here, [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-mo-99-topical-meeting-chief-science-officer-reports-continued-progress-toward-non-uranium-based-production-mo-99/" title="NorthStar Medical Radioisotopes at the Mo-99 Topical Meeting" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 30, 2014 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-signs-emissions-pledge-preparatory-commission-comprehensive-nuclear-test-ban-treaty-organization/" title="NorthStar Medical Radioisotopes Signs Emissions Pledge with Preparatory Commission for the Comprehensive Nuclear-Test-Ban Treaty Organization">NorthStar Medical Radioisotopes Signs Emissions Pledge with Preparatory Commission for the Comprehensive Nuclear-Test-Ban Treaty Organization</a> </div> <div class="news-excerpt"> <p>MADISON, Wis. – June 30, 2014 – NorthStar Medical Radioisotopes LLC has signed a pledge with the Preparatory Commission for the Comprehensive Nuclear-Test-Ban Treaty Organization (CTBTO) designed to help the CTBTO detect nuclear testing. In signing the Radioxenon Emissions Pledge, NorthStar stated that its production of the medical radioisotope molybdenum-99 (Mo-99) does not result in the emission [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-signs-emissions-pledge-preparatory-commission-comprehensive-nuclear-test-ban-treaty-organization/" title="NorthStar Medical Radioisotopes Signs Emissions Pledge with Preparatory Commission for the Comprehensive Nuclear-Test-Ban Treaty Organization" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> June 7, 2014 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-signs-letter-intent-triad-isotopes-bring-new-domestic-source-non-heu-materials-market/" title="NorthStar Medical Technologies Signs Letter of Intent with Triad Isotopes To Bring New Domestic Source of Non-HEU Materials To Market">NorthStar Medical Technologies Signs Letter of Intent with Triad Isotopes To Bring New Domestic Source of Non-HEU Materials To Market</a> </div> <div class="news-excerpt"> <p>ST. LOUIS, MO &#8211; June 7, 2014 &#8211; Signaling progress in the drive to launch the first commercially-viable domestic source of non-HEU materials, NorthStar Medical Technologies, LLC today announced the signing of a non-exclusive Letter of Intent with Triad Isotopes, Inc.  The agreement solidifies Triad’s position as an early adopter of domestically-sourced Non-HEU Molybdenum99 through [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-signs-letter-intent-triad-isotopes-bring-new-domestic-source-non-heu-materials-market/" title="NorthStar Medical Technologies Signs Letter of Intent with Triad Isotopes To Bring New Domestic Source of Non-HEU Materials To Market" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> November 21, 2013 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/nnsa-awards-northstar-medical-technologies-cooperative-agreement-produce-critical-medical-isotope/" title="NNSA awards NorthStar Medical Technologies a Cooperative Agreement to Produce Critical Medical Isotope">NNSA awards NorthStar Medical Technologies a Cooperative Agreement to Produce Critical Medical Isotope</a> </div> <div class="news-excerpt"> <p>MADISON, WI – November 21, 2013 – NorthStar Medical Technologies, LLC (“NorthStar”), today announced it was awarded a $21.8 million cooperative agreement of which $10.9 million will be funded by the Department of Energy’s (DOE) National Nuclear Security Administration (NNSA). The cooperative agreement is part of the NNSA’s Global Threat Reduction Initiative, which aims to [&hellip;]</p> <p><a href="https://www.northstarnm.com/nnsa-awards-northstar-medical-technologies-cooperative-agreement-produce-critical-medical-isotope/" title="NNSA awards NorthStar Medical Technologies a Cooperative Agreement to Produce Critical Medical Isotope" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 17, 2013 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/wisconsins-northstar-medical-technologies-secures-13-5-million-additional-funding-radioisotope-production/" title="Wisconsin’s NorthStar Medical Technologies Secures $13.5 Million in Additional Funding for Radioisotope Production">Wisconsin’s NorthStar Medical Technologies Secures $13.5 Million in Additional Funding for Radioisotope Production</a> </div> <div class="news-excerpt"> <p>MADISON, WI – September 17, 2013 – NorthStar Medical Technologies, LLC (“NorthStar”), a manufacturer and distributor of domestically-produced radioisotopes for the nuclear medicine industry, today announced the closing of a financing round totaling $13.5 million. The round was led by NorthStar’s lead investor, Hendricks Holding Company, Inc., and a group of accredited local investors. Proceeds [&hellip;]</p> <p><a href="https://www.northstarnm.com/wisconsins-northstar-medical-technologies-secures-13-5-million-additional-funding-radioisotope-production/" title="Wisconsin’s NorthStar Medical Technologies Secures $13.5 Million in Additional Funding for Radioisotope Production" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 20, 2013 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-files-new-drug-application-fda/" title="NorthStar Medical Technologies Files New Drug Application with FDA">NorthStar Medical Technologies Files New Drug Application with FDA</a> </div> <div class="news-excerpt"> <p>MADISON, WI – March 20, 2013 – NorthStar Medical Technologies, LLC, (NorthStar) announced that it has submitted a New Drug Application (NDA) with the Food and Drug Administration (FDA).  The FDA has accepted the application for review.  The submission is for NorthStar’s TechneGen™ Generator System, which will allow nuclear pharmacies to process radioisotopes for critical medical [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-files-new-drug-application-fda/" title="NorthStar Medical Technologies Files New Drug Application with FDA" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> November 15, 2012 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-awarded-22-2-million-federal-funds/" title="NorthStar Medical Radioisotopes Awarded $22.2 Million in Federal Funds">NorthStar Medical Radioisotopes Awarded $22.2 Million in Federal Funds</a> </div> <div class="news-excerpt"> <p>MADISON, WI. – November 15, 2012 – NorthStar Medical Radioisotopes, LLC (NorthStar), today announced that it has been awarded $22.2 million in federal funding in a Phase 2 cooperative agreement through the National Nuclear Security Administration&#8217;s (NNSA) Global Threat Reduction Initiative. The cooperative agreement marks successful completion of an Environmental Assessment of NorthStar’s proposed Beloit, Wis. facility. [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-awarded-22-2-million-federal-funds/" title="NorthStar Medical Radioisotopes Awarded $22.2 Million in Federal Funds" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 26, 2012 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-technologies-hendricks-commercial-properties-sign-agreement-beloit-facility-development/" title="NorthStar Medical Technologies, Hendricks Commercial Properties Sign Agreement for Beloit Facility Development">NorthStar Medical Technologies, Hendricks Commercial Properties Sign Agreement for Beloit Facility Development</a> </div> <div class="news-excerpt"> <p>MADISON, WI – September 26, 2012 – NorthStar Medical Technologies, LLC (NorthStar), today announced that it has signed an agreement with Hendricks Commercial Properties, LLC (HCP) to develop a state-of-the-art medical isotope production facility in the Gateway Business Park of Beloit, Wisconsin. The facility will be built to suit for lease. Once complete, the facility [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-technologies-hendricks-commercial-properties-sign-agreement-beloit-facility-development/" title="NorthStar Medical Technologies, Hendricks Commercial Properties Sign Agreement for Beloit Facility Development" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 5, 2012 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/wisconsins-northstar-medical-technologies-secures-5-2-million-additional-funding-safe-domestic-radioisotope-production/" title="Wisconsin&#8217;s NorthStar Medical Technologies Secures $5.2 Million in Additional Funding for Safe, Domestic Radioisotope Production">Wisconsin&#8217;s NorthStar Medical Technologies Secures $5.2 Million in Additional Funding for Safe, Domestic Radioisotope Production</a> </div> <div class="news-excerpt"> <p>MADISON, WI – September 5, 2012 – NorthStar Medical Technologies, LLC (NorthStar), a manufacturer and distributor of domestically-produced radioisotopes for the nuclear medicine field, today announced the closing of a Series D preferred stock financing round totaling $5.2 million. Stateline Angel Investors of Rockford, Illinois, was the lead investor, joined by existing NorthStar investor Hendricks [&hellip;]</p> <p><a href="https://www.northstarnm.com/wisconsins-northstar-medical-technologies-secures-5-2-million-additional-funding-safe-domestic-radioisotope-production/" title="Wisconsin&#8217;s NorthStar Medical Technologies Secures $5.2 Million in Additional Funding for Safe, Domestic Radioisotope Production" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> November 1, 2011 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-receives-additional-funding-award-medical-isotope-program/" title="NorthStar Medical Radioisotopes Receives Additional Funding Award for Medical Isotope Program">NorthStar Medical Radioisotopes Receives Additional Funding Award for Medical Isotope Program</a> </div> <div class="news-excerpt"> <p>(MADISON, Wis. – Nov. 1, 2011) – NorthStar Medical Radioisotopes, LLC (NMR) has signed a follow on cooperative agreement totaling $4.6 million with the National Nuclear Security Administration&#8217;s (NNSA) Global Threat Reduction Initiative for the company&#8217;s medical isotope production program. The cooperative agreement will be funded under a 50-50 cost share arrangement between NMR and [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-receives-additional-funding-award-medical-isotope-program/" title="NorthStar Medical Radioisotopes Receives Additional Funding Award for Medical Isotope Program" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 12, 2011 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/ge-hitachi-nuclear-energy-exelon-announce-potential-production-critical-medical-isotope-clinton-power-station/" title="GE Hitachi Nuclear Energy and Exelon Announce the Potential Production of Critical Medical Isotope at Clinton Power Station">GE Hitachi Nuclear Energy and Exelon Announce the Potential Production of Critical Medical Isotope at Clinton Power Station</a> </div> <div class="news-excerpt"> <p>WILMINGTON, N.C.—September 12, 2011—To help address a shortage of molybdenum-99 (Mo-99), a medical isotope used in millions of medical procedures each year, GE Hitachi Nuclear Energy (GEH) and Exelon have joined to study the feasibility of producing Mo-99 at Clinton Power Station, a nuclear power plant in Clinton, Ill. Mo-99 decays into technetium-99m, an isotope [&hellip;]</p> <p><a href="https://www.northstarnm.com/ge-hitachi-nuclear-energy-exelon-announce-potential-production-critical-medical-isotope-clinton-power-station/" title="GE Hitachi Nuclear Energy and Exelon Announce the Potential Production of Critical Medical Isotope at Clinton Power Station" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> September 8, 2011 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-named-winner-bioforwards-2011-emerging-company-showcase/" title="NorthStar Medical Radioisotopes Named Winner of BioForward’s 2011 Emerging Company Showcase">NorthStar Medical Radioisotopes Named Winner of BioForward’s 2011 Emerging Company Showcase</a> </div> <div class="news-excerpt"> <p>MADISON, Wis. –Sept. 8 &#8212;   NorthStar Medical Radioisotopes was among six Wisconsin bioscience companies to be selected as the winners of BioForward&#8217;s 2011 Emerging Company Showcase. The showcase is part of the 2011 Bioscience Vision Summit, hosted by BioForward, the member-driven state association that is the voice of Wisconsin&#8217;s bioscience industry. The Emerging Company Showcase [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-named-winner-bioforwards-2011-emerging-company-showcase/" title="NorthStar Medical Radioisotopes Named Winner of BioForward’s 2011 Emerging Company Showcase" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> April 7, 2011 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/hendricks-holdings-makes-investment-northstar-medical-radioisotopes/" title="Hendricks Holdings makes Investment in NorthStar Medical Radioisotopes">Hendricks Holdings makes Investment in NorthStar Medical Radioisotopes</a> </div> <div class="news-excerpt"> <p>(MADISON, WI. – April 7, 2011) – NorthStar Medical Radioisotopes, LLC (NorthStar) announced it has received an investment from Hendricks Holdings of Beloit, WI. The investment will allow NorthStar to rapidly pursue introduction of new technologies and production methodologies in the nuclear medicine market for molybdenum-99 and other medically significant radioisotopes. Molybdenum-99 is used to [&hellip;]</p> <p><a href="https://www.northstarnm.com/hendricks-holdings-makes-investment-northstar-medical-radioisotopes/" title="Hendricks Holdings makes Investment in NorthStar Medical Radioisotopes" class="read-more">Read more &raquo;</a></p> </div> <hr> <div class="news-date"> March 1, 2011 &nbsp; &nbsp; &nbsp; Press Releases </div> <div class="news-title"> <a href="https://www.northstarnm.com/northstar-medical-radioisotopes-signs-agreement-missouri-university-supply-molybdenum-99/" title="NorthStar Medical Radioisotopes signs agreement with Missouri University to supply Molybdenum-99">NorthStar Medical Radioisotopes signs agreement with Missouri University to supply Molybdenum-99</a> </div> <div class="news-excerpt"> <p>(MADISON, WI. – March 1, 2011) – NorthStar Medical Radioisotopes, LLC (NorthStar) announced it has signed an agreement with the University of Missouri Research Reactor (MURR) to supply NorthStar with low specific activity molybdenum-99. This agreement allows NorthStar to ramp up over time to 3,000 6-day curies per week. Production operations are expected to begin [&hellip;]</p> <p><a href="https://www.northstarnm.com/northstar-medical-radioisotopes-signs-agreement-missouri-university-supply-molybdenum-99/" title="NorthStar Medical Radioisotopes signs agreement with Missouri University to supply Molybdenum-99" class="read-more">Read more &raquo;</a></p> </div> <hr> </div> </div> </div> </div> </div> <div class="tab-pane fade" id="events" role="tabpanel" aria-labelledby="pills-events-tab"> <div class="row"> <div class="col-md-3 mb-4"> <div class="sticky-top"> <div class="filter-box"> <h3>Filter Events</h3> <form data-sf-form-id='11364' data-is-rtl='0' data-maintain-state='' data-results-url='https://www.northstarnm.com/company/news/' data-ajax-url='https://www.northstarnm.com/?sfid=11364&amp;sf_action=get_data&amp;sf_data=results' data-ajax-form-url='https://www.northstarnm.com/?sfid=11364&amp;sf_action=get_data&amp;sf_data=form' data-display-result-method='shortcode' data-use-history-api='1' data-template-loaded='0' data-lang-code='en' data-ajax='1' data-ajax-data-type='json' data-ajax-links-selector='.pagination a' data-ajax-target='#search-filter-results-11364' data-ajax-pagination-type='normal' data-update-ajax-url='1' data-only-results-ajax='1' data-scroll-to-pos='0' data-init-paged='1' data-auto-update='1' action='https://www.northstarnm.com/company/news/' method='post' class='searchandfilter' id='search-filter-form-11364' autocomplete='off' data-instance-count='1'><ul><li class="sf-field-post-meta-e_start_date" data-sf-field-name="_sfm_e_start_date" data-sf-field-type="post_meta" data-sf-field-input-type="daterange" data-sf-meta-type="date"><h4>Date Range</h4><ul class="sf_date_field" data-date-format="mm/dd/yy" data-date-use-year-dropdown='0' data-date-use-month-dropdown='0'><li> <label> <input class="sf-datepicker sf-input-date sf-input-text" name="_sfm_e_start_date[]" type="text" value="" title=""></label> </li><li> <label> <input class="sf-datepicker sf-input-date sf-input-text" name="_sfm_e_start_date[]" type="text" value="" title=""></label> </li></ul></li><li class="sf-field-search" data-sf-field-name="search" data-sf-field-type="search" data-sf-field-input-type=""><h4>What are you looking for?</h4> <label> <input placeholder="Search..." name="_sf_search[]" class="sf-input-text" type="text" value="" title=""></label> </li></ul></form></div> </div> </div> <div class="col-md-9"> <h4 class="mb-4">Upcoming Events & Presentations</h4> <div class="search-filter-results" id="search-filter-results-11364"> <div class="row events-search row-cols-1 row-cols-md-2" id="results-11364"> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://targeted-radiopharma.com/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/09/TRP-EU-2024-01.png" class="w-100 img-fluid" alt="6th Annual Targeted Radiopharmaceuticals (TRP) Summit Europe" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Dec 3, 2024 - Dec 5, 2024 </div> <div class="event-date blue"> Amsterdam, Netherlands </div> <div class="event-type mb-3 black"> Conference </div> <div class="event-title mb-3 blue"> 6th Annual Targeted Radiopharmaceuticals (TRP) Summit Europe </div> <div class="event-participation lt-gray"> Attending, Sponsoring </div> <div class="event-link"> <a href="https://targeted-radiopharma.com/" target="_blank" class="black">Visit TRP</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.corar.org/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2020/11/corar-2020-01.png" class="w-100 img-fluid" alt="Council on Radionuclides and Radiopharmaceuticals (CORAR) Winter Meeting" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Dec 9, 2024 - Dec 11, 2024 </div> <div class="event-date blue"> Washington, DC </div> <div class="event-type mb-3 black"> Meeting </div> <div class="event-title mb-3 blue"> Council on Radionuclides and Radiopharmaceuticals (CORAR) Winter Meeting </div> <div class="event-participation lt-gray"> Attending, Speaking </div> <div class="event-link"> <a href="https://www.corar.org/" target="_blank" class="black">Visit CORAR</a> </div> </div> </div> </div> </div> </div> <h4 class="mb-4 mt-5">Past Events & Presentations</h4> <div class="search-filter-results" id="search-filter-results-11994"> <div class="row events-search row-cols-1 row-cols-md-2" id="results-11364"> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.astro.org/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/03/ASTRO-TRP-01.png" class="w-100 img-fluid" alt="American Society for Radiation Oncology (ASTRO) Radiopharmaceutical Therapy Roundtable" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Nov 12, 2024 </div> <div class="event-date blue"> Arlington, VA </div> <div class="event-type mb-3 black"> Meeting </div> <div class="event-title mb-3 blue"> American Society for Radiation Oncology (ASTRO) Radiopharmaceutical Therapy Roundtable </div> <div class="event-participation lt-gray"> Sponsoring, Attending </div> <div class="event-link"> <a href="https://www.astro.org/" target="_blank" class="black">Visit ASTRO</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.bioforward.org/bioforward-wisconsin-biohealth-summit-2024/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/08/BioHealth-2024-01.png" class="w-100 img-fluid" alt="Wisconsin BioHealth Summit 2024" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Oct 28, 2024 - Oct 29, 2024 </div> <div class="event-date blue"> Madison, WI </div> <div class="event-type mb-3 black"> Conference </div> <div class="event-title mb-3 blue"> Wisconsin BioHealth Summit 2024 </div> <div class="event-participation lt-gray"> Attending </div> <div class="event-link"> <a href="https://www.bioforward.org/bioforward-wisconsin-biohealth-summit-2024/" target="_blank" class="black">Visit WI BioHealth Summit</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.oecd-nea.org/jcms/pl_93980/second-international-workshop-on-medical-radioisotopes-supply" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/10/NEA-01.png" class="w-100 img-fluid" alt="2nd International Workshop on Medical Radioisotopes Supply" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Oct 24, 2024 - Oct 25, 2024 </div> <div class="event-date blue"> Paris, France </div> <div class="event-type mb-3 black"> Workshop </div> <div class="event-title mb-3 blue"> 2nd International Workshop on Medical Radioisotopes Supply </div> <div class="event-participation lt-gray"> Attending, Speaking </div> <div class="event-link"> <a href="https://www.oecd-nea.org/jcms/pl_93980/second-international-workshop-on-medical-radioisotopes-supply" target="_blank" class="black">Visit NEA</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://rockvalleycollege.edu/calendar#event-details/c8c7bf17-cce4-4c15-81e3-f8a7ace204f4" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/10/RVC-01.png" class="w-100 img-fluid" alt="Rock Valley College Mole Day" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Oct 23, 2024 </div> <div class="event-date blue"> Rockford, IL </div> <div class="event-type mb-3 black"> Career Fair </div> <div class="event-title mb-3 blue"> Rock Valley College Mole Day </div> <div class="event-participation lt-gray"> Exhibiting </div> <div class="event-link"> <a href="https://rockvalleycollege.edu/calendar#event-details/c8c7bf17-cce4-4c15-81e3-f8a7ace204f4" target="_blank" class="black">Visit Rock Valley College</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.rrmc.co/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/10/RRMC-2024-01.png" class="w-100 img-fluid" alt="67th Radiobioassay &#038; Radiochemical Measurements Conference (RRMC)" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Oct 21, 2024 - Oct 25, 2024 </div> <div class="event-date blue"> West Lafayette, IN </div> <div class="event-type mb-3 black"> Conference </div> <div class="event-title mb-3 blue"> 67th Radiobioassay &#038; Radiochemical Measurements Conference (RRMC) </div> <div class="event-participation lt-gray"> Speaking </div> <div class="event-link"> <a href="https://www.rrmc.co/" target="_blank" class="black">Visit RRMC</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://eanm24.eanm.org/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/06/EANM-2024-01.png" class="w-100 img-fluid" alt="37th Annual Congress of the European Association of Nuclear Medicine (EANM)" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Oct 19, 2024 - Oct 23, 2024 </div> <div class="event-date blue"> Hamburg, Germany </div> <div class="event-type mb-3 black"> Conference </div> <div class="event-title mb-3 blue"> 37th Annual Congress of the European Association of Nuclear Medicine (EANM) </div> <div class="event-participation lt-gray"> Attending </div> <div class="event-link"> <a href="https://eanm24.eanm.org/" target="_blank" class="black">Visit EANM-24</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://ispe.org/conferences/2024-annual-meeting-expo" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/08/ISPE-2024-01.png" class="w-100 img-fluid" alt="International Society for Pharmaceutical Engineering (ISPE) 2024 Annual Meeting" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Oct 13, 2024 - Oct 16, 2024 </div> <div class="event-date blue"> Orlando, FL </div> <div class="event-type mb-3 black"> Conference </div> <div class="event-title mb-3 blue"> International Society for Pharmaceutical Engineering (ISPE) 2024 Annual Meeting </div> <div class="event-participation lt-gray"> Attending </div> <div class="event-link"> <a href="https://ispe.org/conferences/2024-annual-meeting-expo" target="_blank" class="black">Visit ISPE</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.oppenheimer.com/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/08/Opp-generic-01.png" class="w-100 img-fluid" alt="Oppenheimer&#8217;s 2nd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Oct 8, 2024 </div> <div class="event-date blue"> New York, NY </div> <div class="event-type mb-3 black"> Meeting </div> <div class="event-title mb-3 blue"> Oppenheimer&#8217;s 2nd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit </div> <div class="event-participation lt-gray"> Attending, Speaking </div> <div class="event-link"> <a href="https://www.oppenheimer.com/" target="_blank" class="black">Visit Oppeneheimer</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.astro.org/meetings-and-education/micro-sites/2024/annual-meeting" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/09/ASTRO-AM-2024-01.png" class="w-100 img-fluid" alt="66th American Society for Radiation Oncology (ASTRO) Annual Meeting" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Sep 29, 2024 - Oct 2, 2024 </div> <div class="event-date blue"> Washington, DC </div> <div class="event-type mb-3 black"> Meeting </div> <div class="event-title mb-3 blue"> 66th American Society for Radiation Oncology (ASTRO) Annual Meeting </div> <div class="event-participation lt-gray"> Attending </div> <div class="event-link"> <a href="https://www.astro.org/meetings-and-education/micro-sites/2024/annual-meeting" target="_blank" class="black">Visit ASTRO</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://targeted-radiopharma-supplychain-manufacturing.com/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/06/TRP-Supply-2024-II-01.png" class="w-100 img-fluid" alt="2nd Annual Targeted Radiopharmaceuticals (TRP) Supply Chain &#038; Manufacturing Summit" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Sep 24, 2024 - Sep 26, 2024 </div> <div class="event-date blue"> Boston, MA </div> <div class="event-type mb-3 black"> Meeting </div> <div class="event-title mb-3 blue"> 2nd Annual Targeted Radiopharmaceuticals (TRP) Supply Chain &#038; Manufacturing Summit </div> <div class="event-participation lt-gray"> Attending, Sponsoring </div> <div class="event-link"> <a href="https://targeted-radiopharma-supplychain-manufacturing.com/" target="_blank" class="black">Visit TRP Supply Chain</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://snmmi.org/Therapeutics2024/Therapeutics2024/Home.aspx" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/08/SNMMI-Ther-2024-01.png" class="w-100 img-fluid" alt="2024 Society of Nuclear Medicine &#038; Molecular Imaging (SNMMI) Therapeutics Conference" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Sep 19, 2024 - Sep 21, 2024 </div> <div class="event-date blue"> Bethesda, MD </div> <div class="event-type mb-3 black"> Conference </div> <div class="event-title mb-3 blue"> 2024 Society of Nuclear Medicine &#038; Molecular Imaging (SNMMI) Therapeutics Conference </div> <div class="event-participation lt-gray"> Attending </div> <div class="event-link"> <a href="https://snmmi.org/Therapeutics2024/Therapeutics2024/Home.aspx" target="_blank" class="black">Visit SNMMI</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://adc-partnering.com/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/08/ADC-2024-01.png" class="w-100 img-fluid" alt="ADC &#038; Radiopharmaceuticals Pharma &#038; Biotech Partnering Summit" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Sep 9, 2024 - Sep 10, 2024 </div> <div class="event-date blue"> Boston, MA </div> <div class="event-type mb-3 black"> Meeting </div> <div class="event-title mb-3 blue"> ADC &#038; Radiopharmaceuticals Pharma &#038; Biotech Partnering Summit </div> <div class="event-participation lt-gray"> Attending, Sponsoring </div> <div class="event-link"> <a href="https://adc-partnering.com/" target="_blank" class="black">Visit ADC & Radiopharmaceuticals Summit</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.iaea.org/events/evt2304148" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/08/IAEA-01.png" class="w-100 img-fluid" alt="Technical Meeting on Ra-226 Targets for Therapeutic Radioisotope Production" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Sep 2, 2024 - Sep 6, 2024 </div> <div class="event-date blue"> Vienna, Austria </div> <div class="event-type mb-3 black"> Meeting </div> <div class="event-title mb-3 blue"> Technical Meeting on Ra-226 Targets for Therapeutic Radioisotope Production </div> <div class="event-participation lt-gray"> Attending, Speaking </div> <div class="event-link"> <a href="https://www.iaea.org/events/evt2304148" target="_blank" class="black">Visit IAEA</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.dkfz.de/en/Radiopharmazeutika-Praeklinische-Studien/WTTC19_welcome.html" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/08/WTTC19-01.png" class="w-100 img-fluid" alt="19th International Workshop on Targetry and Target Chemistry (WTTC19)" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Aug 25, 2024 - Aug 30, 2024 </div> <div class="event-date blue"> Heidelberg, Germany </div> <div class="event-type mb-3 black"> Conference </div> <div class="event-title mb-3 blue"> 19th International Workshop on Targetry and Target Chemistry (WTTC19) </div> <div class="event-participation lt-gray"> Attending </div> <div class="event-link"> <a href="https://www.dkfz.de/en/Radiopharmazeutika-Praeklinische-Studien/WTTC19_welcome.html" target="_blank" class="black">Visit WTTC19</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://intds2024.ornl.gov/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/08/INTDS-2024-II-01.png" class="w-100 img-fluid" alt="31st Conference of the International Nuclear Target Development Society (INTDS 2024)" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Aug 18, 2024 - Aug 23, 2024 </div> <div class="event-date blue"> Knoxville, TN </div> <div class="event-type mb-3 black"> Conference </div> <div class="event-title mb-3 blue"> 31st Conference of the International Nuclear Target Development Society (INTDS 2024) </div> <div class="event-participation lt-gray"> Attending </div> <div class="event-link"> <a href="https://intds2024.ornl.gov/" target="_blank" class="black">Visit INTDS 2024</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://targeted-radiopharma-us.com/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/04/TRP-US-2024-01.png" class="w-100 img-fluid" alt="3rd Annual Targeted Radiopharmaceuticals Summit US" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Jul 30, 2024 - Aug 1, 2024 </div> <div class="event-date blue"> San Diego, CA </div> <div class="event-type mb-3 black"> Conference </div> <div class="event-title mb-3 blue"> 3rd Annual Targeted Radiopharmaceuticals Summit US </div> <div class="event-participation lt-gray"> Sponsoring, Attending </div> <div class="event-link"> <a href="https://targeted-radiopharma-us.com/" target="_blank" class="black">Visit TRP US</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.brainlinx.com/conference/12th-PPLF-USA/index.php#rs-about" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/06/Pharma-Packaging-2024-01.png" class="w-100 img-fluid" alt="12th Pharma Packaging &#038; Labeling Innovation Forum (USA)" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Jun 13, 2024 - Jun 14, 2024 </div> <div class="event-date blue"> Boston, MA </div> <div class="event-type mb-3 black"> Conference </div> <div class="event-title mb-3 blue"> 12th Pharma Packaging &#038; Labeling Innovation Forum (USA) </div> <div class="event-participation lt-gray"> Speaking </div> <div class="event-link"> <a href="https://www.brainlinx.com/conference/12th-PPLF-USA/index.php#rs-about" target="_blank" class="black">Visit PPFL USA</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://sites.snmmi.org/AM" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2023/12/SNMMI-AM-2024-01.png" class="w-100 img-fluid" alt="Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Jun 8, 2024 - Jun 11, 2024 </div> <div class="event-date blue"> Toronto, Canada </div> <div class="event-type mb-3 black"> Meeting </div> <div class="event-title mb-3 blue"> Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting </div> <div class="event-participation lt-gray"> Attending, Exhibiting, Speaking </div> <div class="event-link"> <a href="https://sites.snmmi.org/AM" target="_blank" class="black">Visit SNMMI</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.jefferies.com/about/conferences-events/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2023/03/Jeffries-2023-01.png" class="w-100 img-fluid" alt="Jefferies Radiopharma Innovation Summit" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Apr 11, 2024 </div> <div class="event-date blue"> New York, NY </div> <div class="event-type mb-3 black"> Conference </div> <div class="event-title mb-3 blue"> Jefferies Radiopharma Innovation Summit </div> <div class="event-participation lt-gray"> Speaking </div> <div class="event-link"> <a href="https://www.jefferies.com/about/conferences-events/" target="_blank" class="black">Visit Jefferies</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.astro.org/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/03/ASTRO-TRP-01.png" class="w-100 img-fluid" alt="American Society for Radiation Oncology (ASTRO) Radiopharmaceutical Therapy Roundtable" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Mar 21, 2024 </div> <div class="event-date blue"> Arlington, VA </div> <div class="event-type mb-3 black"> Meeting </div> <div class="event-title mb-3 blue"> American Society for Radiation Oncology (ASTRO) Radiopharmaceutical Therapy Roundtable </div> <div class="event-participation lt-gray"> Sponsoring, Attending </div> <div class="event-link"> <a href="https://www.astro.org/" target="_blank" class="black">Visit ASTRO</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.jlab.org/conference/AcceleratorApplications2024/ScientificProgram" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/02/AccApp-2024-01.png" class="w-100 img-fluid" alt="2024 International Topical Meeting on Nuclear Applications of Accelerators (AccelApp &#8217;24)" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Mar 17, 2024 - Mar 21, 2024 </div> <div class="event-date blue"> Norfolk, VA </div> <div class="event-type mb-3 black"> Meeting </div> <div class="event-title mb-3 blue"> 2024 International Topical Meeting on Nuclear Applications of Accelerators (AccelApp &#8217;24) </div> <div class="event-participation lt-gray"> Attending </div> <div class="event-link"> <a href="https://www.jlab.org/conference/AcceleratorApplications2024/ScientificProgram" target="_blank" class="black">Visit AccelApp '24</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.hcnmc.org/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2023/07/HC-2024-01.png" class="w-100 img-fluid" alt="High Country Nuclear Medicine Conference 2024" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Mar 2, 2024 - Mar 5, 2024 </div> <div class="event-date blue"> Park City, UT </div> <div class="event-type mb-3 black"> Conference </div> <div class="event-title mb-3 blue"> High Country Nuclear Medicine Conference 2024 </div> <div class="event-participation lt-gray"> Sponsoring, Attending </div> <div class="event-link"> <a href="https://www.hcnmc.org/" target="_blank" class="black">Visit High Country 2024</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.niu.edu/ceet/resources/careers/fair.shtml" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2023/01/NIU-CEET-01.png" class="w-100 img-fluid" alt="Northern Illinois University CEET Job &#038; Internship Fair" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Feb 27, 2024 </div> <div class="event-date blue"> DeKalb, IL </div> <div class="event-type mb-3 black"> Career Fair </div> <div class="event-title mb-3 blue"> Northern Illinois University CEET Job &#038; Internship Fair </div> <div class="event-participation lt-gray"> Exhibiting </div> <div class="event-link"> <a href="https://www.niu.edu/ceet/resources/careers/fair.shtml" target="_blank" class="black">Visit NIU</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.bipm.org/en/committees/cc/ccri/wg/ccri-rtwg/2024-02-22" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/02/BIPM-2024-01.png" class="w-100 img-fluid" alt="International Workshop on Standards and Measurements for Alpha Emitting Nuclides in Therapeutic Nuclear Medicine" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Feb 22, 2024 - Feb 23, 2024 </div> <div class="event-date blue"> Sevres, France </div> <div class="event-type mb-3 black"> Workshop </div> <div class="event-title mb-3 blue"> International Workshop on Standards and Measurements for Alpha Emitting Nuclides in Therapeutic Nuclear Medicine </div> <div class="event-participation lt-gray"> Attending, Speaking </div> <div class="event-link"> <a href="https://www.bipm.org/en/committees/cc/ccri/wg/ccri-rtwg/2024-02-22" target="_blank" class="black">Visit BIPM</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.bioforward.org/events/women-in-biohealth-presents-pulling-back-the-curtain-on-career-advancement-networking-mastery/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2024/02/BF-WIB-HR-2024-01.png" class="w-100 img-fluid" alt="BioForward&#8217;s WI Women in Biohealth &#8211; HR Panel Session" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Feb 21, 2024 </div> <div class="event-date blue"> Madison, WI </div> <div class="event-type mb-3 black"> Conference </div> <div class="event-title mb-3 blue"> BioForward&#8217;s WI Women in Biohealth &#8211; HR Panel Session </div> <div class="event-participation lt-gray"> Speaking </div> <div class="event-link"> <a href="https://www.bioforward.org/events/women-in-biohealth-presents-pulling-back-the-curtain-on-career-advancement-networking-mastery/" target="_blank" class="black">Visit BioForward</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://ecs.wisc.edu/students/career-fairs/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2022/08/UW-STEM-CF-SM-01.png" class="w-100 img-fluid" alt="University of Wisconsin-Madison Spring 2024 Engineering &#038; STEM Career Fair" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Feb 12, 2024 - Feb 14, 2024 </div> <div class="event-date blue"> Madison, WI </div> <div class="event-type mb-3 black"> Career Fair </div> <div class="event-title mb-3 blue"> University of Wisconsin-Madison Spring 2024 Engineering &#038; STEM Career Fair </div> <div class="event-participation lt-gray"> Exhibiting </div> <div class="event-link"> <a href="https://ecs.wisc.edu/students/career-fairs/" target="_blank" class="black">Visit UW-Madison</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.corar.org/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2020/11/corar-2020-01.png" class="w-100 img-fluid" alt="Council on Radionuclides and Radiopharmaceuticals (CORAR) Meeting" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Dec 11, 2023 - Dec 13, 2023 </div> <div class="event-date blue"> Washington, DC </div> <div class="event-type mb-3 black"> Meeting </div> <div class="event-title mb-3 blue"> Council on Radionuclides and Radiopharmaceuticals (CORAR) Meeting </div> <div class="event-participation lt-gray"> Attending, Speaking </div> <div class="event-link"> <a href="https://www.corar.org/" target="_blank" class="black">Visit CORAR</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://targeted-radiopharma.com/" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2023/09/TRP-EU-2024-01.png" class="w-100 img-fluid" alt="Targeted Radiopharmaceuticals Summit (TRP) Europe" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Dec 5, 2023 - Dec 7, 2023 </div> <div class="event-date blue"> Berlin, Germany </div> <div class="event-type mb-3 black"> Conference </div> <div class="event-title mb-3 blue"> Targeted Radiopharmaceuticals Summit (TRP) Europe </div> <div class="event-participation lt-gray"> Sponsoring, Attending </div> <div class="event-link"> <a href="https://targeted-radiopharma.com/" target="_blank" class="black">Visit TRP Europe</a> </div> </div> </div> </div> <div class="col mb-4"> <div class="h-100 event-block bg-white"> <div class="event-img mb-3"> <a href="https://www.truistsecurities.com/sales-trading-research?cid=PS-LKIN-oshs10173&CampIDMaj=AAAON&CampIDMin=AAA" target="_blank" class="black"> <img src="https://www.northstarnm.com/wp-content/uploads/2023/10/Truist-2023.png" class="w-100 img-fluid" alt="Truist Securities BioPharma Symposium" /> </a> </div> <div class="event-block-inner p-3"> <div class="event-date blue"> Nov 8, 2023 - Nov 9, 2023 </div> <div class="event-date blue"> New York, NY </div> <div class="event-type mb-3 black"> Symposium </div> <div class="event-title mb-3 blue"> Truist Securities BioPharma Symposium </div> <div class="event-participation lt-gray"> Speaking </div> <div class="event-link"> <a href="https://www.truistsecurities.com/sales-trading-research?cid=PS-LKIN-oshs10173&CampIDMaj=AAAON&CampIDMin=AAA" target="_blank" class="black">Visit Truist</a> </div> </div> </div> </div> </div> </div> </div> </div> </div> <div class="tab-pane fade" id="social" role="tabpanel" aria-labelledby="pills-social-tab"> <div class="tagembed-container" style=" width:100%;height:100%;overflow: auto;"><div class="tagembed-socialwall" data-wall-id="18990" view-url="https://widget.tagembed.com/18990"> </div> <script src="//widget.tagembed.com/embed.min.js" type="text/javascript"></script></div> </div> </div> </div> </div> </section> </div> </section> </div> <footer class="py-5"> <div class="container"> <div class="row"> <div class="col-12 col-md-4 mb-4 mb-md-0 py-md-2"> <p class="footer-brand"><img src="https://www.northstarnm.com/wp-content/themes/northstar/img/logo-w.svg" alt="NorthStar Medical Radioisotopes, LLC" class="w-100 img-fluid" /></p> <div class="contact-box"> <p>1800 Gateway Boulevard<br /> Beloit, WI 53511<br /> <strong>Phone:</strong> <a href="tel:8444386659">(844) 438-6659</a><br /> <strong>Phone:</strong> <a href="tel:6083138000">(608) 313-8000</a></p> </div> </div> <div class="col-md-4 py-md-2 mb-4 mb-md-0"> <div class="menu-main-menu-container"><ul id="menu-main-menu-2" class="menu" itemscope itemtype="http://www.schema.org/SiteNavigationElement"><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12125"><a href="https://www.northstarnm.com/radiopharmaceutical-therapy/">Radiopharmaceutical Therapy</a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-12604"><a href="https://www.northstarnm.com/cdmo-cmo/">CDMO/CMO</a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-10982"><a href="https://www.northstarnm.com/development/">Development</a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page current-page-ancestor current-menu-ancestor current-menu-parent current-page-parent current_page_parent current_page_ancestor menu-item-10981"><a href="https://www.northstarnm.com/company/">Company</a></li> <li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-10980"><a href="https://www.northstarnm.com/careers/">Careers</a></li> <li class="searchlink menu-item menu-item-type-custom menu-item-object-custom menu-item-10984"><a href="#search"><i class="fas fa-search"></i> <span class="navhide">Search</span></a></li> </ul></div> </div> <div class="col-12 col-md-4 mb-4 mb-md-0 border-left px-md-4 py-md-2"> <div class="f-col-title"> HOW CAN WE HELP? </div> <div class="f-col-content"> <p>Questions about our company, products, supply solutions, careers or anything else?</p> </div> <div class="f-col-link"> <a href="https://www.northstarnm.com/company/contact-us/" target="" class="btn btn-wire">Contact Us</a> </div> <div class="inline-links"> <ul class="social-links"> <li><a href="https://www.linkedin.com/company/northstar-medical-radioisotopes-llc/" target="_blank" title=""><span class="social-text">LinkedIn</span><span class="fa-stack" style="vertical-align: top;"> <i class="fas fa-circle fa-stack-2x"></i> <i class="fab fa-linkedin-in fa-stack-1x fa-inverse"></i> </span></a></li> <li><a href="https://www.instagram.com/northstarmedicalradioisotopes/" target="_blank" title=""><span class="social-text">Instagram</span><span class="fa-stack" style="vertical-align: top;"> <i class="fas fa-circle fa-stack-2x"></i> <i class="fab fa-instagram fa-stack-1x fa-inverse"></i> </span></a></li> </ul> </div> </div> <div class="col-12 footer-copyright py-3 mb-5 white"> ©<script>var CurrentYear = new Date().getFullYear(); document.write(CurrentYear);</script> NMR. All rights reserved. <a href="/privacy-policy/" class="white">Privacy Policy</a>. <a href="/terms-conditions/" class="white">Terms &amp; Conditions</a>. </div> </div> </div> </footer> </div> <div class="modal fade video-modal" id="videomodal" tabindex="-1" role="dialog" aria-labelledby="videomodal"> <div class="modal-dialog modal-dialog-centered modal-lg" role="document"> <div class="modal-content"> <div class="modal-body"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">&times;</span></button> <div class="modalhelper"></div> <div class="clearfix"></div> </div> </div> </div> </div> <div id="form-block" class="bg-dk-blue white" style="display:none;"> <div class="fb-close"> <a href="#"><i class="far fa-times"></i></a> </div> <div class="form-block-inner"> <h3 class="white mb-3">Stay Up To Date</h3> <p>For more information on NorthStar and to receive future announcements about our products and company, fill out this simple form.</p> <p> <div class=" mailpoet_form_popup_overlay "></div> <div id="mailpoet_form_1" class=" mailpoet_form mailpoet_form_php mailpoet_form_position_ mailpoet_form_animation_ " > <style type="text/css"> #mailpoet_form_1 .mailpoet_form { } #mailpoet_form_1 .mailpoet_column_with_background { padding: 10px; } #mailpoet_form_1 .mailpoet_form_column:not(:first-child) { margin-left: 20px; } #mailpoet_form_1 .mailpoet_paragraph { line-height: 20px; margin-bottom: 20px; } #mailpoet_form_1 .mailpoet_segment_label, #mailpoet_form_1 .mailpoet_text_label, #mailpoet_form_1 .mailpoet_textarea_label, #mailpoet_form_1 .mailpoet_select_label, #mailpoet_form_1 .mailpoet_radio_label, #mailpoet_form_1 .mailpoet_checkbox_label, #mailpoet_form_1 .mailpoet_list_label, #mailpoet_form_1 .mailpoet_date_label { display: block; font-weight: normal; } #mailpoet_form_1 .mailpoet_text, #mailpoet_form_1 .mailpoet_textarea, #mailpoet_form_1 .mailpoet_select, #mailpoet_form_1 .mailpoet_date_month, #mailpoet_form_1 .mailpoet_date_day, #mailpoet_form_1 .mailpoet_date_year, #mailpoet_form_1 .mailpoet_date { display: block; } #mailpoet_form_1 .mailpoet_text, #mailpoet_form_1 .mailpoet_textarea { width: 200px; } #mailpoet_form_1 .mailpoet_checkbox { } #mailpoet_form_1 .mailpoet_submit { } #mailpoet_form_1 .mailpoet_divider { } #mailpoet_form_1 .mailpoet_message { } #mailpoet_form_1 .mailpoet_form_loading { width: 30px; text-align: center; line-height: normal; } #mailpoet_form_1 .mailpoet_form_loading > span { width: 5px; height: 5px; background-color: #5b5b5b; }#mailpoet_form_1{border-radius: 0px;text-align: left;}#mailpoet_form_1 form.mailpoet_form {padding: 20px;}#mailpoet_form_1{width: 100%;}#mailpoet_form_1 .mailpoet_message {margin: 0; padding: 0 20px;}#mailpoet_form_1 .mailpoet_paragraph.last {margin-bottom: 0} @media (max-width: 500px) {#mailpoet_form_1 {background-image: none;}} @media (min-width: 500px) {#mailpoet_form_1 .last .mailpoet_paragraph:last-child {margin-bottom: 0}} @media (max-width: 500px) {#mailpoet_form_1 .mailpoet_form_column:last-child .mailpoet_paragraph:last-child {margin-bottom: 0}} </style> <form target="_self" method="post" action="https://www.northstarnm.com/wp-admin/admin-post.php?action=mailpoet_subscription_form" class="mailpoet_form mailpoet_form_form mailpoet_form_php" novalidate data-delay="" data-exit-intent-enabled="" data-font-family="" data-cookie-expiration-time="" > <input type="hidden" name="data[form_id]" value="1" /> <input type="hidden" name="token" value="20ea6fa8b7" /> <input type="hidden" name="api_version" value="v1" /> <input type="hidden" name="endpoint" value="subscribers" /> <input type="hidden" name="mailpoet_method" value="subscribe" /> <label class="mailpoet_hp_email_label" style="display: none !important;">Please leave this field empty<input type="email" name="data[email]"/></label><div class="mailpoet_paragraph "><input type="text" autocomplete="given-name" class="mailpoet_text" id="form_first_name_1" name="data[form_field_ZmVmM2I5Yzg3ZDc5X2ZpcnN0X25hbWU=]" title="First name" value="" style="width:100%;box-sizing:border-box;padding:5px;margin: 0 auto 0 0;" data-automation-id="form_first_name" placeholder="First name *" aria-label="First name *" data-parsley-errors-container=".mailpoet_error_fp8jl" data-parsley-names='[&quot;Please specify a valid name.&quot;,&quot;Addresses in names are not permitted, please add your name instead.&quot;]' data-parsley-required="true" required aria-required="true" data-parsley-required-message="This field is required."/><span class="mailpoet_error_fp8jl"></span></div> <div class="mailpoet_paragraph "><input type="text" autocomplete="family-name" class="mailpoet_text" id="form_last_name_1" name="data[form_field_NmI1OWYxNDY4ZTc1X2xhc3RfbmFtZQ==]" title="Last name" value="" style="width:100%;box-sizing:border-box;padding:5px;margin: 0 auto 0 0;" data-automation-id="form_last_name" placeholder="Last name" aria-label="Last name" data-parsley-errors-container=".mailpoet_error_1wf33" data-parsley-names='[&quot;Please specify a valid name.&quot;,&quot;Addresses in names are not permitted, please add your name instead.&quot;]'/><span class="mailpoet_error_1wf33"></span></div> <div class="mailpoet_paragraph "><input type="text" autocomplete="on" class="mailpoet_text" id="form_1_1" name="data[cf_1]" title="Company" value="" style="width:100%;box-sizing:border-box;padding:5px;margin: 0 auto 0 0;" placeholder="Company *" aria-label="Company *" data-parsley-errors-container=".mailpoet_error_v1wg5" data-parsley-required="true" required aria-required="true" data-parsley-required-message="This field is required."/><span class="mailpoet_error_v1wg5"></span></div> <div class="mailpoet_paragraph "><input type="text" autocomplete="on" class="mailpoet_text" id="form_2_1" name="data[cf_2]" title="Occupation" value="" style="width:100%;box-sizing:border-box;padding:5px;margin: 0 auto 0 0;" placeholder="Occupation *" aria-label="Occupation *" data-parsley-errors-container=".mailpoet_error_1cjc8" data-parsley-required="true" required aria-required="true" data-parsley-required-message="This field is required."/><span class="mailpoet_error_1cjc8"></span></div> <div class="mailpoet_paragraph "><input type="email" autocomplete="email" class="mailpoet_text" id="form_email_1" name="data[form_field_MmIwY2I2OGUzODU4X2VtYWls]" title="Email" value="" style="width:100%;box-sizing:border-box;padding:5px;margin: 0 auto 0 0;" data-automation-id="form_email" placeholder="Email *" aria-label="Email *" data-parsley-errors-container=".mailpoet_error_1fox1" data-parsley-required="true" required aria-required="true" data-parsley-minlength="6" data-parsley-maxlength="150" data-parsley-type-message="This value should be a valid email." data-parsley-required-message="This field is required."/><span class="mailpoet_error_1fox1"></span></div> <div class="mailpoet_paragraph "><input type="submit" class="mailpoet_submit" value="Subscribe" data-automation-id="subscribe-submit-button" style="width:100%;box-sizing:border-box;padding:5px;margin: 0 auto 0 0;border-color:transparent;" /><span class="mailpoet_form_loading"><span class="mailpoet_bounce1"></span><span class="mailpoet_bounce2"></span><span class="mailpoet_bounce3"></span></span></div> <div class="mailpoet_message"> <p class="mailpoet_validate_success" style="display:none;" >Check your inbox or spam folder to confirm your subscription. </p> <p class="mailpoet_validate_error" style="display:none;" > </p> </div> </form> </div> </p> </div> </div> <script src="https://kit.fontawesome.com/b7b382cbdd.js" crossorigin="anonymous"></script> <script src="https://www.northstarnm.com/wp-content/themes/northstar/js/bootstrap.bundle.min.js"></script> <script src="https://www.northstarnm.com/wp-content/themes/northstar/js/bootstrap-select.min.js"></script> <script src="https://www.northstarnm.com/wp-content/themes/northstar/js/northstar.js?1451718279"></script> <script src="https://www.northstarnm.com/wp-content/themes/northstar/js/parallax.js"></script> <script src="https://www.northstarnm.com/wp-content/themes/northstar/js/visible.js"></script> <script src="https://www.northstarnm.com/wp-content/themes/northstar/js/cookie.js"></script> <script src="https://www.northstarnm.com/wp-content/themes/northstar/js/form-cookie.js?v=1762657123"></script> <link rel='stylesheet' id='mailpoet_public-css' href='https://www.northstarnm.com/wp-content/plugins/mailpoet/assets/dist/css/mailpoet-public.b1f0906e.css?ver=6.6.1' type='text/css' media='all' /> <link rel='stylesheet' id='mailpoet_custom_fonts_0-css' href='https://fonts.googleapis.com/css?family=Abril+FatFace%3A400%2C400i%2C700%2C700i%7CAlegreya%3A400%2C400i%2C700%2C700i%7CAlegreya+Sans%3A400%2C400i%2C700%2C700i%7CAmatic+SC%3A400%2C400i%2C700%2C700i%7CAnonymous+Pro%3A400%2C400i%2C700%2C700i%7CArchitects+Daughter%3A400%2C400i%2C700%2C700i%7CArchivo%3A400%2C400i%2C700%2C700i%7CArchivo+Narrow%3A400%2C400i%2C700%2C700i%7CAsap%3A400%2C400i%2C700%2C700i%7CBarlow%3A400%2C400i%2C700%2C700i%7CBioRhyme%3A400%2C400i%2C700%2C700i%7CBonbon%3A400%2C400i%2C700%2C700i%7CCabin%3A400%2C400i%2C700%2C700i%7CCairo%3A400%2C400i%2C700%2C700i%7CCardo%3A400%2C400i%2C700%2C700i%7CChivo%3A400%2C400i%2C700%2C700i%7CConcert+One%3A400%2C400i%2C700%2C700i%7CCormorant%3A400%2C400i%2C700%2C700i%7CCrimson+Text%3A400%2C400i%2C700%2C700i%7CEczar%3A400%2C400i%2C700%2C700i%7CExo+2%3A400%2C400i%2C700%2C700i%7CFira+Sans%3A400%2C400i%2C700%2C700i%7CFjalla+One%3A400%2C400i%2C700%2C700i%7CFrank+Ruhl+Libre%3A400%2C400i%2C700%2C700i%7CGreat+Vibes%3A400%2C400i%2C700%2C700i&#038;ver=6.6.1' type='text/css' media='all' /> <link rel='stylesheet' id='mailpoet_custom_fonts_1-css' href='https://fonts.googleapis.com/css?family=Heebo%3A400%2C400i%2C700%2C700i%7CIBM+Plex%3A400%2C400i%2C700%2C700i%7CInconsolata%3A400%2C400i%2C700%2C700i%7CIndie+Flower%3A400%2C400i%2C700%2C700i%7CInknut+Antiqua%3A400%2C400i%2C700%2C700i%7CInter%3A400%2C400i%2C700%2C700i%7CKarla%3A400%2C400i%2C700%2C700i%7CLibre+Baskerville%3A400%2C400i%2C700%2C700i%7CLibre+Franklin%3A400%2C400i%2C700%2C700i%7CMontserrat%3A400%2C400i%2C700%2C700i%7CNeuton%3A400%2C400i%2C700%2C700i%7CNotable%3A400%2C400i%2C700%2C700i%7CNothing+You+Could+Do%3A400%2C400i%2C700%2C700i%7CNoto+Sans%3A400%2C400i%2C700%2C700i%7CNunito%3A400%2C400i%2C700%2C700i%7COld+Standard+TT%3A400%2C400i%2C700%2C700i%7COxygen%3A400%2C400i%2C700%2C700i%7CPacifico%3A400%2C400i%2C700%2C700i%7CPoppins%3A400%2C400i%2C700%2C700i%7CProza+Libre%3A400%2C400i%2C700%2C700i%7CPT+Sans%3A400%2C400i%2C700%2C700i%7CPT+Serif%3A400%2C400i%2C700%2C700i%7CRakkas%3A400%2C400i%2C700%2C700i%7CReenie+Beanie%3A400%2C400i%2C700%2C700i%7CRoboto+Slab%3A400%2C400i%2C700%2C700i&#038;ver=6.6.1' type='text/css' media='all' /> <link rel='stylesheet' id='mailpoet_custom_fonts_2-css' href='https://fonts.googleapis.com/css?family=Ropa+Sans%3A400%2C400i%2C700%2C700i%7CRubik%3A400%2C400i%2C700%2C700i%7CShadows+Into+Light%3A400%2C400i%2C700%2C700i%7CSpace+Mono%3A400%2C400i%2C700%2C700i%7CSpectral%3A400%2C400i%2C700%2C700i%7CSue+Ellen+Francisco%3A400%2C400i%2C700%2C700i%7CTitillium+Web%3A400%2C400i%2C700%2C700i%7CUbuntu%3A400%2C400i%2C700%2C700i%7CVarela%3A400%2C400i%2C700%2C700i%7CVollkorn%3A400%2C400i%2C700%2C700i%7CWork+Sans%3A400%2C400i%2C700%2C700i%7CYatra+One%3A400%2C400i%2C700%2C700i&#038;ver=6.6.1' type='text/css' media='all' /> <script type="text/javascript" src="https://www.northstarnm.com/wp-includes/js/jquery/ui/core.min.js?ver=1.13.3" id="jquery-ui-core-js"></script> <script type="text/javascript" src="https://www.northstarnm.com/wp-includes/js/jquery/ui/datepicker.min.js?ver=1.13.3" id="jquery-ui-datepicker-js"></script> <script type="text/javascript" id="jquery-ui-datepicker-js-after"> /* <![CDATA[ */ jQuery(function(jQuery){jQuery.datepicker.setDefaults({"closeText":"Close","currentText":"Today","monthNames":["January","February","March","April","May","June","July","August","September","October","November","December"],"monthNamesShort":["Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"nextText":"Next","prevText":"Previous","dayNames":["Sunday","Monday","Tuesday","Wednesday","Thursday","Friday","Saturday"],"dayNamesShort":["Sun","Mon","Tue","Wed","Thu","Fri","Sat"],"dayNamesMin":["S","M","T","W","T","F","S"],"dateFormat":"MM d, yy","firstDay":0,"isRTL":false});}); /* ]]> */ </script> <script type="text/javascript" id="mailpoet_public-js-extra"> /* <![CDATA[ */ var MailPoetForm = {"ajax_url":"https:\/\/www.northstarnm.com\/wp-admin\/admin-ajax.php","is_rtl":"","ajax_common_error_message":"An error has happened while performing a request, please try again later."}; /* ]]> */ </script> <script type="text/javascript" src="https://www.northstarnm.com/wp-content/plugins/mailpoet/assets/dist/js/public.js?ver=5.4.0" id="mailpoet_public-js" defer="defer" data-wp-strategy="defer"></script> </body> </html>

Pages: 1 2 3 4 5 6 7 8 9 10